Learn from Translation by Gall, H. (Henning)
Learn from Translation 
Pulmonary hypertension:  
insights from population and patient studies
Henning Gall
13106_Gall_BW.indd   1 22-01-16   15:11
 Layout: Nikki Vermeulen - Ridderprint BV
Printing: Ridderprint BV - www.ridderprint.nl
Cover: Remco Wetzels
ISBN:  978-94-6299-294-8
© The copyright is by the holder of the copyright of the respective chapters.
13106_Gall_BW.indd   2 22-01-16   15:11
 Learn from Translation 
Pulmonary hypertension: insights from population and patient studies
Lessen uit translationeel onderzoek
Pulmonale hypertensie: inzichten uit populatie- en patiëntgebonden onderzoek
Thesis
to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the
rector magnificus
Prof.dr. H.A.P. Pols
and in accordance with the decision of the Doctorate Board.
The public defence shall be held on
Friday, 19th of February 2016, at 9:30 hrs
by
Henning Gall born in Lünen, Germany
13106_Gall_BW.indd   3 22-01-16   15:11
Doctoral committee 
Supervisors:  Prof.dr. O.H. Franco
  Prof.dr. H.A. Ghofrani
Other members: Prof.dr. G.G.O. Brusselle
  Prof.dr. A. Vonk Noordegraaf
  Prof.dr. I.K.M. Reiss
Cosupervisor:  Dr. J.F. Felix
13106_Gall_BW.indd   4 22-01-16   15:11
Contents
Chapter 1  Introduction 7
Chapter 2.1  Prevalence of Pulmonary Hypertension in the General Population: 15
 the Rotterdam Study
Chapter 2.2  Left Ventricular and Left Atrial Echocardiographic Measures  31
 and Pulmonary Arterial Pressure in the General Population: 
 the Rotterdam Study
Chapter 3.1  The Giessen Pulmonary Hypertension Registry:  47
 Survival in Pulmonary Hypertension Subgroups
Chapter 3.2  New Potential Diagnostic Biomarkers for Pulmonary Hypertension 73
Chapter 3.3  HbA1c in Pulmonary Arterial Hypertension  87
 A Marker of Prognostic Relevance?
Chapter 4.1  Assessment and Prognostic Relevance of Right Ventricular  101
 Contractile Reserve in Patients with Severe Pulmonary 
 Hypertension 
Chapter 4.2  Sildenafil vs Nitric Oxide for Acute Vasodilator Testing  123
 in Pulmonary Arterial Hypertension
Chapter 4.3  Survival with Sildenafil and Inhaled Iloprost in a Cohort  143
 with Pulmonary Hypertension
Chapter 5 Discussion 159
 Summary
 Samenvatting




13106_Gall_BW.indd   5 22-01-16   15:11
13106_Gall_BW.indd   6 22-01-16   15:11
„Vom Ganzen über die Details zurück zum Ganzen.“ 
brought to me by my teacher Dr. Widar Lehnemann, modified from Goethe:
 „Willst du dich am Ganzen erquicken, so musst du das Ganze im Kleinsten erblicken.“
13106_Gall_BW.indd   7 22-01-16   15:11
13106_Gall_BW.indd   8 22-01-16   15:11
For my parents Ellinor and Helmut Gall
13106_Gall_BW.indd   9 22-01-16   15:11
13106_Gall_BW.indd   10 22-01-16   15:11
1 |
Introduction
13106_Gall_BW.indd   11 22-01-16   15:11




Pulmonary Hypertension at the population level
Pulmonary hypertension (PH) is a disease of the pulmonary vasculature, characterized 
by a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg measured by right heart 
catheterization (RHC).1
On the population level, aging combined with smoking and other unhealthy lifestyle 
habits leads to an increase in incidence of non-communicable diseases, including left 
heart disease and chronic obstructive pulmonary disease (COPD), two important diseases 
underlying PH.2 As a consequence, pulmonary hypertension might become more prevalent 
in the future, especially in the elderly. 
The prevalence of PH in the population is not known, and as patients suffer from 
unspecific symptoms, diagnosis is challenging and often delayed.3 The gold standard for 
diagnosing PH is RHC. However, RHC cannot be performed on a population basis because 
of its invasiveness and cost. Screening for PH in the general population may be done 
by means of echocardiography, as echocardiography can be used to estimate pulmonary 
artery systolic pressure (PASP).4,5 6  Besides the clinical extreme of PH, an increased PASP 
in the general population has been associated with poor health outcomes, such as an 
increased mortality.7 Even though the extreme fully developed PH is rare, an increase 
in pressure within the normal spectrum may have consequences at the population level.
Existing evidence from epidemiological studies and patient registries does not yet enable 
us to describe the missing link between factors that predispose to the development of 
PH and the actual disease. In this thesis we combine insights from population-based 
studies and registry data from a PH-referral clinic to address research questions about 
the prevalence and associated factors in the general population, as well as diagnosis, 
prognosis, and treatment of patients with PH.
Pulmonary Hypertension risk factors and etiology
PH is a heterogeneous phenotype. Various subgroups of PH can be distinguished based 
on underlying etiology, and adequate treatment will depend on the subgroup. After a 
diagnosis of PH, a diagnostic algorithm is initiated to determine the etiologic group of 
PH for each individual patient. A detailed list of etiologic groups is shown in Table 1.8 
The overall reported prevalences of the etiologic groups vary substantially between PH 
registries.9 Only a small proportion of PH patients are classified as having pulmonary 
arterial hypertension (PAH, group I). An etiologic classification is important to optimize 
treatment for individual patients, but also to identify groups of persons at risk of developing 
PH. Risk factors for PH include several non-communicable diseases such as COPD, left 
ventricular dysfunction, liver cirrhosis, and infectious diseases such as Schistosomiasis 
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and HIV.8 Genetic characteristics may also pre-dispose to or protect from pulmonary 
vascular disease. 10
 Table 1 Etiologic classification for pulmonary hypertension, according to the world symposium on 
pulmonary hypertension in Nice 2013
1. Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic PAH
1.2 Hereditable PAH: BMPR2,ALK1, ENG, SMAD9, CAV1, KCNK3, unknown
1.3 Drugs and toxins induced PAH
1.4 PAH associated with: Connective tissue diseases, HIV infection, Portal hypertension, Con-
genital heart disease, Schistosomiasis
        1´ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
        1´´ Persistent pulmonary hypertension of the newborn




2.4 Congenital /acquired left heart inﬂow/outﬂow tract obstruction and congenital cardiomy-
opathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other lung disease with mixed obstructive and restrictive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4. Chronic Thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary Hypertension with unclear and/or multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenecto-
my
5.2 Systemic disorders: Sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: Glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
BMPR2=bone morphogenic protein receptor type II; CAV1=caveolin-1; ALK1= activin-like receptor kinase-1; 
ENG=endoglin; HIV=human immunodeficiency virus; SMAD9= decapentaplegic 9; KCNK3= potassium channel super 
family K member-3 8




Pulmonary hypertension diagnosis, treatment and prognosis
PH patient registries, which collect demographic, medical, and treatment data, have 
helped to improve understanding of many aspects of the disease, especially diagnosis, 
prognosis, and treatment. 11 Globally, there are a few well-established registries, with 
some focusing on the full spectrum of patients with PH, and others with a more specific 
focus on a particular subgroup, such as PAH or chronic thromboembolic PH (CETPH). 9,12–14 
In Germany there is only one single center registry in Giessen. Other PH centers take part 
in multi-center and multi-national registries such as the Compera registry. 15 The registry 
in Giessen is the largest single center registry worldwide that has included all patients 
with PH, irrespective of their etiological group. Additionally, patient data are linked to 
a large biobank which contains blood samples from each patient taken at the time of 
diagnosis and throughout the course of the disease. This large data source provides a 
unique opportunity and resource to identify new diagnostic and prognostic tools that may 
lead to a better understanding of the disease. 16–18 Response to treatment can be studied 
in different etiological groups and modern read out techniques can be applied to identify 
possible targets for future treatment.
Given the complexity of diagnosing PH, not all patients who are referred with suspected 
PH will be diagnosed with the disease. 4 To date, no minimally invasive, low cost, and 
highly accurate diagnostic test is available to exclude or prove PH. The gold standard for 
the diagnosis of PH is RHC. 19 Having a more practical diagnostic marker would facilitate 
the diagnosis of PH and could lower the associated risks. As the Giessen registry contains 
all patients referred to the Giessen University Hospital with suspected PH who underwent 
RHC for exclusion of PH, this is an excellent setting to study the value of novel and 
alternative diagnostic tests.
Despite the availability of several treatment options, the prognosis for patients who have 
PH is still poor.20 Patients with PH tend to suffer from progressive right heart failure and 
die soon after diagnosis.21 The 1-, 3-, and 5-year survival rates for patients with PAH are 79-
87%, 51-71%, and 48-58%, respectively. 9 Prognostic research has identified several factors 
associated with clinical worsening or mortality, including hemodynamic measurements, 
exercise tests results, echocardiographic parameters, and biomarkers, such as changes in 
glucose metabolism.22 Such changes are well-documented in patients with PAH.23 However, 
no association of glucose metabolism with survival has been established, sp it remains 
unclear if markers of glucose metabolism may be used in prognostication of patients with 
PH.24 
After establishing the diagnosis, treatment should be targeted to the individual patient to 
improve efficacy and prognosis. Therapeutic options include general measures, supportive 
therapy, and specific treatment based on the underlying etiology. While an operation for 
desobliteration of the pulmonary arteries may be curative in selected patients, especially 
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those with chronic-thromboembolic pulmonary hypertension (CTEPH), medical treatment 
is generally the best option for most patients.25 
The available drugs for the treatment of PH can be divided into four groups according to 
their mechanism of action: endothelin receptor antagonists (ERAs), phosphodiesterase 
type 5 inhibitors (PDE5i) and soluble guanylate cyclase (sGC) stimulators in the nitric 
oxide (NO) pathway, prostacyclin, and tyrosine kinase inhibitors.26 Most of these available 
drugs that may be used to treat PH are approved for treatment of PAH only. Patients 
with PH of other etiologies do not have equivalent pharmacological options. Personalized 
treatment and combination therapy are two important aspects in the management of PH 
patients remain major challenges for patients, clinicians, and researchers.
Aims and outline of this thesis
This thesis will focus on PH from complementary perspectives with the overall aim of 
providing a comprehensive view of PH at the population and clinical level. The ultimate 
aim is to provide valuable information about the etiology, diagnosis, treatment, prognosis 
and population burden of the disease. In chapter 2 PH is investigated from a population 
perspective. Chapter 2.1 gives insight into the prevalence and associated factors of PH in 
the Rotterdam Study, a large population-based cohort study. The association of left heart 
parameters and pulmonary artery pressure is evaluated in the same population in chapter 
2.2. Chapter 3 changes the perspective to that of the patient registry. In chapter 3.1 
the Giessen PH registry is introduced and predictors of mortality are described. Chapter 
3.2 presents two new potential diagnostic biomarkers for PH, sFlt-1 and PlGF, studied in 
the Giessen PH registry. The prognostic implications of markers of glucose metabolism in 
patients with PH are presented in chapter 3.3. In chapter 4 clinical and therapeutical 
aspects are discussed. In chapter 4.1 the right ventricular contractile reserve is presented 
including its prognostic relevance. Chapter 4.2 compares sildenafil with inhaled nitric 
oxide for acute vasodilator testing in PAH patients. Chapter 4.3 gives insight into survival 
with sildenafil and inhaled iloprost in a cohort of patients with pulmonary hypertension. 
Finally, chapter 5 is a general discussion and conclusion.
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Prevalence of Pulmonary Hypertension 
in the General Population: 
the Rotterdam Study
Eduardo M Moreira, Henning Gall, Maarten JG Leening, Lies Lahousse, 
Daan W Loth, Bouwe P Krijthe, Jessica C Kiefte-de Jong1, Guy G Brusselle, 
Albert Hofman, Bruno H Stricker, Hossein A Ghofrani, Oscar H Franco, Janine F Felix




Background: Pulmonary hypertension is characterized by increased pulmonary artery 
pressure and carries an increased mortality. Population-based studies into pulmonary 
hypertension are scarce and little is known about its prevalence in the general population. 
We aimed to describe the distribution of echocardiographically-assessed pulmonary 
artery systolic pressure (ePASP) in the general population, to estimate the prevalence of 
pulmonary hypertension, and to identify associated factors. 
Methods: Participants (n=3381, mean age 76.4 years, 59% women) from the Rotterdam 
Study, a population-based cohort, underwent echocardiography. Echocardiographic 
pulmonary hypertension was defined as ePASP>40 mmHg. 
Results: Mean ePASP was 26.3 mmHg (SD 7.0). Prevalence of echocardiographic pulmonary 
hypertension was 2.6% (95%CI: 2.0; 3.2). Prevalence was higher in older participants 
compared to younger ones (8.3% in those over 85 years versus 0.8% in those between 65 
and 70), and in those with underlying disorders versus those without (5.9% in subjects with 
COPD versus 2.3%; 9.2% in those with left ventricular systolic dysfunction versus 2.3%; 
23.1% in stages 3 or 4 left ventricular diastolic dysfunction versus 1.9% in normal or stage 
1). Factors independently associated with higher ePASP were older age, higher BMI, left 
ventricular diastolic dysfunction, COPD and systemic hypertension. 
Conclusion: In this large population-based study, we show that pulmonary hypertension 
as measured by echocardiography has a low prevalence in the overall general population 
in the Netherlands, but estimates may be higher in specific subgroups, especially in 
those with underlying diseases. Increased pulmonary arterial pressure is likely to gain 
importance in the near future due to population aging and the accompanying prevalences 
of underlying disorders.
Key words: Hypertension, pulmonary; Echocardiography; Epidemiology; Population. 
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Introduction
Pulmonary hypertension (PH) is a severe disorder defined by a mean pulmonary artery 
pressure of ≥ 25 mmHg at rest [1-4]. Pulmonary hypertension can occur as an isolated 
disease or as a consequence of a number of underlying diseases and conditions, such as 
heart failure and chronic obstructive pulmonary disease (COPD) [4-11]. Although higher 
levels of pulmonary pressure have been associated with increased mortality both in 
patients and in the general populations, general population prevalence estimates are 
scarce [7, 10, 12-15]. 
The diagnostic method of choice for PH is right-heart catheterization [1]. However, its 
invasive nature renders it unsuitable in population-based studies. Transthoracic Doppler 
echocardiography is a non-invasive tool used in clinical practice for screening and 
monitoring of PH progression. Although some studies describe under- or overestimation of 
pulmonary arterial pressures by echocardiography, a meta-analysis has shown it to have good 
sensitivity (83%), reasonable specificity (72%) and a correlation 0.7 with invasively acquired 
measurements [16, 17]. Most deviations from measurements by right heart catheterization 
seem to occur in patients with very high pressure estimates [18]. In echocardiograms, 
the pulmonary artery systolic pressure is the most frequently used parameter. 
We aimed to describe the distribution of echocardiographic pulmonary artery systolic 
pressure (ePASP) and to estimate the prevalence of pulmonary hypertension measured 
by echocardiography (ePH) in the general population. Furthermore, we sought to identify 
factors independently associated with ePASP.
Material and methods
Setting
This study was embedded in the Rotterdam Study, an ongoing population-based, 
prospective cohort study, which started in 1990-1993 in a suburb of Rotterdam, the 
Netherlands. The design and rationale has been described in detail elsewhere [19]. 
Brieﬂy, the original subcohort (RS-I) enrolled 7983 participants aged 55 years or older. 
Two additional subcohorts (RS-II, n = 3011 participants of 55 years and older; and RS-III, 
n = 3768 participants of 45 years and older) were recruited into the study in 2000-2001 and 
2006-2008, respectively. Every 3-4 years the participants are invited for re-examination. 
Information routinely collected includes anthropometry, cardiovascular risk factors, 
medication use, and extensive functional and imaging tests [19]. Left- and right-sided 
echocardiographic measurements are available only for the most recent follow-up round 
of RS-I (fifth follow-up) and RS-II (third follow-up) (from 2009 to 2012). Participants from 
those two subcohorts who visited the research centre were eligible for this study.
13106_Gall_BW.indd   21 22-01-16   15:11
Chapter 2.1
22
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing 
the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All 
participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians.
Echocardiography
Three trained echocardiographers obtained resting transthoracic echocardiograms in all 
participants visiting the research center. The standardized protocol included 2-dimensional 
scanning in the parasternal long and short axis views, apical and subcostal views. In 
addition, left ventricular dimensions were measured using 2-dimension guided M-mode. 
Tricuspid regurgitation peak velocity (TRV) was measured using Continuous Wave Doppler. 
Tissue Doppler imaging was done in the apical 4-chamber view. 
Echocardiograms were made using a commercially available ultrasonography system (Vivid 
I, GE Healthcare, Little Chalfont, UK), with a 2.5 MHz transducer. All images obtained were 
digitally stored and assessed ofﬂine by the echocardiographers. Abnormal findings were 
confirmed by clinical experts and communicated to the participants and their general 
practitioners according to a pre-defined protocol.
Pulmonary Artery Systolic Pressure
Pulmonary artery systolic pressure was calculated as the sum of the estimated right 
atrial pressure (RAP) and the pressure gradient over the tricuspid valve [20] as: ePASP 
= 4*TRV2 + RAP. The pressure gradient was computed from the highest Doppler tricuspid 
regurgitation velocity gathered from several windows using the simplified Bernoulli 
equation (4*TRV2) [20]. RAP was estimated according to the guidelines of the American 
Society of Echocardiography: if the inferior vena cava diameter was ≤ 21 mm and its 
forced inspiratory collapse (“sniff test”) was > 50%, RAP was estimated to be 3 mmHg; 
if the diameter was > 21 mm and the collapse < 50%, RAP was estimated as 15 mmHg; in 
intermediate cases, a value of 8 mmHg was assigned[20].
Participants were deemed to have ePH if they had ePASP > 40 mmHg[2, 20, 21]. If data on 
RAP was missing, a tricuspid pressure gradient > 36 mmHg (TRV > 3.0 m/s) criterion was 
used instead. Participants in whom TRV was too small to measure or absent were included 
in the prevalence analyses as non-cases, as we they were most likely to have normal 
pulmonary pressures.
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Left ventricular function
As ejection fraction was not available in our cohort, we assessed left ventricular (LV) 
function through LV fractional shortening. LV fractional shortening (%) at the endocardium 
was calculated by: (LV end-diastolic diameter - LV end-systolic diameter) / LV end-diastolic 
diameter * 100% [22]. LV systolic dysfunction was defined as a LV fractional shortening 
< 29% [23]. 
Pulsed Doppler recordings of transmitral filling velocities were obtained in the apical 
4-chamber view, with the sample volume placed in the mitral valve orifice near the tips 
of the leaﬂets. Doppler peak E and peak A velocities were averaged over three cycles. 
Early mitral valve velocity deceleration time was measured as the time between the peak 
E wave and the upper deceleration slope extrapolated to the zero baseline. The E/E’ 
ratio was calculated by dividing E-top velocity by early diastolic longitudinal velocity 
of the septal mitral annulus E’-top. LV diastolic function was categorized in line with 
previous publications [24, 25], using an algorithm which takes into account E/A ratio, 
E/E’ ratio and E’, dividing participants into 3 categories of diastolic function: normal or 
relaxation abnormality (stage 1), pseudonormal (stage 2), and restrictive (including both 
reversible [stage 3] and fixed [stage 4] LV diastolic dysfunction). For participants with 
atrial fibrillation, the categorization was based on mitral valve inﬂow deceleration time 
instead of the E/A ratio [24, 25].
Other covariates
Anthropometric and laboratory measurements were assessed in a standardized manner 
during the same visit as the echocardiography. Body mass index (BMI) was calculated as 
weight (kg) / height squared (m2). Systemic hypertension was defined as blood pressure ≥ 
140/90 mmHg or use of anti-hypertensive medication (Anatomical Therapeutic Chemical 
[ATC] codes C02, C03, C07, C08 and C09). Blood pressure was averaged between two 
measurements, taken with the participant in sitting position. Diabetes mellitus was 
defined as either fasting glucose level > 7.0 mmol/L, or a non-fasting glucose level > 11.0 
mmol/L (if fasting serum was unavailable) or use of anti-diabetic medication (ATC code 
A10) [26, 27]. Smokers were classified into never, former and current smokers. COPD was 
diagnosed by an obstructive spirometry (proportion of the forced vital capacity exhaled 
in the first second [FEV1/FVC] < 70%) at the research centre or by a pulmonologist or 
general practitioner. Participants with a spirometry suggestive of a restrictive syndrome 
and asthma patients were not considered to have COPD.




We also estimated ePH prevalence using 2 alternative definitions. The first one included 
those with a dilated right-ventricle (basal right ventricular end-diastolic diameter > 42 
mm) in addition to those with ePASP > 40 mmHg[20]. This was done to take into account 
variables suggestive of PH beyond ePASP, as recommended by the European Society of 
Cardiology [1]. The second definition used a more stringent ePASP threshold of 50 mmHg 
or a tricuspid pressure gradient of 46 mmHg (TRV > 3.4 m/s) instead of the 40 mmHg cut-
off [1], without taking right ventricular diameter into account. 
Statistical analyses
Prevalence estimates with confidence intervals (Wald) of ePH were calculated for the full 
population and for subgroups defined by age, sex, smoking status, BMI, and presence of LV 
systolic dysfunction, LV diastolic dysfunction, COPD, systemic hypertension and diabetes 
mellitus. 
To identify factors associated with ePASP, we created 2 linear regression models. In model 
A, each factor was adjusted for age and sex. Model B was a multivariate model in which 
all variables that were significant in model A were entered simultaneously.
Missing data (maximum proportion of missing values per covariate: 6%) was imputed with 
a multiple imputation procedure (5 imputations) using the Markov Chain Monte Carlo 
method. TRV, RAP and right ventricular end-diastolic diameter were used as predictors 
in the imputation model, but were not imputed. Missing data on smoking and COPD was 
dealt with using the last observation carried forward method. 
We used Stata version 12 (StataCorp. College Station, TX, U.S.) and IBM SPSS Statistics 
version 20.0 (IBM Corp. Armonk, NY, U.S.) for the statistical analysis.
Results
The response-rate for the analysed rounds of examination was 63.4% for RS-I and 75.1% 
for RS-II, yielding a total of 3381 participants eligible for the study. Of those, we excluded 
558 (16.5%) due to the fact that no data on the tricuspid regurgitation jet were recorded. 
The excluded population was younger, with a higher proportion of men, diabetics and 
current or past smokers, had better ventricular diastolic and lower systolic function and 
a higher BMI (table 1). The final study population was composed of 2823 participants with 
a mean age of 76.4 years (SD 6.2), 59% women, 10.4% had COPD and 3.5% had LV diastolic 
dysfunction stages 3 or 4 (table 1). 
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Table 1. Participant characteristics
Study population (n = 2823) Excluded population (n = 558)
n Mean (SD) or % n Mean (SD) or % p
Age, years 2823 76.4 (6.2) 558 74.7 (5.8) <0.001
Women 2823 59% 558 53% 0.01
Body mass index, kg/m2 2811 27.2 (4.0) 548 29.3 (4.7) <0.001
Smoking 2823 558 0.004
  Never 997 35.3% 158 28.3%
  Former 1566 55.5% 336 60.2%
  Current 260 9.2% 64 11.5%
TRV, m/s 2153 2.3 (0.3) NA NA
RAP, mmHg 2473 3.9 (2.2) 368 3.7 (1.8) 0.02
ePASP, mmHg 1945 26.3 (7.0) NA NA
RVEDD, mm 2558 33.0 (4.4) 380 32.7 (4.1) 0.16
FS, % 2788 41.1 (5.9) 497 40.4 (6.3) 0.01
LV systolic dysfunction 2788 4.2% 497 4.0% 0.89
LV diastolic dysfunction 2790 510 0.002
  Normal and stage 1 1716 61.5% 353 69.2%
  Stage 2 977 35.0% 147 28.8%
  Stages 3 and 4 97 3.5% 10 2.0%
COPD 2823 10.4% 558 9.7% 0.60
Diabetes mellitus 2706 12.8% 519 21.8% <0.001
Systemic hypertension 2773 87.1% 545 89.7% 0.08
TRV = tricuspid regurgitation peak velocity; RAP = right atrial pressure; ePASP = pulmonary artery systolic pressure; 
RVEDD = right ventricular end-diastolic diameter; FS = left ventricular fractional shortening; LV = left ventricle; 
COPD = chronic obstructive pulmonary disease. 
Prevalence of ePH
The overall prevalence of ePH in our study was 2.6% (95%CI 2.0; 3.2). Older participants, 
and those with COPD, LV systolic or diastolic dysfunction had a significantly higher 
prevalence of ePH than their counterparts (table 2).
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Table 2. Prevalence of echocardiographic pulmonary hypertension, overall and in subgroups
ePH prevalence (95% CI) p
Overall 2.6% (2.0; 3.2)
Sex Women 2.6% (1.8; 3.4) 0.93
Men 2.7% (1.7; 3.6)
Age 65 to 70 years 0.8% (0.02; 1.6) <0.001
70 to 75 years 1.6% (0.7; 2.5)
75 to 80 years 1.8% (0.9; 2.8)
80 to 85 years 4.1% (2.4; 5.9)
85 years or older 8.3% (5.0; 11.6)
Smoking Never 2.7% (1.7; 3.7) 0.32
Former 2.8% (2.0; 3.6)
Current 1.2% (0.0; 2.5)
Body mass index < 25 kg/m2 2.4% (1.4; 3.4) 0.66
≥ 25 kg/m2 2.7% (2.0; 3.4)
COPD Yes 5.9% (3.1; 8.5) 0.001
No 2.3% (1.7; 2.8)
Systemic hypertension Yes 2.8% (2.1; 3.5) 0.15
No 1.4% (0.2; 2.7)
Diabetes mellitus Yes 4.1% (2.0; 6.2) 0.07
No 2.4% (1.8; 3.0)
LV systolic dysfunction Yes 9.2% (4.0; 14.4) < 0.001
No 2.3% (1.8; 2.9)
LV diastolic dysfunction Normal or stage 1 1.9% (1.2; 2.5) < 0.001
Stage 2 2.8% (1.7; 3.8)
Stages 3 and 4 23.1% (11.3; 34.9)
COPD = chronic obstructive pulmonary disease; LV = left ventricle; ePH = pulmonary hypertension.
An enlarged right ventricle was strongly associated with higher ePASP, even after 
adjustments for age, sex and BMI (p < 0.001). Sensitivity analyses accounting for it (that 
is, using a definition of ePH based on either an ePASP of > 40 mmHg or a right ventricular 
end-diastolic dimension > 42 mm) yielded an overall prevalence of 4.5% (95%CI 3.7; 5.2) 
with a significantly higher prevalence in men than women (6.2% vs 3.2%, p < 0.001; table 
3). A more stringent ePASP threshold of 50 mmHg, regardless of RV size, yielded an overall 
prevalence of 0.5% (95%CI: 0.2; 0.8), and no sex difference (p = 0.91).
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Table 3. Prevalence of echocardiographic-defined pulmonary hypertension, alternative diagnostic 
criteria
Diagnostic criteria
ePASP > 40 mmHg ePASP > 40 mmHg or right ventricle > 42 mm ePASP > 50 mmHg
(n = 2823) p (n = 2828) p (n = 2823) p
Overall 2.6% (2.0; 3.2) 4.5% (3.7; 5.2) 0.5% (0.2; 0.8)
Women 2.6% (1.8; 3.4) 0.93 3.2% (2.4; 4.0) <0.001 0.5% (0.1; 0.9) 0.91
Men 2.7% (1.7; 3.6) 6.2% (4.7; 7.6) 0.5% (0.2; 0.8)
Data are shown as prevalences (95% confidence interval) 
RAP = right atrial pressure; TRV = tricuspid regurgitation velocity; ePASP = pulmonary artery systolic pressure, 
calculated as 4*TRV2 + RAP. If RAP could not be estimated, the case definition was based on TRV > 3.0 m/s and 3.4 
m/s to correspond to ePASP > 40 mmHg and 50 mmHg, respectively
Participants with absent or too-small-to-measure TRV were included as non-cases.
Factors independently associated with ePASP
In 208 participants, data on right atrial pressure were missing and in 670 participants, 
we could not measure tricuspid regurgitation velocity because the regurgitation jet was 
either absent or too small to measure. Hence, ePASP could only be estimated in 1945 of 
the 2823 participants. In those, mean ePASP was 26.3 mmHg (SD 7.0) and the median 
was 25.3 mmHg (inter-quartile range 21.5; 29.8). It followed a slightly right-skewed 
distribution (Fig. 1).
Figure 1. Distribution of pulmonary artery systolic pressure in 1945 participants in whom it could be 
estimated
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In the fully adjusted model, a 10-year increase in age was associated with a 2.2 mmHg 
(95%CI 1.8; 2.7) higher ePASP. A 5 kg/m2 increase in BMI was associated with a 0.7 mmHg 
(95%CI 0.3; 1.1) pressure increment (table 4). In comparison with participants with normal 
LV diastolic function or stage 1 LV diastolic dysfunction, participants with LV diastolic 
dysfunction stages 3 or 4 had higher ePASP estimates (7.1 mmHg change, 95%CI 5.0; 9.1). 
Sex, LV fractional shortening and diabetes mellitus were significantly associated with 
ePASP in model A, adjusting for age and sex, but were not after further adjustments. 
Systemic hypertension was significantly associated with higher ePASP even after adjusting 
for other factors (1.3 mmHg change; 95%CI 0.4; 2.1).
Table 4. Associations with pulmonary artery systolic pressure in linear regression models in 1945 
participants in whom ePASP could be estimated
Model A Model B
Change in ePASP, mmHg Change in ePASP, mmHg
(95%CI) p (95%CI) p
Age, per 10 years 2.6 (2.1; 3.1) <0.001 2.2 (1.8; 2.7) <0.001
Women -0.7 (-1.3; -0.1) 0.03 -0.6 (-1.2; 0.004) 0.05
Body mass index, per 5 kg/m2 0.8 (0.4; 1.1) <0.001 0.7 (0.3; 1.1) 0.001
Smoking 0.67
  Never Reference
  Former -0.3 (-1.0; 0.4)
  Current -0.2 (-1.4; 0.9)
LV fractional shortening, per 10% -1.0 (-1.5; -0.5) <0.001 -0.5 (-1.0; 0.06) 0.09
LV diastolic dysfunction <0.001 <0.001
  Normal and stage 1 Reference Reference
  Stage 2 1.1 (0.5; 1.7) 1.1 (0.4; 1.7)
  Stages 3 and 4 7.8 (5.7; 9.8) 7.1 (5.0; 9.1)
COPD 2.3 (1.3; 3.3) <0.001 2.4 (1.4; 3.4) <0.001
Diabetes mellitus 1.0 (0.003; 2.0) 0.05 0.3 (-0.7; 1.3) 0.56
Systemic hypertension 1.8 (0.9; 2.7) <0.001 1.3 (0.4; 2.1) 0.01
Dependent variable is ePASP (mmHg).
LV = left ventricular; COPD = chronic obstructive pulmonary disease; 95%CI = 95% confidence interval.
In model A, each variable is adjusted for age and sex.
In model B, adjustments were made for all the variables which had p < 0.05 in model A.
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Discussion
Overall, we found that pulmonary hypertension as assessed by echocardiography has a 
prevalence of 2.6% in the general population in the Netherlands. The prevalence of ePH 
was higher in older persons, and in those with COPD, LV systolic or diastolic dysfunction. 
Factors independently associated with higher ePASP in a multivariate model were older 
age, higher BMI, left ventricular diastolic dysfunction, COPD and systemic hypertension.
Prevalence of ePH
Increased levels of pulmonary pressure has been associated with increased all-cause 
mortality in the general population, as well as increased admission rates in heart failure 
patients [15, 28]. Yet, data on the prevalence of increased ePASP in the general population 
is scarce [29]. Given the population aging and the known association of PH with heart and 
lung diseases, an increasing PH prevalence could be expected [29].  The prevalence of 
ePASP > 40 mmHg has recently been estimated to be 8% in healthy volunteers aged > 50 
years in Italy and ePH was found in 6.8% of participants in an African-American population 
[30, 31].  A study in Armadale reported a prevalence of 9.1%[21]. However, this estimate 
may be inﬂated, as the study included participants referred for echocardiography, likely 
representing a population with increased risk as compared to the general population. 
Still, our estimates are low, considering that the populations in the other studies were 
likely to be as healthy or healthier than ours based on age and comorbidities [30, 31]. Our 
case-definition method (that is, including those with absent or unmeasurable TRV as non-
cases, instead of excluding them) may have led to conservative estimates. Removal of 
those participants from the analyses, hence basing the definition of ePH on ePASP or TRV 
(in those without RAP) measurements only, yields a 3.4% prevalence estimate. Additional 
exclusion of participants without an RAP estimate, thus basing the cases only on ePASP, 
yields a prevalence of 3.6%, still leaving part of the difference unexplained.
The prevalence of pulmonary hypertension in patients with COPD has been reported to 
be as high as 47-49% in clinical studies [6, 7]. Such difference from our estimates (5.9%) 
may be explained by differences in study populations (patient cohorts versus general 
population) [6, 7]. Our population likely does not include the most severe cases of COPD, 
as they may have been unable to visit the research centre.
Since the European Society of Cardiology suggests the inclusion of “additional 
echocardiographic variables suggestive of PH” in the echocardiographic assessment of PH, 
secondary analyses were done with an additional criterion (dilated right ventricle) [1]. 
This increased prevalence estimates to 4.5% with a significant difference between men 
and women (6.2% versus 3.2%, p < 0.001). The overall larger size of the right ventricle in 
men probably underlies this difference. We also performed analyses with a more stringent 
threshold of 50 mmHg, which yielded a prevalence of 0.5% and no sex-related differences.
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ePASP and associated factors
Our ePASP estimates (median 25.3 mmHg and mean 26.3 mmHg) were similar to values 
reported in three previously published studies, even though the other population were 
younger and overall healthier [15, 30, 32]. As ePASP is known to increase with older age, 
we had expected a greater difference [6, 15, 30, 33]. Patterns of age-related ePASP 
increase may be variable across generations and locations, therefore longitudinal studies 
would serve well in elucidating the trajectories of pulmonary pressures across the life 
course [15, 30, 33].
We did not find sex-related differences in the prevalence of ePH, and sex was not 
independently associated with ePASP. Previous literature is divided on this point, as some 
studies have found differences and others have not [6, 7, 15, 31, 33].
LV fractional shortening was not found to be independently associated with ePASP, despite 
our finding of a significantly higher ePH prevalence in those with LV systolic dysfunction 
(9.2% versus 2.3%, p < 0.001). Others also could not demonstrate consistent associations 
between ejection fraction and ePASP[10, 15]. Instead, literature suggests that ePASP is 
more associated with LV diastolic function, as we also demonstrated[10].
Strengths of this study are the large sample size and the population-based nature. 
Other strong points are a structured and standardized echocardiographic assessment 
and the availability of large number of covariates. One of the limitations is the lack 
of the diagnostic gold standard for PH, right heart catheterization[1, 2]. Right heart 
catheterization is unsuitable for a general-population setting because of its invasive 
nature. Echocardiography is frequently used as the first step in PH evaluation[2]. Although 
echocardiographic estimates of pulmonary arterial pressure may over or underestimate 
invasive measurements, they deviate most at the very high end of the pulmonary arterial 
pressure spectrum, particularly in poor quality exams [34]. In this study, the vast majority 
of the population have normal pulmonary pressures and only 2% of the exams were deemed 
of poor quality. Furthermore, echocardiography has a sensitivity of 83%, a specificity of 
72%, and a correlation of 0.7 with invasively acquired estimates [16, 17]. Thus, although 
echocardiography should not be used for clinical diagnosis of PH, it is arguably one of the 
best exams available for epidemiologic research. We only had ePASP estimates for 57% 
of the cohort, but we were able to include 83% of it in the ePH prevalence analyses. In 
comparison, a similar study reported that 69% of their participants had analyzable jets 
[15]. Lastly, our population is elderly and predominantly white, so caution should be 
taken to generalize it to other age groups and ethnicities.
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Conclusions
Pulmonary hypertension as measured by echocardiography has low prevalence in the 
overall general population in the Netherlands, but estimates may be higher in specific 
subgroups, especially in those with left ventricular dysfunction or COPD. BMI and systemic 
hypertension were associated with ePASP independently of heart or lung disease.
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Background: The relation between left heart parameters and pulmonary arterial 
pressures has rarely been studied in the general population. Our objective was to study 
the associations of left heart parameters with pulmonary artery systolic pressure in a 
large population-based study.
Methods: This study was conducted within the population-based Rotterdam Study. In 2592 
participants with a mean age of 72.6 years (61.4% women), we studied associations of left 
heart structure and systolic and diastolic function with echocardiographically measured 
pulmonary artery systolic pressure (ePASP). 
Results: ePASP was associated with E/A ratio (ePASP (95% CI) per 1-SD increase: 0.96 (0.71, 
1.21) mmHg), left atrial diameter (ePASP per 1-SD increase: 0.77 (0.48, 1.07) mmHg), 
E/E’ ratio (ePASP per 1-SD increase: 0.65 (0.39, 0.92) mmHg), and left ventricular volume 
(ePASP per 1-SD increase: 0.57 (0.21, 0.94) mmHg), fractional shortening (ePASP per 1-SD 
increase: 0.49 (0.21, 0.77) mmHg), aortic root diameter (ePASP per 1-SD increase: -0.52 
(-0.81, -0.24) mmHg), and mitral valve deceleration time (ePASP per 1-SD increase: -0.34 
(-0.60, -0.08) mmHg). Results did not materially differ when restricting the analyses to 
participants free of shortness of breath symptoms. 
Conclusion: Structural and functional left heart echocardiographic parameters in the 
normal range are associated with pulmonary arterial pressure in the general population.
Keywords: Echocardiography; pulmonary artery systolic pressure; pulmonary hypertension; 
epidemiology; population-based
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Introduction
Pulmonary hypertension (PH) can occur idiopathically or, most frequently, in association 
with a number of common clinical conditions, including left ventricular dysfunction and 
chronic obstructive pulmonary disease  1, 2. PH represents the extreme form of increased 
pulmonary artery systolic pressure (PASP). Both PH and increased PASP within the normal 
range are associated with significant morbidity and mortality, both in patients with 
underlying disorders and in the general population 1-3. However, increased PASP often 
remains undetected until it is in an advanced stage, most likely due to its nonspecific 
symptoms, such as shortness of breath and fatigue1-4.
Left ventricular failure represents a severe clinical phenotype on the extreme end of a 
continuum of left ventricular function. Data on the associations of left heart parameters 
within the normal range with pulmonary artery pressure in the general ageing population 
are scarce and not much is known about the increase in PASP related to subclinical 
abnormalities in structure and function of the left-sided heart 2, 5, 6. 
Therefore, we aimed to determine the associations of echocardiographically measured 
left heart parameters across the full spectrum with PASP in the general population. 
Material and methods
Study Population and Setting
This study was conducted within the Rotterdam Study, an ongoing prospective population-
based cohort study in the city of Rotterdam, the Netherlands. The rationale and design of 
the Rotterdam Study have been described in detail elsewhere 7, 8. In short, the Rotterdam 
Study started in 1990-1993 with a single cohort (RS-I, n=7983 participants of 55 years and 
older). Two additional cohorts (RS-II, n=3011 participants of 55 years and older, and RS-III, 
n=3932 participants of 45 years and older) were recruited in 2000-2001 and 2006-2008, 
respectively. 
Every 3-4 years, participants undergo a home interview and clinical examinations at the 
Rotterdam Study research center. All 4423 participants who visited the research center 
during the fifth examination of RS-I (2009-2011), the third examination of RS-II (2011-2012) 
and the second examination of RS-III (2012) were eligible for this analysis. We excluded 
participants who did not undergo echocardiography (mostly due to logistic reasons, such 
as non-availability of the echocardiographers or the ultrasound machine), those with poor 
quality of echocardiography, and those in whom tricuspid valve regurgitation values were 
too small to measure or missing, making it impossible to calculate ePASP. We also excluded 
participants without measurements of resting heart rate or body surface area (BSA), 
which were used as covariables. Our final analyses included 2592 participants (Figure 1). 
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The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Dutch Ministry of Health, Welfare and Sport, implementing the “Wet 
Bevolkings Onderzoek: ERGO (Population Screening Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information 
from their treating physicians.
 
Participants examined at the research 
center 
(n = 4423) 
Participants who underwent 
echocardiography 
(n = 4398) 
Participants with acceptable quality of 
echocardiography images 
(n = 4206) 
Excluded: poor image quality 
(n = 192) 
Participants with ePASP estimate 
(n = 2735) 
Excluded: tricuspid valve regurgitation 
observed but too small to quantify 
(n = 800) 
Analysis of all participants 
(n = 2592) 
Analysis of participants free of shortness 
of breath symptoms 
(n = 1711) 
Participants with information on tricuspid 
valve regurgitation 
(n = 3535) 
Excluded: missing and no tricuspid valve 
regurgitation  
(n = 671) 
Excluded: no echocardiography 
(n = 25) 
Excluded: missing values for heart rate 
and body surface area 
(n = 143) 
Participants with complete data 
(n = 2592) 
Figure 1. Flow chart of study participants
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Echocardiography
Resting transthoracic 2-dimensional echocardiography was performed by experienced 
echocardiographers, using an identical standardized protocol for all participants. 
Echocardiography was obtained using a commercially available ultrasonography system 
(Vivid I, GE Healthcare, Little Chalfont, UK), with a 2.5 MHz transducer. All images were 
digitally stored and assessed ofﬂine by the echocardiographers. 
Left-sided measurements were aortic root diameter (AoD), left atrial diameter (LAD), left 
ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), 
interventricular septum thickness (IVST), and left ventricular posterior wall thickness 
(LVPWT). Left ventricular mass (LVmass) in grams was calculated according to the formula 
by Devereux and colleagues as 0.8 * {1.04 * ([LVEDD + IVST + LVPWT]3 - LVEDD3)} + 0.6 
9. Left ventricular volume (LVvol) in milliliters was calculated according to the formula 
by Teichholz and colleagues as 7 * LVEDD3 / (2.4 + LVEDD) 10. Left ventricular fractional 
shortening (LVFS) was calculated using the formula: LVFS = (LVEDD-LVESD)/LVEDD * 100% 11. 
Pulsed wave Doppler was used to measure the early transmitral ventricular diastolic filling 
velocity (E wave) and late diastolic filling velocity (A wave) during 3 cardiac cycles. Tissue 
Doppler was used to measure the early diastolic longitudinal filling velocity of the septal 
mitral annulus (E’) during 3 cardiac cycles. The means of the E wave, A wave and E’ were 
calculated and used to calculate E/A ratio and E/E’ ratio. Mitral valve deceleration time 
was measured as the time between the peak E-top wave and the upper deceleration slope 
extrapolated to the zero baseline. 
Echocardiographically measured pulmonary artery systolic pressure (ePASP) was calculated 
as the sum of the estimated right atrial pressure (RAP, based on inferior vena cava 
diameter and forced inspiratory collapse) and the pressure gradient over the tricuspid 
valve. RAP was estimated according to the algorithm recommended by the ASE/EAE/
CSE 12: if the inferior vena cava diameter was ≤ 21 mm and its forced inspiratory collapse 
(“sniff test”) was > 50%, RAP was considered to be 3 mmHg; if the diameter was > 21 
mm and the collapse < 50%, RAP was considered as 15 mmHg; in intermediate cases, a 
value of 8 mmHg was assigned. Tricuspid regurgitation peak velocity (TRV) was measured 
using Continuous Wave Doppler. The tricuspid pressure gradient was estimated using the 
simplified Bernoulli formula 12: 4*TRV2 . Thus, ePASP was estimated as 4*TRV2 + RAP. All 232 
participants with measured TRV values but missing RAP were assigned a conservative RAP 
of 3 mmHg.




We collected information about shortness of breath during the home interview, which 
included the following question: “Do you ever have shortness of breath?”. If the answer 
was yes, the participant was asked “Do you have shortness of breath at rest?”. If the 
answer was no, the participant was asked “Do you have shortness of breath when walking 
on a ﬂat surface?”. If the answer was no, the participant was asked “Do you have shortness 
of breath when climbing stairs?”. If participants answered no to the first question, or if 
they answered yes to the first question but no to the other 3, they were classified as being 
free of significant shortness of breath. This is in line with the New York Heart Association 
(NYHA) validity class 1 13.
Covariables
Information routinely collected in every follow-up round of the Rotterdam Study 
includes anthropometrics, cardiovascular risk factors, and medication use. BSA in m2 was 
calculated as: BSA = 0.007184 * (height in cm)0.725 * (weight in kg)0.425 14. Resting heart 
rate was measured during blood pressure measurement using an Omron M7 pulse blood 
pressure monitoring device. Heart rate was measured twice with a time-interval of 5 
minutes between both measurements. The mean of the 2 measurements was used in the 
analyses. Medication use was coded according to the Anatomical Therapeutical Chemical 
coding system of the World Health Organization 15.
Data Analysis
We fitted basic multivariable linear regression models to study the association of ePASP 
as the dependent variable with each of the following independent echocardiographic 
variables separately: LAD, AoD, mitral valve deceleration time, IVST, LVPWT, LVmass, 
LVvol, LVEDD, left ventricular fractional shortening, E/A ratio, and E/E’ ratio. All basic 
models were adjusted for sex, age, resting heart rate, and BSA. We also fitted a large 
multivariable linear regression model with ePASP as the dependent variable and LAD, AoD, 
mitral valve deceleration time, LV mass, LVvol, left ventricular fractional shortening, E/A 
ratio, and E/E’ ratio, as well as sex, age, resting heart rate, and BSA. LVvol and LVmass 
are calculated based on the measured LVEDD, IVST, and LVPWT. Therefore, we chose to 
use the clinically more relevant measures of LVvolume and LVmass in the larger model 
instead of the underlying measurements. To calculate the percentage of variance in ePASP 
explained by the left-sided measurements, we used an F-test to compare a model which 
only included age, sex, resting heart rate, and BSA, with a model which additionally 
included LAD, AoD, mitral valve deceleration time, LVmass, LVvolume, left ventricular 
fractional shortening, E/A ratio and E/E’ ratio. We also analyzed the effect of clinical 
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categories of E/A ratio and E/E’ ratio instead of using the continuous measures. E/A ratio 
was divided into 3 categories: ≤ 0.75, > 0.75 and < 1.50, and ≥ 1.50. We divided E/E’ ratio 
also into 3 categories: ≤ 8, > 8 and < 15, and ≥ 1516. 
We tested for potential interaction between the echocardiographic variables and sex 
by adding multiplicative interaction terms to the regression models. The interaction 
terms were not significant after Bonferroni correction for multiple testing (P-value cutoff 
was 0.00625), thus we did not stratify by sex. To study whether our results were driven 
by symptomatic individuals we repeated the analysis in participants free of significant 
shortness of breath.
Effect estimates are presented as βs (both per 1-unit increase and per 1-standard 
deviation (SD) increase in the left-sided variable) with 95% confidence intervals (CIs). We 
considered P-values of < 0.05 statistically significant. All analyses were done using IBM 
SPSS Statistics version 21.0 (IBM Corp., Somers, NY, USA).
Results
Participant characteristics and echocardiographic measurements are presented in Table 1.
The mean age was 72.6 (SD 8.7) years and 61.4% of the participants were women. The 
mean ePASP was 25.4 (SD 6.7) mmHg.
In the basic model, all parameters studied were significantly related to ePASP, except for 
IVST. Table 2 and Figure 2a show the results per unit and per 1-SD increase, respectively. 
The variables with the strongest associations with ePASP were LAD, E/A ratio, E/E’ ratio, 
and LVvol.
In the large multivariable model, ePASP was associated with E/A ratio (ePASP (95% CI) per 
1-SD increase: 0.96 (0.71, 1.21) mmHg), left atrial diameter (ePASP per 1-SD increase: 
0.77 (0.48, 1.07) mmHg), E/E’ ratio (ePASP per 1-SD increase: 0.65 (0.39, 0.92) mmHg), 
and left ventricular volume (ePASP per 1-SD increase: 0.57 (0.21, 0.94) mmHg), fractional 
shortening (ePASP per 1-SD increase: 0.49 (0.21, 0.77) mmHg), aortic root diameter (ePASP 
per 1-SD increase: -0.52 (-0.81, -0.24) mmHg), and mitral valve deceleration time (ePASP 
per 1-SD increase: -0.34 (-0.60, -0.08) mmHg). Table 3 and Figure 3a show the results per 
1-unit and per 1-SD increase in measurements, respectively. The directions of effect for 
all associations remained the same as in the basic models (Table 2 and Figure 2a), except 
for LVFS, which was associated with a lower  ePASP in the basic model and with a higher 
ePASP in the large model. 
The echocardiographic parameters combined explained 8.7% of the variance in ePASP in 
addition to the variance explained by age, sex, resting heart rate and BSA, (p < 0.001).
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Table 1. Demographic, clinical and echocardiographic characteristics of included participants, n = 2592
 n measured Mean (SD) or n (%)
Age (years) 2592 72.6 (8.7)
Women 2592 1591 (61.4%)
Height (cm) 2592 167 (9)
Weight (kg) 2592 75.0 (13.4)
Body surface area (m2) 2592 1.83 (0.19)
Body mass index (kg/m2) 2592 26.9 (4.0)
Systolic blood pressure (mmHg) 2591 147 (22)
Diastolic blood pressure (mmHg) 2591 84 (11)
Resting heart rate (bpm) 2592 68 (11)
Chronic obstructive pulmonary disease 2592 267 (10.3%)
Atrial Fibrillation 2369 163 (6.9%)
Shortness of breath * 2337  
     Validity class 1 1711 (73.2%)
     Validity class 2 220 (9.4%)
Validity class 3 271 (11.6%) 
Validity class 4 135 (5.8%)
Smoking 2590  
Never 944 (36.4%)
     Former 1377 (53.2%)
Current 269 (10.4%)
Diabetes mellitus 2520 243 (9.6%)
Medication use **  2022  
    Blood pressure lowering drugs 1131 (55.9%)
         Diuretics 419 (20.7%)
     Potassium sparing agents 46 (2.3%)
     β-blockers 639 (31.6%)
     Calcium blockers 232 (11.5%)
     RAAS inhibitors 640 (31.7%)
     Other blood pressure lowering drugs 15 (0.7%)
Serum lipid reducing agents 617 (30.5%)
Echocardiography  2592  
Pulmonary arterial systolic pressure (mmHg) 2592 25.4 (6.7)
Left ventricular mass (g) 2575 130 (38)
Left ventricular volume (ml) 2582 126 (31)
Interventricular septum thickness (mm) 2578 8 (2)
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Table 1. Continued
 n measured Mean (SD) or n (%)
Left ventricular posterior wall thickness (mm) 2581 7 (1)
Diameter of left atrium (mm) 2586 42 (6)
Left ventricular fractional shortening (%) 2575 42 (6)
Left ventricular end-diastolic dimension (mm) 2582 51 (5)
Diameter of the aortic root (mm) 2586 34 (4)
E/A ratio 2457 0.93 (0.35)
     ≤ 0.75 2475 741 (29.9%)
     > 0.75, and < 1.50 2457 1636 (66.1%)
     ≥ 1.50 2475 98 (4.0%)
E/E’ ratio 2548 11.0 (4.8)
     ≤ 8 2548 620 (23.1%)
     > 8, and < 15 2548 1714 (63.8%)
     ≥ 15 2548 352 (13.1%)
 Mitral valve inﬂow deceleration-time, 2566 204 (42)
bpm: beats per minute; E/A ratio: E wave divided by A wave; E/E’ ratio: E wave divided by E’; HDL: high density 































Figure 2a. Basic model: Associations of individual left heart echocardiographic parameters with 
ePASP in the Rotterdam Study, n = 2592a,b 
a Number of participants for which we had at least information of one left heart echocardiographic parameter and ePASP
b Adjusted for age, sex, resting heart rate, and body surface area
LVmass: left ventricular mass; LVPWT: left ventricular posterior wall thickness; IVST: interventricular septum 
thickness; LVvol: left ventricular volume; LVEDD: left ventricular end-diastolic diameter; LAD: left atrial diameter; 
LVFS: left ventricular fractional shortening; AoD: aortic root diameter; E/A ratio: E wave divided by A wave; E/E’ 
ratio: E wave divided by E’
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Table 2. Basic model: associations of individual left heart echocardiographic parameters with ePASP 
in the Rotterdam Study
 Full study population, n = 2592 a, b
Restricted to free of 
shortness of breath,
 n = 1711 a, b
 
Difference in ePASP 
per 1-unit increase 
(95% CI)
p -value 
Difference in ePASP 
per 1-unit increase 
(95% CI)
p -value 
Left ventricular mass 
(per 10 grams) 0.23 (0.15 to 0.30) <0.001 0.19 (0.10 to 0.29) <0.001
Left ventricular volume 
(per 10 mL) 0.26 (0.27 to 0.35) <0.001 0.22 (0.11 to 0.34) <0.001
Left ventricular posterior wall 
thickness (mm) 0.28 (0.05 to 0.51) 0.016 0.28 (0.00 to 0.55) 0.048
Interventricular septum 
thickness (mm) 0.15 (-0.02 to 0.32) 0.078 0.12 (-0.09 to 0.32) 0.264
Diameter of left atrium (mm) 0.27 (0.22 to 0.31) <0.001 0.25 (0.19 to 0.30) <0.001
Left ventricular fractional 
shortening (%) -0.07 (-0.12 to -0.03) 0.002 -0.05 (-0.11 to 0.01) 0.102
Left ventricular end-diastolic 
dimension (mm) 0.14 (0.09 to 0.20) <0.001 0.13 (0.06 to 0.19) <0.001
Diameter of the aortic root (mm) -0.12 (-0.20 to -0.05) 0.001 -0.15 (-0.24 to -0.07) 0.001
Mitral valve inﬂow deceleration-
time 
(per 10 msec)
-0.22 (-0.28 to -0.15) <0.001 -0.20 (-0.27 to -0.13) <0.001
E/A ratio 3.94 (3.23 to 4.65) <0.001 3.60 (2.67 to 4.53) <0.001
        ≤ 0.75 0.00 (reference)  0.00 (reference)  
        > 0.75, and < 1.50 1.55 (0.98 to 2.12) <0.001 1.47 (0.79 to 2.15) <0.001
        ≥ 1.50 6.24 (4.94 to 7.54) <0.001 5.69 (4.05 to 7.32) <0.001
E/E’ ratio 0.27 (0.22 to 0.32) <0.001 0.27 (0.19 to 0.35) <0.001
    ≤ 8 0.00 (reference)  0.00 (reference)  
    > 8 and < 15 1.08 (0.46 to 1.70) 0.001 1.09 (0.36 to 1.83) 0.003
    ≥ 15 3.36 (2.44 to 4.28) <0.001 3.36 (2.24 to 4.48) <0.001
a Number of participants for which we had at least information of one left heart echocardiographic parameter and 
ePASP 
b Adjusted for age, sex, resting heart rate, and body surface area
ePASP: echocardiographic pulmonary artery systolic pressure; SD: standard deviation; CI: confidence interval; E/A 
ratio: E wave divided by A wave; E/E’ ratio: E wave divided by E’
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Table 3. Large model: Multivariable analysis of associations of left heart echocardiographic parameters 
and ePASP in the Rotterdam Study
Full study populationbll, 
n = 2400 a, b
Restricted to free of 
shortness of breath,
 n = 1604 a, b
 β per -1unit (%95 CI) p - value β per -1unit (%95 CI) p - value
Left ventricular mass 
(per 10 grams) 0.06 (-0.03 to 0.16) 0.272 0.07 (-0.05 to 0.18) 0.202
Diameter of left atrium (mm) 0.13 (0.08 to 0.18) <0.001 0.15 (0.09 to 0.20) <0.001
Left ventricular fractional 
shortening (%) 0.09 (0.04 to 0.14) 0.036 0.07 (0.00 to 0.13) 0.001
Left ventricular volume 
(per 10 mL) 0.18 (0.07 to 0.30) 0.015 0.18 (0.04 to 0.33) 0.002
Diameter of the aortic root (mm) -0.13 (-0.20 to -0.06) <0.001 -0.17 (-0.26 to -0.08) <0.001
Mitral valve inﬂow 
deceleration-time, per 10 msec -0.08 (-0.14 to -0.02) 0.059 -0.07 (-0.15 to 0.00) 0.011
E/A ratio 2.87 (2.12 to 3.62) <0.001 2.75 (1.77 to 3.73) <0.001
        ≤ 0.75 0.00 (reference) NA 0.00 (reference) NA
        > 0.75, and < 1.50 1.10 (0.53 to 1.67) 0.001 1.15 (0.47 to 1.83) <0.001
        ≥ 1.50 4.40 (3.07 to 5.73) <0.001 4.21 (2.53 to 5.89) <0.001
E/E’ ratio 0.14 (0.09 to 0.20) 0.001 0.15 (0.06 to 0.23) <0.001
    ≤ 8 0.00 (reference) NA 0.00 (reference) NA
    > 8, and < 15 0.45 (-0.13 to 1.04) 0.087 0.61 (-0.09 to 1.31) 0.131
    ≥ 15 1.58 (0.66 to 2.50) 0.001 1.97 (0.84 to 3.10) 0.001
a Number of participants for which we had at least information of one left heart echocardiographic parameter and 
ePASP 
b  Adjusted for age, sex, resting heart rate, body surface area, and all other continuous left heart echocardiographic 
parameters in this table
ePASP: echocardiographic pulmonary artery systolic pressure; SD: standard deviation; CI: confidence interval; E/A 
ratio: E wave divided by A wave; E/E’ ratio: E wave divided by E’
When restricting the analysis to the 1604 participants free of shortness of breath and 
with full data on all covariates in the large model, point estimates were similar to those 
obtained in the full study population. Table 3 and Figure 3b show the results per 1-unit 
and per 1-SD increase in the left heart measurements, respectively. In the large model, 
all echocardiographic parameters remained significantly associated with ePASP, except 
LVmass and mitral valve deceleration time. In this model the strongest associations with 
ePASP were found for E/A ratio, LAD, and AoD. 





























Figure 3a. Large multivariable model: Associations of left heart echocardiographic parameters with 
ePASP in the Rotterdam Study, n = 2400a,b 
a Number of participants for which we had at least information of one left heart echocardiographic parameter and 
ePASP 
b Adjusted for age, sex, heart rate, and body surface area and all other left heart echocardiographic parameters in 
this figure
LVmass: left ventricular mass; LAD: left atrial diameter; LVFS: left ventricular fractional shortening; LVvol: left 




























Figure 3b. Large multivariable model: Associations of left heart echocardiographic parameters with 
ePASP in the Rotterdam Study, restricted to participants without shortness of breath, n = 1604a,b 
a Number of participants for which we had at least information of one left heart echocardiographic parameter and 
ePASP 
b Adjusted for age, sex, heart rate, and body surface area and all other left heart echocardiographic parameters in 
this figure
LVmass: left ventricular mass; LAD: left atrial diameter; LVFS: left ventricular fractional shortening; LVvol: left 
ventricular volume; AoD: aortic root diameter; E/A ratio: E wave divided by A wave; E/E’ ratio: E wave divided by E’
13106_Gall_BW.indd   46 22-01-16   15:11
2.2
Left Ventricular and Left Atrial Echocardiographic Measures
47
Discussion
In our study among older community-dwelling adults, structural and functional left heart 
parameters were associated with ePASP. Most of the associations persisted when we 
restricted the analysis to participants free of shortness of breath, suggesting that these 
associations are not driven by those with overt symptoms of heart failure. 
Our findings are in line with a study including 6598 male recruits from the Israeli air 
force. The authors reported significant associations of, LAD, and LVEDD with ePASP 5. 
Furthermore, LVmass was not significantly related to ePASP in the Israeli study, which 
also corresponds with our findings. In contrast to our findings, the authors observed no 
significant association of LVFS with ePASP. This difference might be explained by the 
differences in age and health status of the study populations. When we restricted our 
analysis to participants without shortness of breath, and hence to the healthier part 
of our population, left ventricular fractional shortening was also no longer significantly 
related to ePASP in our study. 
A recent study in 1480 Italians free of structural heart disease with a mean age of 36 years 
showed similar results to ours, with a significant association of left ventricular stroke volume 
and E/E’ ratio with ePASP and no significant association with left ventricular mass index4.
Furthermore, Choudhary and colleagues did a similar study in 3282 African Americans 
with a mean age of 56 years, evaluating echocardiographic correlates of pulmonary 
hypertension rather than the entire spectrum of pulmonary artery pressures 6. The authors 
reported a significant association of LAD and for a LV ejection fraction below 50% with 
presence of pulmonary hypertension. These results are overall in line with ours, although 
the latter association attenuated in our multivariable analysis.
We hypothesized that left-sided echocardiographic parameters across the full spectrum 
would be associated with ePASP, as early alterations in left heart structure and function 
can herald manifest heart failure, which is a known important cause of pulmonary 
hypertension. The effect sizes for most left heart parameters attenuated when studied in 
the large multivariable model, but overall, the associations remained. Only LVFS showed 
a change in the direction of effect. This warrants further research to elucidate the 
underlying mechanisms involved. Also, we observed that a greater AoD was associated 
with a lower ePASP. A similar association between AoD and ePASP was reported in the 
Israeli study 5. Other authors have reported an association between higher arterial 
systolic blood pressure and aortic root size in a population-based setting 17. Concomitant 
stiffening of both the aortic and pulmonary artery walls, reducing the compliance of 
both, might explain these findings. This reduced compliance would cause a higher pulse 
pressure in the aortic root and a higher pressure in the pulmonary artery, as well as with 
a smaller aortic root diameter 17. However, this hypothesis warrants further fundamental 
experimental research.




The unselected nature of the population included in this study and the large sample 
size enabled us to investigate the associations of the full spectrum of left heart 
echocardiographic parameters with pulmonary arterial pressures in the general older 
population. Some limitations need to be addressed. First, right heart catheterization 
is the gold standard for pulmonary arterial pressure measurements, but due to its 
invasiveness, heart catheterization is not suitable for population-based studies. However, 
several studies have shown that ePASP correlates well with invasively measured pulmonary 
arterial pressure and that echocardiography is appropriate for measurement of PASP in 
this setting 18, 19. Also, the largest differences between pulmonary pressure measured by 
heart catheterization and echocardiography arise in those with high pressures. The vast 
majority of our participants had pressure estimates in the normal range20. Secondly, we 
had a number of missing measurements for the echocardiographic parameters (Figure 1 
and Table 1). Participants with missing echocardiographic variables were on average older 
(mean age 74.7 (SD 8.2) years), had a higher BMI (mean BMI 32.0 (SD 6.2) kg/m2), had a 
slightly worse systolic function (mean fractional shortening 40 (SD 7) %), and were more 
likely to report shortness of breath (47.5%). Thus, these participants were overall less 
healthy. In addition, 800 participants had undergone echocardiography, but did had a TRV 
that was too small to quantify and therefore have a very low ePASP. These missing values 
will have affected the distribution of the studied echocardiographic parameters in our 
sample, but are unlikely to have affected the β estimates since we found no indications 
for nonlinearity in the data (data not shown). Thirdly, by assigning a conservative RAP 
of 3 mmHg to all participants with measured TRV values but missing RAP, we may have 
underestimated ePASP in some participants. This would bias our results towards the 
null. Fourthly, our population was older (mean age 72.6 years) and predominantly white 
(96.5%). Whether our results can be directly generalized to other populations remains 
unclear. Lastly, ePASP values were measured once, and follow-up is not yet available. 
Therefore, the temporal relation between left heart abnormalities and ePASP remains 
to be established, as well as the clinical sequelae. Moreover, it remains to be studied 
whether progression to PH could be halted or controlled by pharmacological treatment in 
persons with (subclinical) left heart disease 21-24. 
Conclusion
Structural and functional echocardiographic parameters of the left heart are associated 
with pulmonary arterial pressures in the general ageing population.
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Pulmonary hypertension (PH) is a severe progressive disease. Though five subgroups are 
recognised, reports on survival focus mainly on pulmonary arterial hypertension (PAH). 
Long-term transplant-free survival, and its determinants, were investigated in patients 
with different PH subtypes within a prospective registry at a single referral centre. 
In total, 2067 patients with PH were enrolled (PAH, n=685 [33.1%]; pulmonary venous 
hypertension, n=307 [14.9%]; PH due to lung diseases, n=546 [26.4%; mainly interstitial 
lung disease and chronic obstructive pulmonary disease]; chronic thromboembolic PH, 
n=459 [22.2%]; PH owing to miscellaneous/unknown causes, n=70 [3.4%]). Differences in 
transplant-free survival between aetiological groups were highly significant (p<0.001), 
with 1-, 3-, and 5-year survival rates of 88.2%, 72.2%, and 59.4%, respectively, for those 
with PAH compared with 79.5%, 52.7%, and 38.1%, respectively, for patients with PH 
caused by lung disease. Patients’ age, sex, and 6-minute walk test distance, but not 
New York Heart Association (NYHA) functional class, associated significantly with survival 
across all PH subtypes in multivariate Cox regression analyses.
This is the largest reported single-centre PH cohort. Some parameters used in clinical 
practice do not independently predict survival. Age, sex, and 6-minute walk test distance 
outperformed NYHA functional class in predicting survival across all aetiologic groups.
Key words: hypertension, pulmonary; registries; survival.
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Introduction
Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature that is 
defined by an elevated mean pulmonary artery pressure (PAP) of ≥25 mmHg. PH is associated 
with increased pulmonary vascular resistance (PVR) which can lead to right heart failure 
and subsequent death [1]. The World Health Organization (WHO) discriminates five main 
PH subtypes [2], but most PH survival studies concern one subtype (pulmonary arterial 
hypertension [PAH], particularly idiopathic PAH [IPAH]); data regarding other subtypes are 
rare. 
In an early registry (started in 1981), 68%, 48%, and 34% of patients with IPAH survived 1, 
3, and 5 years, respectively [3, 4]. Survival has since improved: 1-year survival was 83–91% 
in more recent French and US-based PAH registries [5-7], and median survival was 3.8 and 
5.6 years for women and men with IPAH, respectively, in a Scottish registry [8]. The UK-
based ASPIRE registry provided 1- and 3-year survival data for several PH groups: PAH (88% 
and 68%), pulmonary venous hypertension (PVH, 90% and 73%), lung disease-associated PH 
(LD-PH, 65% and 44%), and CTEPH (89% and 71%) [9].
Several clinical factors predict PAH course and outcome, including exercise tolerance and 
New York Heart Association (NYHA) functional class [10-13]. Haemodynamic parameters 
such as mean right atrial pressure (RAP) and cardiac index are also associated with survival 
[3, 14]. Serum markers such as brain natriuretic peptide and uric acid are independently 
related to survival, as is hyponatremia [15-17]. However, equivalent information is lacking 
for other PH aetiologies.
This report presents, for the first time, comprehensive long-term transplant-free survival 
data from more than 2000 PH patients from a single referral centre (the Giessen Pulmonary 
Hypertension Registry [Gi-PH-Reg]), including data for different PH subtypes.
Methods
Data collection
The single-centre Gi-PH-Reg started in March 1993 at the University Hospital Giessen. 
Eligible patients were recruited by 13 October 2011, with PH defined as mean PAP ≥25 
mmHg at rest by right heart catheterisation. Patients with isolated exercise-induced 
PH (mean PAP >30 mmHg at exercise) were excluded. The Dana Point classification [2] 
and STROBE guidelines [18] were applied. The definition of a prevalent case was both a 
diagnosis of PH and PH target therapy started before the first visit to our centre; incident 
cases were those diagnosed initially at our centre or referred after diagnosis without target 
therapy. Survival status was determined by contacting the patient or their local physician. 
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The date and cause of deaths were obtained from medical records; if no information 
was available the patient was classified as lost to follow-up and censored at the date 
of the last visit. Patients undergoing lung transplantation were considered to have had 
an event at the transplantation date. Baseline demographics, PH aetiology, medication 
use, echocardiographic parameters, and exercise testing, lung function and right heart 
catheterisation data were entered into an electronic database. Date of first visit was 
taken as the start date, and patients were classified into modified NYHA functional classes 
I–IV (hereafter referred to as NYHA I–IV) [19]. The study was approved by the University of 
Giessen institutional review board (#266/11). All patients gave written informed consent.
Right heart catheterisation
At their baseline visit, 1422 patients underwent right heart catheterisation, usually via 
the internal jugular vein with a 7F Swan–Ganz catheter. Other patients were diagnosed 
invasively before referral; heart catheterisation data from these patients were excluded 
unless the catheterisation was repeated at Giessen. Cardiac output (CO) was measured 
by thermodilution. Pulmonary capillary wedge pressure (PCWP) was registered and PVR 
calculated as: (mean PAP–PCWP)×80/CO [20]. Arterial partial oxygen pressure (paO2) was 
determined from a capillary blood test, while mixed venous oxygen saturation (venSO2) 
was measured from blood sampled from the Swan–Ganz catheter.
Six–minute walk test
The six-minute walk test (6MWT) was performed in 1290 patients according to the 
American Thoracic Society guidelines [21]. Other patients received spiroergometry as a 
baseline cardiopulmonary exercise test, or were not able to walk for different reasons, 
so data were not available.
Statistical methods
Data were collected, checked, and entered by independent research assistants, and two 
PH specialists checked medical information independently. Kaplan–Meier curves were 
constructed and log rank tests performed to compare survival distributions. For survival 
analysis, patients who underwent a pulmonary endarterectomy (PEA) were considered 
as withdrawn alive at the date of the PEA. Association of parameters with survival was 
tested using univariate and multivariate Cox regression. Regression analysis parameters 
were selected on clinical grounds, own prior analyses, and literature review. Comparisons 
between groups used the t-test or chi-square test, as appropriate. P-values of <0.05 
were considered statistically significant. Bonferroni correction for multiple testing was 
performed for multivariate Cox regression (cut-off for significance 0.0029). Statistical 
analyses were performed using SPSS 20.0 (IBM Armonk, NY, USA).
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In total, 2067 patients were enrolled and analysed (table 1). Mean age was 59.6 years, 
with a female-to-male ratio of 1.24:1. Of the total study population, 33.1% had PAH, 
22.2% had CTEPH, 14.9% had PVH, and 26.4% had LD-PH, the latter consisting mainly of 
interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Seventy 
patients (3.4%) had PH due to miscellaneous or unknown causes (not shown in table 1). 
Incident cases (n=1861) accounted for 90% of the study population; the remaining 10% 
were prevalent cases (n=206). Of 294 patients with IPAH, 226 were incident cases (76.9%). 
In the subgroups with CTEPH, PVH, ILD-associated PH, and COPD-associated PH, 93.0%, 
94.8%, 95.9%, and 93.6% were incident cases, respectively.
Table 1. Baseline characteristics.
PAH (n=685) CTEPH (n=459) PVH (n=307) LD-PH (n=546)










Age, mean (SD), y 51 (16) 62 (13) 67 (11) 64 (11)
NYHA FC, No. (%)
  II 106 (19) 52 (15) 41 (18) 39 (12)
  III 338 (59) 206 (60) 149 (64) 182 (54)
  IV 126 (22) 84 (25) 43 (19) 119 (35)
6MWT, mean (SD), m 325 (126) 308 (116) 302 (110) 263 (115)
RAP, mean (SD), mmHg 8 (6) 8 (5) 10 (6) 5 (4)
mPAP, mean (SD), mmHg 51 (16) 44 (13) 34 (12) 34 (11)
PCWP, mean (SD), mmHg 8 (4) 9 (4) 18 (7) 8 (4)
CI, mean (SD), L/min/m2 2.3 (0.8) 2.2 (0.6) 2.3 (0.6) 2.5 (0.7)
PVR, median (IQR), dyne.s/cm5 846 (720) 720 (558) 253 (214) 407 (329)
venSO2, mean (SD), % 61 (10) 60 (9) 63 (8) 65 (8)
paO2, mean (SD), mmHg 68 (14) 65 (12) 71 (12) 67 (16)
Abbreviations: CI, cardiac index; CTEPH, chronic thromboembolic pulmonary hypertension; IQR, interquartile 
range; LD-PH, pulmonary hypertension due to lung disease; mPAP, mean pulmonary artery pressure; NYHA FC, 
New York Heart Association functional class; PAH, pulmonary arterial hypertension; paO2, arterial oxygen partial 
pressure; PCWP, pulmonary capillary wedge pressure; PVH, pulmonary hypertension due to left heart disease; PVR, 
pulmonary vascular resistance; RAP, right atrial pressure; venSO2, mixed venous oxygen saturation; 6MWT, 6-minute 
walk test. 
* A total of 70 patients (with PH due to miscellaneous or unknown causes) were not included in this table, but 
formed the remainder of the 2067 patients enrolled and included in the analysis.




By the end of the observation period, 924 patients (44.7%) had died or had undergone lung 
or heart and lung transplantation (n=52), and 162 patients (7.8%) were lost to follow-up. 
Overall survival at 1, 3, and 5 years was 85.5%, 66.7%, and 53.6%, respectively. The risk 
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Figure 1. Kaplan–Meier transplant-free survival estimates for a) all PH aetiological groups (significant 
difference between groups, log rank p<0.001), b) the main PAH subgroups (significant difference 
between groups, log rank p<0.001), c) patients with PVH categorised by transpulmonary pressure 
gradient (≤12 mmHg vs >12 mmHg; no significant difference between groups, log rank p=0.516), and 
d) the main LD-PH subgroups (COPD and ILD; significant difference between groups, log rank p<0.001).
Abbreviations: CHD, congenital heart disease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic 
thromboembolic pulmonary hypertension; CTD, connective tissue disease; ILD, interstitial lung disease; IPAH, 
idiopathic pulmonary arterial hypertension; LD-PH, pulmonary hypertension due to lung disease; PAH, pulmonary 
arterial hypertension; PH, pulmonary hypertension; PVH, pulmonary venous hypertension.
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More deaths occurred among men (483/922; 52.4%) than women (441/1145; 38.5%; 
p<0.001). Baseline NYHA data were available for 1533 patients, and classes I and II were 
pooled as only 16 patients were class I. Five-year survival was 78.3%, 58.2%, and 39.4% 
for patients in NYHA I/II, III, and IV, respectively (overall p<0.001). Survival showed no 
significant difference between incident and prevalent patients across all aetiologies (log 
rank p=0.447; online supplementary fig. 1).
 Supplementary Figure 1. Comparison of transplant-free survival for all pulmonary hypertension 
aetiologies grouped as incident (n=1861) or prevalent (n=206) case
PAH (WHO group 1 PH)
The subtype distribution among the 685 patients with PAH was: IPAH, 42.9%; connective 
tissue disease (CTD), 21.2%; congenital heart disease (CHD), 13.3%; porto-PH, 7.4%; 
pulmonary veno-occlusive disease (PVOD), 4.1%; human immunodeficiency virus 
(HIV), 3.9%; and PAH from other causes, 7.2% (online supplementary table 1). Women 
predominated (table 1).
Overall, 295 patients with PAH (43.1%) died within the observation period; this included 
180 (40.3%) of the female patients and 115 (48.3%) of the male patients (5-year survival: 
63.4% vs 51.9%, respectively; p=0.032). Of the patients with PAH, those with CHD had the 
highest survival rates, followed by IPAH and CTD, whereas patients with PVOD had the 
worst prognosis (table 2). A comparison between the largest PAH subgroups (IPAH, CTD and 
CHD) in fig. 1b shows a significant difference in survival (p<0.001). 
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Supplementary Table 1. Baseline characteristics of PAH patients by main aetiologic sub-type.
PAH IPAH CTD CHD
Patients, No. 685 294 145 91
Female sex, No. (%) 447 (65) 193 (66) 122 (84) 54 (59)
Age, mean (SD), y 51 (16) 49 (16) 57 (15) 47 (16)
NYHA FC, No. (%)
  II 106 (19) 43 (17) 19 (16) 19 (23)
  III 338 (59) 157 (63) 60 (51) 54 (65)
  IV 126 (22) 48 (19) 39 (33) 10 (12)
6MWT, mean (SD), m 325 (126) 347 (121) 273 (135) 345 (102)
RAP, mean (SD), mmHg 8 (6) 7 (6) 8 (6) 8 (5)
mPAP, mean (SD), mmHg 51 (16) 53 (16) 46 (14) 58 (25)
PCWP, mean (SD), mmHg 8 (4) 7 (3) 8 (4) 10 (5)
CI, mean (SD), L/min/m2 2.3 (0.8) 2.1 (0.6) 2.2 (0.7) 2.8 (1.0)
PVR, median (IQR), dyne.s/cm5 846 (720) 1080 (582) 924 (541) 948 (675)
venSO2, mean (SD), % 61 (10) 61 (10) 60 (10) 67 (9)
paO2, mean (SD), mmHg 68 (14) 68 (14) 68 (13) 64 (14)
Abbreviations: CHD, pulmonary arterial hypertension associated with congenital heart disease; CI, cardiac index; 
CTD, pulmonary arterial hypertension associated with connective tissue disease; IPAH, idiopathic pulmonary 
arterial hypertension; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NYHA FC, New York Heart 
Association functional class; PAH, pulmonary arterial hypertension; paO2, arterial oxygen partial pressure; PCWP, 
pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; venSO2, mixed 
venous oxygen saturation; 6MWT, 6-minute walk test.
Table 2. Survival in patients with pulmonary arterial hypertension or pulmonary venous occlusive 
disease.
PAH IPAH CTD CHD PVOD
Patients, No. 685 294 145 91 28
Survival (%)
At 1 year 88.2 89.7 85.3 95.4 78.6
At 3 years 72.2 76.2 65.6 84.2 41.2
At 5 years 59.4 65.3 50.9 74.5 18.7
Abbreviations: CHD, pulmonary arterial hypertension associated with congenital heart disease; CTD, pulmonary 
arterial hypertension associated with connective tissue disease; IPAH, idiopathic pulmonary arterial hypertension; 
PAH, pulmonary arterial hypertension; PVOD, pulmonary venous occlusive disease.
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Survival for incident vs prevalent cases of PAH is shown in table 3. A significant difference 
in survival was detected between incident and prevalent cases for patients with associated 
PAH (log rank p=0.023, online supplementary fig. 2), but not IPAH (log rank p=0.201; 
online supplementary fig. 3); however, numbers at risk were low in the prevalent groups 
(associated PAH: n=49 at first visit, n=8 after 5 years; IPAH: n=68 at first visit, n=24 after 
5 years).
 Supplementary Figure 2. Comparison of transplant-free survival for patients with associated 
pulmonary arterial hypertension (APAH) grouped as incident (n=325) or prevalent (n=38) cases.
 
Supplementary Figure 3. Comparison of transplant-free survival for patients with idiopathic 
pulmonary arterial hypertension (IPAH) grouped as incident (n=226) or prevalent (n=68) cases.
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Table 3. Survival in subgroups with incident or prevalent pulmonary arterial hypertension.
IPAH APAH
Incident Prevalent Incident Prevalent
Patients, No. 226 68 325 38
Survival (%)
At 1 year 90.6 86.8 88.2 79.2
At 3 years 77.8 71.3 70.5 61.1
At 5 years 67.1 58.9 56.8 39.2
At 10 years 54.9 47.3 37.2 19.6
Abbreviations: APAH, associated pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension.
PVH (WHO group 2 PH)
Of 307 patients with PVH, 111 (36.2%) died within the follow-up period; survival at 1, 3, 
and 5 years was 86.7%, 68.6%, and 55.6%, respectively. Women predominated (table 1), 
and 5-year survival was 61.8% for women vs 47.1% for men (p=0.004). NYHA data were 
available for 233 patients with PVH; 5-year survival was worse for patients in NYHA III 
(59.3%) and NYHA IV (32.5%) than for those in NYHA I/II (85.9%; overall p<0.001).
Categorising PVH patients by transpulmonary pressure gradient (TPG; ≤12 mmHg vs >12 
mmHg), 78 patients (42%) had low TPG (passive PVH) and 108 (58%) had high TPG (reactive 
PVH; online supplementary table 2). The haemodynamic measures between these groups 
differed regarding mean PAP and PVR (p<0.001) with no significant differences in cardiac 
index, PCWP, or RAP (p>0.20). NYHA functional class also showed no significant difference 
(p=0.619), though exercise capacity was better in the group with passive rather than 
reactive PVH (p=0.019). Survival at 1, 3, and 5 years was comparable in both groups (passive 
PVH: 86.6%, 73.5 %, and 60.4%; reactive PVH: 87.0%, 67.9%, and 47.8%, respectively; log 
rank p=0.516) (fig. 1c). More patients with reactive than passive PVH were treated with 
PAH-specific medications (46% vs 26%, respectively).
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Supplementary Table 2. Baseline characteristics of patients with pulmonary hypertension due to left 
heart disease (PVH), categorised by transpulmonary gradient.
“Passive” PVH† (n=78) “Reactive” PVH‡ (n=108)
Female sex, No. (%) 44 (56) 64 (59)
Age, mean (SD), y 67 (11) 68 (11)
NYHA FC, No. (%)
  II 11 (20) 15 (19)
  III 36 (65) 49 (62)
  IV 8 (15) 15 (19)
6MWT, mean (SD), m 331 (117) 281 (111)
RAP, mean (SD), mmHg 9 (6) 10 (5)
mPAP, mean (SD), mmHg 26 (6) 40 (11)
PCWP, mean (SD), mmHg 18 (6) 18 (8)
CI, mean (SD), L/min/m2 2.3 (0.6) 2.4 (0.6)
PVR, median (IQR), dyne.s/cm5 170 (60) 440 (251)
venSO2, mean (SD), % 65 (7) 62 (9)
paO2, mean (SD), mmHg 73 (10) 69 (14)
Abbreviations: CI, cardiac index; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NYHA FC, New 
York Heart Association functional class; paO2, arterial oxygen partial pressure; PCWP, pulmonary capillary wedge 
pressure; PVH, pulmonary hypertension owing to left heart disease; PVR, pulmonary vascular resistance; RAP, right 
atrial pressure; venSO2, mixed venous oxygen saturation; 6MWT, 6-minute walk test.
*Of 307 patients with PVH, 186 had transpulmonary gradient data and are presented in this table.
†Transpulmonary gradient equal or below 12.
‡Transpulmonary gradient above 12.
LD-PH (WHO group 3 PH)
Most of the 546 patients with LD-PH had COPD (n=218; 39.9%) or ILD (n=283; 51.8%; online 
supplementary table 3). All patients with LD-PH were treated with optimised therapy for 
their lung disorder and received PAH-specific medications if necessary (table 4). Survival 
was better in patients with COPD than in those with ILD (1-, 3-, and 5-year survival: 87.7%, 
66.3%, and 54.0% vs 71.9%, 40.3%, and 22.5%; p<0.001) (fig. 1d). Men predominated (table 
1), and 5-year survival was 44.0% for women vs 34.3% for men (p=0.001). Survival after 1, 
3, and 5 years was 90.9%, 74.2%, and 52.4% for patients in NYHA I/II (n=39), 83.2%, 56.2%, 
and 37.7% for patients in NYHA III (n=182), and 76.6%, 42.5%, and 33.2% for patients in 
NYHA IV (n=119), respectively (p=0.011).
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Supplementary Table 3. Baseline characteristics of patients with pulmonary hypertension owing to 
lung disease (LD-PH), and its two main aetiologic sub-types.
LD-PH (n=546)* COPD (n=218) ILD (n=283)
Female sex, No. (%) 218 (40) 87 (40) 115 (41)
Age, mean (SD), y 64 (11) 64 (10) 64 (12)
NYHA FC, No. (%)
  II 39 (12) 13 (9) 21 (12)
  III 182 (54) 87 (61) 85 (49)
  IV 119 (35) 42 (30) 68 (39)
6MWT, m (SD) 263 (115) 259 (105) 263 (123)
RAP, mean (SD), mmHg 5 (4) 5 (4) 5 (4)
mPAP, mean (SD), mmHg 34 (11) 32 (10) 34 (12)
PCWP, mean (SD), mmHg 8 (4) 8 (4) 8 (3)
CI, mean (SD), L/min/m2 2.5 (0.7) 2.6 (0.7) 2.4 (0.6)
PVR, median (IQR), dyne.s/cm5 407 (329) 416 (245) 536 (334)
venSO2, mean (SD), % 65 (8) 66 (7) 64 (8)
paO2, mean (SD), mmHg 67 (16) 67 (17) 67 (16)
Abbreviations: CI, cardiac index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; IQR, 
interquartile range; LD-PH, pulmonary hypertension due to lung disease; mPAP, mean pulmonary artery pressure; 
NYHA FC, New York Heart Association functional class; paO2, arterial oxygen partial pressure; PCWP, pulmonary 
capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; venSO2, mixed venous 
oxygen saturation; 6MWT, 6-minute walk test.
*Most patients with LD-PH (n=546) had COPD (n=218; 39.9%) or ILD (n=283; 51.8%). The remaining patients (n=45) 
had LD-PH from various other causes. 
Table 4. Initial therapy*.
PAH CTEPH PVH LD-PH
Complete data, No. 510 310 83 357
Monotherapy, No. (%):
  PDE5i 170 (33) 200 (65) 29 (35) 209 (59)
  ERA 102 (20) 12 (4) 1 (1) 36 (10)
  Prost. inh. 86 (17) 17 (6) - 11 (3)
  Other 8 (2) 2 (1) - 1 (0)
Combination therapy, No. (%):
  PDE5i+ERA 37 (7) 16 (5) 2 (2) 15 (4)
  PDE5i+prost. inh. 21 (4) 7 (2) 1 (1) 4 (1)
  Other 16 (3) - - 1 (0)
Triple therapy, No. (%) 12 (2) 2 (1) - -
No specific therapy, No. (%) 58 (11) 54 (17) 50 (60) 80 (22)
Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist; LD-
PH, pulmonary hypertension due to lung disease; PAH, pulmonary-arterial hypertension; PDE5i, phosphodiesterase 
type 5 inhibitor; prost. inh., inhalative prostacyclins; PVH, pulmonary hypertension due to left heart disease. 
*Data are presented as absolute numbers and percent of patients with complete data on drug use.
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CTEPH (WHO group 4 PH)
Of 459 patients with CTEPH, 138 (30.1%) died and 91 (19.8%) underwent PEA; survival at 
1, 3, and 5 years was 89.2%, 77.4%, and 66.7%, respectively. Survival over 5 years was 
71.6% for women and 60.1% for men (p=0.012). Survival at 1, 3, and 5 years was 97.8%, 
92.2%, and 87.8%, respectively, for patients in NYHA I/II (n=52); the corresponding rates 
were 93.6%, 85.6%, and 73.5% for those in NYHA III (n=206), and 83.4%, 62.9%, and 45.6% 
for those in NYHA IV (n=84; overall p<0.001).
PH owing to miscellaneous causes (WHO group 5 PH)
No analyses were performed on this group owing to its small size (n=70) and heterogeneity.
Causes of death
The cause of death was known in 592 patients (from the group of 924 patients who 
died). Main causes of death were right heart failure related to PH (23.8%), respiratory 
insufficiency (21.8%), combined left and right heart failure (9.5%), malignancy (9.0%), 
sepsis (7.6%), pulmonary infection (5.4%), and sudden cardiac death (4.4%). 
Factors associated with mortality
The relationship between survival and prognostic factors (NYHA, age, sex, and 6MWT) 
was assessed by calculating hazard ratios in a univariate model (table 5). All factors 
were prognostic in the PAH group, and NYHA was predictive in all aetiologic groups 
except LD-PH. Age was predictive of survival for patients from all aetiologic groups (age 
<50 vs >71 years), for PAH, PVH and LD-PH (age <50 vs 63–71 years), and for PAH and 
PVH (age <50 vs 50–63 years). Sex predicted survival in all aetiologic groups, with male 
sex associated with a worse prognosis. 6MWT was prognostic for all aetiologic groups 
(except for 311–390m vs reference category for PVH and LD-PH). NYHA lost its predictive 
value, but 6MWT (all etiologic groups), age (PAH), and gender (PAH and CTEPH) were 
still predictive for mortality when placed in one multivariate model per aetiologic group 
(online supplementary table 4).
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Abbreviations: CI, confidence interval; CTEPH, chronic thromboembolic pulmonary hypertension; HR, hazard 
ratio; LD-PH, pulmonary hypertension due to lung disease; NYHA New York Heart Association functional class; PAH, 
pulmonary arterial hypertension; PVH, pulmonary hypertension due to left heart disease; 6MWT, 6-minute walk test. 
*Age groups represent quartiles.†6MWT groups represent quartiles of the full population.
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Abbreviations: CI, confidence interval; CTEPH, chronic thromboembolic pulmonary hypertension; HR, hazard 
ratio; LD-PH, pulmonary hypertension due to lung disease; NYHA New York Heart Association functional class; PAH, 
pulmonary arterial hypertension; PVH, pulmonary hypertension due to left heart disease; 6MWT, 6-minute walk 
test. *Age groups represent quartiles.†6MWT groups represent quartiles of the full population.
Comparison with other key registries
A systematic literature search (described in online supplementary material) identified 11 
key registries which are summarised alongside the Gi-PH-Reg in table 6 (PAH populations) 
and table 7 (CTEPH populations). 
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Table 7. Comparison of patients with chronic thromboembolic pulmonary hypertension in the Giessen 
Pulmonary Hypertension Registry and other key registries. 
Registry
Gi-PH Reg ASPIRE [9] International CTEPH [26]
REHAP 










Recruitment period, y 1993–2011 2001–2010 2007–2009 1998–2008 2001–2006 2001–2006
CTEPH population, n 459 242 386 162 321 148
Female sex, % 56 54 46 60 47 56
Mean age, y 62 61 60* 61 58 60
NYHA FC, %
  II 15 – – 23 12 16
  III 60 70 68 68 73 68
  IV 25 17 13 9 15 16
Mean 6MWT, m 308 – 341* 317 243 239
Mean RAP, mmHg 8 11 8 9* 10*
Mean mPAP, mmHg 44 48 48* 47 48 49
Mean PCWP, mmHg 9 11 – – – –
Mean CI, L/min/m2 2.2 2.5 2.2* 2.3 2.1 2.1
Mean PVR, dyne.s/cm5 
(or WU where specified)
720* 735 728* 10 WU 1091 1098 
Survival, %
  at 1 year 89.2 89 93 93 88† 82
  at 3 years 77.4 71 – 75 76† 70
  at 5 years 66.7 – – 65 – –
Abbreviations: ASPIRE, Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre; CI, cardiac 
index; CTEPH, chronic thromboembolic pulmonary hypertension; Gi-PH-Reg, Giessen Pulmonary Hypertension 
Registry; mPAP, mean pulmonary artery pressure; NYHA FC, New York Heart Association functional class; PCWP, 
pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial 
pressure; REHAP, Spanish Registry of Pulmonary Arterial Hypertension; WU, Wood Units; 6MWT, 6-minute walk test.
*Median.
†Survival was reported for 236 patients who underwent pulmonary endarterectomy. 




Comparison with other key registries – systematic literature search
In order to discuss the results of our study within the context of other published studies, 
we performed a systematic literature search to identify registry studies of patients with 
pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) that reported 
survival data. This was performed on 8 April 2014 in PubMed and used the following 
search string: (“pulmonary hypertension” OR “pulmonary arterial hypertension”) AND 
(registry OR cohort) AND (survival OR survived OR surviving OR mortality OR died OR dying 
OR death) [no limits]. This strategy retrieved 715 publications. Studies were considered 
for inclusion by manual screening of article titles (and subsequently, of full articles) to 
identify registry studies in relevant populations, published in English, which also included 
mortality data. The search identified a range of national and international registry studies 
[1–19]. Results from registries of particular historical relevance [1] or of a reasonable size 
(i.e. more than 250 patients with PH) have been reported in the main manuscript [2–13]. 
Some additional references fulfilled the systematic search criteria but were too small 
to draw meaningful comparisons concerning overall mortality rates, and thus are not 
discussed [14–18]. Nevertheless, the mortality rates described in most of these smaller 
studies broadly agree with those from larger studies of the same era. Another study, 
whilst large (i.e. a cohort of 1283 patients with incident PAH) concerned the effect of 
anticoagulant use on patients’ survival and thus was not included as it focused exclusively 
on areas beyond the scope of this article [19].
Discussion
This study encompasses the largest single-centre PH patient cohort reported to date. This 
single-centre approach has inherent advantages, namely homogeneity of data quality and 
consistency of standards and procedures. Only two other single-centre registries of any 
size have been reported, one based in the UK including 1344 incident PH cases [9] and a 
US registry encompassing 587 patients with PAH [28]. The overall survival rates we report 
here are similar to results published from other registries covering a similar era. We 
found significant variation between survival rates for PH subtypes, though these subgroup 
survival rates were similar to those reported in the literature for PAH and CTEPH, slightly 
better for LD-PH [9] and slightly worse for PVH [9] (owing at least in part to baseline 
differences).
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Patients with PAH in the Gi-PH-Reg were comparable with those in other national 
registries in terms of mean age, 6MWT, NYHA distribution, female-to-male ratio, and main 
haemodynamic parameters [7, 22, 29, 30]. This concordance underlines the appropriate 
allocation of patients to group 1. We found that patients with IPAH were younger on 
average than patients with other PAH subtypes, and had more severely impaired 
haemodynamics. Nevertheless, the NYHA distribution and 6MWT were more favourable in 
patients with IPAH than in those with CTD-PAH. Patients with CHD had the best survival 
in the PAH group; this agrees with previous publications, showing good long-term survival 
in patients with CHD/Eisenmenger syndrome [9, 30]. The survival of patients with IPAH 
(table 2) compares favourably with outcomes from registries in France (82.9% and 58.2% 
at 1 and 3 years), UK/Ireland (93%, 73%, and 61% at 1, 3, and 5 years), and the US (77% 
at 3 years) [25, 30, 31]. However, when comparing patients with incident and prevalent 
IPAH, no clinically relevant or statistically significant difference was observed within our 
registry. This is in contrast to the French PAH registry which showed greater survival 
in prevalent versus incident cohorts, suggesting “immortal time bias” in the prevalent 
cohort [30]. The discrepancy may be at least partly due to differences in definitions: in 
the French registry, prevalent cases were patients diagnosed before the start of the study, 
whereas prevalent cases in the Gi-PH-Reg were patients who were diagnosed and had 
started PH therapy elsewhere before referral to our centre. It can also be speculated that 
environmental and/or socio-economic differences between different regions may affect 
“immortal time bias”.
Patients with CTEPH were the third largest group in our database, and had slightly less 
severe haemodynamic impairment and slightly better overall survival than the PAH group. 
The phenotype of our CTEPH group was very similar to that of other CTEPH registries [9, 
22, 26]. Moreover, the 1- and 3-year survival rates reported in the current study were 
similar to those reported in a large UK CTEPH registry (table 7 [27]).
Our patients with PVH had poorer survival than those in the ASPIRE registry [9]. In ASPIRE, 
patients with PVH had better survival than those with PAH, whereas the opposite was 
observed in the Gi-PH-Reg, despite the PVH group having less compromised haemodynamics 
than the PAH group. The Gi-PH-Reg PVH group showed classical features of an elderly 
population with more severely impaired exercise ability than the younger PAH group, 
which could at least partly explain the reduced survival in the PVH group. 
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The 2009 European PH guidelines distinguished reactive and passive PVH on the basis of 
TPG (>12 mmHg and ≤12 mmHg, respectively) [32], and some studies have shown worse 
survival in patients with reactive vs passive PVH using this definition [33, 34]. However, 
the TPG is sensitive to changes in cardiac output and pulmonary vascular recruitment and 
distension; a fixed TPG threshold may therefore not be a reliable indicator of reactive 
PVH [35]. A study of patients with heart failure with reduced ejection fraction found no 
difference in mortality between reactive and passive PVH defined on the basis of TPG 
[36], which is consistent with our findings. The diastolic pulmonary gradient has been 
suggested as a more suitable measure than TPG to distinguish reactive and passive PVH 
[34, 35]. 
The LD-PH group was the only subgroup in which men outnumbered women. The outcome 
of this group overall was worse than for patients with PAH or CTEPH. Comparing COPD and 
ILD patients, the latter had a considerably worse outcome, consistent with epidemiological 
data for these populations [9]. The ASPIRE registry included 178 LD-PH patients with 1- 
and 3-year survival of 65% and 44%, respectively [9]; our patients lived slightly longer, but 
this may be because of different proportions of COPD and ILD.
Basic clinical parameters known to be of prognostic value for patients with PAH 
(particularly IPAH), have been examined thoroughly in our study for other forms of PH: 
the 6MWT remains the strongest predictor across all groups of PH. Following current 
guidelines, patients are classified according to PH aetiology. This specific diagnosis should 
be considered when judging which prognostic factor is relevant. 
NYHA functional class has been previously highlighted as an important prognostic factor 
in PAH [32, 37]. However, in our PAH subgroup, NYHA was identified as a predictor of 
mortality only by univariate and not multivariate analysis. This is consistent with the 
findings of several previous studies [38], though a large study of 2716 patients with PAH 
did identify functional class as an independent prognostic factor [5]. Prognosis may be 
better assessed by considering a combination of factors rather than one factor in isolation 
[39]. 
Limitations
We studied a single-centre cohort, but our reference centre is one of the largest in Germany 
and therefore data may be representative of the PH population – although milder cases 
may not be referred to us. We did not have complete data on right heart catheterisation 
at baseline: some patients came with clinically acceptable right heart catheterisation 
values from secondary centres but these data were not entered in the database.
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Conclusions
This is the largest single-centre PH patient cohort reported to date. We have presented 
transplant-free survival data from a large number of patients with PH, including all 
different subtypes of PH, and examined survival determinants in these populations. 
Overall survival at 1, 3, and 5 years was 85.5%, 66.7%, and 53.6%, respectively, and survival 
differences were significant between PH subtypes. Although NYHA functional class is used 
commonly to predict the likelihood of survival, it was a less powerful predictor across all 
aetiologic groups than patients’ age, sex, and 6MWT. 
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This study aimed to determine whether the VEGF family members soluble VEGF receptor 
1 (sVEGFR1/soluble fms-like tyrosine kinase 1, sFlt-1) and placental growth factor (PlGF) 
could be used as biomarkers for PH.
Consecutive patients undergoing right heart catheterization were enrolled (those with 
mPAP ≥25 mmHg were classed as having PH; those with mPAP <25 mmHg acted as non-PH 
controls). Plasma from the time of PH diagnosis was analyzed for PlGF and sFlt-1 using 
enzyme immunoassays.
In total, 247 patients with PH were enrolled: 62 with idiopathic pulmonary arterial 
hypertension (IPAH), 14 with associated pulmonary arterial hypertension (APAH), 21 with 
collagen vascular disease (CVD), 26 with pulmonary venous hypertension, 67 with lung 
disease-associated PH, and 57 with chronic thromboembolic PH. The non-PH control group 
consisted of 40 patients. sFlt-1 plasma levels were significantly higher in patients with 
IPAH, APAH, CVD and LD-PH vs controls; PlGF levels were significantly higher in all PH 
groups vs controls. PlGF and sFlt-1 combined had a sensitivity of 62.4% and a specificity 
of 100% to detect any PH etiology. There was no association between sFlt-1 or PlGF and 
hemodynamic parameters, 6-minute walking distance, or survival. 
In summary, PlGF and sFlt-1 are promising diagnostic biomarkers for PH.
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Introduction
Pulmonary hypertension (PH) is defined as resting mean pulmonary arterial pressure 
(mPAP) ≥25 mm Hg (1). Different PH etiologies have resulted in a classification of PH into 
five groups, but regardless of etiology, PH involves vasoconstriction, media hypertrophy, 
and in situ thrombosis, leading to an increase in pulmonary arterial pressure, ultimately 
resulting in right heart failure (2).
Early diagnosis and monitoring of disease progression are critical for therapy decisions. 
Right heart catheterization remains the gold standard for diagnosing PH and managing 
those patients who are receiving PH therapy (1, 3). Brain natriuretic peptide (BNP) is an 
established prognostic biomarker to monitor right heart failure in PH (4), and reﬂects 
myocardial stress. There is, nevertheless, still a need for other non-invasive PH biomarkers 
that mirror pathological alterations that occur in the pulmonary vasculature, and which 
also help to diagnose PH.
Vascular endothelial growth factor (VEGF) signaling is known to be associated with PH 
pathogenesis, particularly in vascular remodeling (5). VEGF expression can be induced by 
hypoxia through upregulation of hypoxia-inducible factor-1α (HIF-1α) (6). Moreover, VEGF 
and VEGF receptor 2 (VEGFR-2) are overexpressed in plexiform lesions of patients with 
PH (7) and plasma VEGF levels are elevated in patients with idiopathic pulmonary arterial 
hypertension (IPAH) (8).
VEGF receptors are membrane-bound receptor tyrosine kinases. The soluble form of 
the VEGF receptor 1 (sVEGFR-1/soluble fms-like tyrosine kinase 1, sFlt-1) results from 
alternative splicing or cleavage of the full-length receptor, Flt-1 (9). The VEGF family 
member placental growth factor (PlGF) binds exclusively to Flt-1 (10), which leads to 
pro-angiogenic signaling through several mechanisms, including direct intracellular 
activation of Flt-1 and downstream target genes, and transphosphorylation of VEGFR-2 by 
activated Flt-1, thereby increasing the response to VEGF (11). Moreover, the PlGF/VEGF-A 
heterodimer can bind and activate Flt-1, and induce Flt-1/VEGFR-2 dimerization (12).
PlGF and sFlt-1 have shown diagnostic and prognostic potential in hypoxia-associated 
preeclampsia (13, 14), in sickle cell disease-associated PH (8, 15) and peripheral and 
coronary artery disease (16). In a recent study Malhotra et al. showed significantly 
upregulated sFlt-1 serum levels in PAH patients. Serum sFlt-1 levels were associated with 
increased New York Heart Association (NYHA) functional class and predict survival (17).
We hypothesize that Flt-1 and PlGF represent important factors in PH and can be used as 
biomarkers.




Patients and biomarker study design
Plasma levels of PlGF and sFlt-1 were measured in patients with five different subtypes of 
PH and compared with a non-PH control group, all undergoing right heart catheterization. 
Furthermore, plasma levels were correlated with hemodynamics, NYHA functional class, 
and survival.
For this case control study consecutive patients with suspicion of PH, undergoing right 
heart catheterization at the Giessen PH referral center, were enrolled in the study. Blood 
samples were taken at the baseline visit during right heart catheterization. The baseline 
visit was the first right heart catheter and the diagnosis or exclusion of PH for all patients. 
Patients with mPAP ≥25 mmHg were defined as having PH. Patients undergoing right heart 
catheterization with mPAP <25 mmHg were defined as non-PH controls. The non-PH 
controls underwent right heart catheterization because symptoms led to suspicion of 
PH, but by right heart catheterization PH was excluded. PH Patients were classified into 
etiological groups according to current guidelines (3). Plasma was collected using EDTA as 
an anticoagulant followed by centrifugation at 3000 g for 10 minutes and samples were 
then frozen at –80°C until analysis. The approval of the Local Research Ethics Committee 
at the University Hospital of Giessen was obtained. All patients gave written, informed 
consent for use and storage of plasma and future biomarker analyses on the day the 
samples were obtained.
Biomarker measurements
PlGF and sFlt-1 were measured with commercially available enzyme immunoassays 
(Quantikine, R&D Systems, Minneapolis, USA). Samples were assayed in duplicate 
according to manufacturer’s instructions.
Statistical analysis
Baseline characteristics are presented as mean +/- standard deviation or median and 
interquartile range where appropriate. Kaplan–Meier curves were constructed and log-
rank tests performed to compare survival distributions. The association of biomarker 
concentrations with survival was tested using univariate and multivariate Cox regression 
analyses. PlGF and sFlt-1 plasma levels were expressed as means (± SEM). One-way ANOVA, 
Tukey post-hoc test, chi-square test, or Kruskal–Wallis test were used for comparisons 
between groups, as appropriate. In order to evaluate the performance of sFlt-1 and 
PlGF as predictors for mortality rates, the area under the curve (AUC) of the receiver 
operating characteristics (ROC) curve was calculated. Correlation analyses were done 
with Pearson’s or Spearman’s co-efficient, as appropriate. A p value <0.05 was considered 
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statistically significant. Statistical analyses were performed using IBM SPSS Statistics 21.0 
(IBM, Armonk, New York, USA).
Results
Demographic characteristics
The demographic characteristics of all patients enrolled in the main biomarker study 
are shown in Table 1. In total, 247 patients with PH were enrolled: 62 patients with 
IPAH, 14 with associated PAH (APAH, i.e. Eisenmenger’s syndrome, HIV, portopulmonary 
hypertension), 21 with collagen vascular disease (CVD), 26 with pulmonary venous 
hypertension (PVH), 67 with lung disease associated pulmonary hypertension (LD-PH), and 
57 with chronic thromboembolic PH (CTEPH). Non-PH controls consisted of 40 patients 
with invasive exclusion of PH due to similar symptoms as PH patients.
Circulating sFlt-1 and PIGF in patients with PH
Blood samples were taken from all patients at the baseline visit, and sFlt-1 and PlGF levels 
measured. Fig. 1 shows sFlt-1 (Fig. 1A) and PIGF (Fig. 1B) plasma levels from patients 
with PH and the non-PH control group. Mean levels of sFlt-1 were markedly elevated 
in all PAH subgroups (IPAH, APAH and CVD). Furthermore, sFlt-1 was also significantly 
elevated in patients with LD-PH. No statistically significant difference was detected 
between either the CTEPH or the PVH groups and the non-PH control group. Actual 
mean plasma sFlt-1 concentrations and p-values for PH groups in comparison with the 
non-PH control group (mean sFlt-1 plasma concentration 3091.6±246.5 pg/mL) were as 
follows: IPAH, 5049.2±460.3 pg/mL (p = 0.045); APAH, 6906.1±1022.1 pg/mL (p = 0.003); 
CVD, 7174.4±1056.1 pg/mL (p < 0.001); PVH, 3945.1±628.9 pg/mL (p = 0.940); LD-PH, 
5338.2±390 pg/mL (p = 0.009); CTEPH, 3701.4±353 pg/mL (p = 0.969). sFlt-1 plasma levels 
were significantly higher in patients with APAH (p = 0.016) or CVD (p = 0.001) compared 
with CTEPH patients, as well as in patients with CVD vs those with PVH (p = 0.012).
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 Figure 1. Levels of (A) sFlt-1 (soluble fms-like tyrosine kinase 1) and (B) PIGF (placental growth 
factor) in patients with pulmonary hypertension (PH) and controls without PH (exclusion), expressed 
as mean±SEM.
Results for all PH groups were compared with the control group (exclusion) using one-way ANOVA with Tukey post-
hoc test: *p < 0.05, **p < 0.01, ***p < 0.001.
APAH = associated pulmonary arterial hypertension; CTEPH = chronic thromboembolic pulmonary hypertension; CVD 
= collagen vascular disease; IPAH = idiopathic pulmonary arterial hypertension; LD-PH = lung disease associated 
pulmonary hypertension; PVH = pulmonary venous hypertension.
PlGF levels were elevated significantly in all PH subgroups compared with the non-PH 
control group (Fig. 1B). Actual mean plasma PlGF concentrations and p-values for PH 
groups in comparison with the non-PH control group (mean PlGF plasma concentration 
21.8±1.5 pg/mL) were as follows: IPAH, 45.6±3.6 pg/mL (p < 0.001); APAH, 54.3±9.1 pg/
mL (p < 0.001); CVD, 56.3±4 pg/mL (p < 0.001); PVH, 40±3.7 pg/mL (p = 0.030); LD-PH, 
53.4±3.4 pg/mL (p < 0.001); CTEPH, 39.3±3.1 pg/mL (p = 0.005).
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No significant differences in sFlt-1 and PlGF levels were detected between men and 
women. Mean plasma concentrations across all PH groups for men and women were as 
follows: sFlt-1, 5071 and 4916 pg/mL, respectively (p = 0.733); PlGF, 48.6 and 45.8 pg/mL, 
respectively (p = 0.393). Mean plasma concentrations across PAH groups (i.e. IPAH, APAH 
and CVD) for men and women were as follows: sFlt-1, 6389 and 5491 pg/mL, respectively 
(p = 0.307); PlGF, 53.3 and 48.1 pg/mL, respectively (p = 0.376). 
sFlt-1 and PlGF as diagnostic markers for PH
ROC analysis was performed and the best cut-off values chosen for sFlt-1 (5753 pg/mL) 
with an AUC of 0.662 (95% CI 0.592–0.733, p = 0.001; Fig. 2) and for PlGF (29.2 pg/mL) 
with an AUC of 0.847 (95% CI 0.797–0.898, p < 0.001; Fig. 2). Specificity was 100% for sFlt-
1 and 85% for PlGF when using the aforementioned cut-off-values. Likewise, sensitivity 
values were 36% for sFlt-1 and 77% for PlGF. The combination of sFlt-1 and PlGF resulted 
in a sensitivity of 62.4% and specificity of 100% (chi-square p < 0.001 for both). For 
combination analysis only patients with both biomarker values above or both below the 


















Figure 2. s-Flt (soluble fms-like tyrosine kinase 1) and PlGF (placental growth factor) as diagnostic 
markers for all pulmonary hypertension (PH) etiologic groups.
Receiver operating characteristic (ROC) curves of sFlt-1 (blue) and PlGF (green) to predict a diagnosis of PH. 
Area under the ROC curve (AUC) for sFlt-1 is 0.765 (95% CI 0.681–0.848; p < 0.001) and for PlGF is 0.905 (95%CI 
0.849–0.960; p < 0.001).
 If ROC analysis was performed only for the PAH group (i.e. IPAH, APAH and CVD), the 
best cut-off value for sFlt-1 was 5753 pg/mL with an AUC of 0.765 (95% CI 0.681–0.848; 
p < 0.001) and the best cut-off value for PlGF was 29.2 pg/mL with an AUC of 0.905 (95% 
CI 0.849–0.960; p < 0.001). For the PAH group the specificity was 100% for sFlt-1, and 85% 
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for PlGF, whilst the sensitivity was 43.3% for sFlt-1 and 83.7% for PlGF. The combination 
of sFlt-1 and PlGF resulted in a sensitivity of 83.7% with specificity of 100% (chi-square 
p < 0.001 for both).
BNP was added to the analysis for diagnostic accuracy. ROC analysis reveals an AUC of 
0.574 with p=0.18 for BNP alone, and an AUC of 0.577 with p=0.16 when combined with 
PlGF and sFlt-1.
sFlt-1 and PlGF to estimate severity of disease
Neither sFlt-1 nor PlGF correlated with mPAP, pulmonary vascular resistance (PVR), 
6-minute walking distance (6MWD) or BNP. Across all PH etiologies the plasma concentration 
of sFlt-1 was significantly different between NYHA classes (p = 0.015; Kruskal–Wallis), and 
PlGF borderline non-significant (p = 0.064, Kruskal–Wallis).
No correlations for PlGF or sFlt-1 with age and creatinine plasma levels were found.
sFlt-1 and PlGF as prognostic markers
Mean survival time was 91 month, in total 130 of 247 patients died. Survival analysis 
showed no statistically significant difference between patients below and above cut-off 
concentrations or median concentrations of sFlt-1 or PlGF. These results were confirmed 
by Cox regression analysis. This was true for both the whole cohort and each etiological 
group in isolation (results not shown).
Discussion
VEGF signaling is known to be involved in vascular remodeling in PH (18).VEGF family 
members are overexpressed in lungs from PH patients and circulating VEGF is elevated in 
plasma of PH patients (8). Inhibition of the VEGFR1 and VEGFR2 with the tyrosine kinase 
inhibitor SU5416 in combination with chronic hypoxia causes severe PAH in rats (19). The 
role of VEGF signaling in PH development is not fully understood, but PlGF is thought 
to act pro-angiogenic by binding to Flt-1, whereas sFlt-1 can bind VEGF and thereby 
decrease its activity (11, 20).
In this study, sFlt-1 and PlGF plasma levels were measured in a population of 247 patients 
with PH of various etiologies, and in 40 patients without PH who served as controls. 
Consecutive patients with suspicion of PH coming to the Giessen PH referral center were 
included in the study. Right heart catheterization was performed in every patient at 
baseline visit, in parallel with blood sample collection. 
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Plasma levels of sFlt-1 were significantly increased in patients with IPAH, APAH, CVD, 
and LD-PH compared with the non-PH controls, whereas PlGF levels were significantly 
increased in all PH groups. Use of PlGF for diagnosing PH resulted in a higher sensitivity 
than for sFlt-1, but sFlt-1 had an associated specificity of 100% for diagnosing PH in our 
patient cohort. When both parameters are combined the specificity still reaches 100% 
and sensitivity levels reach 62.4%. These data show a high potential for PlGF and sFlt-1 as 
diagnostic biomarkers for PH.
The natriuretic peptides, BNP and its N-terminal fragment NT-proBNP, are established 
biomarkers for PH and are in routine use for the clinical management of patients with PH. 
BNP levels are elevated in different groups of PH (4, 21-23) and correlate with hemodynamic 
parameters (24), exercise capacity, WHO functional class (25) and are strong predictors of 
survival in PH (26, 27). Also in direct comparison BNP is a poor diagnostic tool in this study 
and should therefore be used differently than PlGF and sFlt-1. Whilst NT-proBNP and BNP 
can be used as prognostic biomarkers for patients with PH, and can also mirror patients’ 
therapeutic response, their plasma levels can also be normal in severely ill patients with 
PH, and thus cannot be used to exclude a PH diagnosis. 
It is important to emphasize that this is in contrast with the results of the current study, 
where PlGF and sFlt-1 levels show no correlation with PH disease severity – and thus PlGF 
and sFlt-1 have no prognostic potential. Nevertheless, PlGF and sFlt-1 seem likely to be 
useful diagnostic biomarkers for PH.
With their moderate sensitivity and their high specificity for PH (and PAH respectively), 
sFlt-1 and PlGF are reasonably suitable screening tools, however their main strength lies 
in their almost unfailing specificity. Therefore, in the decision making tree of diagnostic 
workup of patients with suspected PH, in cases of a negative test, confirmation by means 
of invasive hemodynamic assessment remains obligatory provided other non-invasive tests 
(e.g. echocardiography) remain suggestive of PH. In case of a positive test, sFlt-1 and 
PlGF are novel tools that confirm PH with high certainty already at an early stage of 
diagnostic evaluation. It must be kept in mind; however that right heart catheterization 
remains mandatory for purposes of diagnostic classification and assessment of current 
hemodynamic severity of the disease. In addition, if the majority of non-invasive diagnostic 
tools are suggestive for a low probability of having PH during early work-up of symptomatic 
patients, but the novel biomarkers are positive, this in itself may become a novel means 
by which the likelihood to oversee PH in symptomatic patients is substantially reduced.
Malhotra et al. measured sFlt-1 serum levels in PAH patients, first degree IPAH and HPAH 
relatives, and healthy controls (17). They find significantly increased sFlt-1 levels in PAH 
patients, with an AUC for diagnosing PAH that is comparable to this study. Furthermore 
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they find an association with increased NYHA and improved survival in patients below the 
median sFlt-1 level. We could confirm the association of sFlt-1 plasma levels with NYHA 
class in our study population, but we find no difference in survival time. Like in our study 
no correlation with hemodynamic parameters could be found.
In summary, we could confirm the diagnostic potential of sFlt-1 and furthermore combined 
sFlt-1 plasma levels with PlGF and which results in a sensitivity of 83.7% with a specificity 
of 100% to diagnose PAH.
The missing correlation of sFlt-1 and PlGF with mPAP, PVR, 6MWD and BNP suggests a 
pathological role that is not directly linked to the increased pressure in the pulmonary 
vasculature and the resulting changes of the right ventricle. Immunohistochemical stains 
of lungs from patients with PAH and from healthy donor lungs showed that the VEGF 
family members Flt-1 and PlGF are expressed in pulmonary arterial smooth muscle cells 
(see online supplement). As vascular remodeling in PH is mainly driven by smooth muscle 
cell proliferation, PlGF and Flt-1 may play a role in remodeling processes in PH. Moreover, 
as smooth muscle cells seem to be the main source of Flt-1 and PlGF in the PH lung, 
increased plasma levels of these molecules may mirror these changes in smooth muscle 
cells. 
It is important to consider what pathophysiological mechanism might underlie the 
presence of PlGF and sFlt-1 as biomarkers for PH, firstly by examining the documented 
role of these molecules in other conditions. Elevated sFlt-1 levels cause endothelial 
dysfunction during preeclampsia by binding circulating VEGF and PlGF, thereby preventing 
their interaction with endothelial cell-surface receptors. Levels of sFlt-1 are also elevated 
in sickle cell disease-PH compared with patients who have sickle cell disease without PH, 
and a correlation with urinary albumin secretion was reported (15). PlGF plasma levels 
are raised in sickle cell disease and higher levels associate with an increased incidence of 
vascular occlusive events (28)
Furthermore, in patients with peripheral and coronary artery disease, sFlt-1 plasma levels 
were lower than in healthy controls (16). It is also notable that PlGF can be induced by 
HIF-1α after exposure to hypoxia, both in vitro and in vivo (29-31). 
In conclusion to this section, the relevance of sFlt-1 and PlGF plasma levels to specific 
pathophysiological mechanisms is unclear, but certainly warrants further research. 
The control group in this study consists of patients visiting our clinic with symptoms 
similar to that in PH patients, and therefore underwent right heart catheterization. This 
is an adequate control group to evaluate potential diagnostic biomarkers as a physician 
wants to differentiate patients with and without PH presenting with similar symptoms 
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rather than to differentiate PH patients from healthy people. We included patients from 
different groups of the World PH classification to test the diagnostic potential of PlGF and 
sFlt-1 for PH vs non-PH in patients showing the same symptoms. In the literature plasma 
levels in healthy controls are reported to be 94.8 pg/ml for sFlt-1 and 13.7 pg/ml for PlGF 
(32). Our control group shows higher levels for both biomarker, but still significantly lower 
levels than PH patients.
Moreover, as plasma was only tested at the time of PH diagnosis, this may represent an 
early window into a mechanism that, conceivably, may only be present at this early stage. 
As such, this study showed a high potential for PlGF and sFlt-1 as diagnostic biomarkers for 
PH. Both proteins were expressed in remodeled vessels of patients with PH, but increased 
plasma levels did not correlate with hemodynamic parameters, 6MWD and BNP. 
This study focused on the diagnostic potential of sFlt-1 and PlGF in PH patients, although 
the sensitivity was higher in PAH than for unselected PH patients. The decision, whether a 
patient should undergo invasive right heart catheterization, is based on a variety of non-
invasive measurements like echocardiography, imaging, clinical symptoms, and circulating 
biomarkers, respectively. sFlt-1 and PlGF may become useful additional parameters which 
help to decide whether or not invasive assessment by means of right heart catheterization 
is required.
 
Undoubtedly, further studies are necessary to understand the role of PlGF and sFlt-1 
in PH, and greater numbers of patients may be needed to investigate correlations with 
disease parameters. We find comparable results to the study of Malhotra et al. (17), 
but confirmations in other patient cohorts are definitely needed. Furthermore, the 
investigation of patient cohorts over time is needed to reveal whether PlGF and sFlt-1 are 
only increased in the early phase of disease, and whether their plasma levels change in 
response to specific therapy.
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HbA1c in Pulmonary Arterial Hypertension
A Marker of Prognostic Relevance? 
SM. J. Belly, H. Tiede, R. E. Morty, R. Schulz, R. Voswinckel, C. Tanislav, 
H. Olschewski, H. A. Ghofrani, W. Seeger, F. Reichenberger




Background: Patients with pulmonary arterial hypertension (PAH) exhibit impaired 
glucose metabolism and increased insulin resistance. The clinical consequences of these 
metabolic changes are not known.
Patients and methods: We assessed HbA1c levels in 115 patients newly diagnosed with PAH 
(79 female, 36 male; mean age 49.2 years; idiopathic n=67, collagen vascular disease n=16, 
congenital heart defect n=19, pulmonary veno-occlusive disease n=8, porto-pulmonary 
n=5). No patients suffered from diabetes, or received antidiabetic medication or systemic 
steroids. After initiation of pulmonary vasoactive treatment, patients remained in long-
term follow-up.
Results: Initially, patients were in an advanced stage of disease (mean pulmonary arterial 
pressure 53±18 mmHg, cardiac index 2.3±0.8 l.min-1.m-2) with a six-minute walking 
distance of 337±123 m, and in NYHA functional class 3.0±0.7. The HbA1c was 5.73±0.75%. 
A moderate but statistically significant positive correlation was observed between HbA1c 
levels and BNP (rp=0.41, p=0.014) but no correlation was found with hemodynamics or 
six-minute walk distance.
The 5-year survival rate for the entire group was 68%. Kaplan-Meier analysis and 
multivariate Cox proportional hazard models correcting for demographic and clinical 
covariates revealed that patients with HbA1c <5.7% had a significantly better 5-year 
survival compared to patients with higher initial values (85.1% versus 55.9%; log-rank 
p=0.002). HbA1c was a predictor of all-cause mortality with a hazard ratio of 2.23 (95% 
CI, 1.06 to 4.70; p=0.034) per 1 Unit increase of HbA1c. 
Conclusion: In patients with pulmonary arterial hypertension, the HbA1c level at time of 
diagnosis is an independent predictor of long-term prognosis.





Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease 
characterized by progressive pulmonary vascular remodelling leading to right ventricular 
dysfunction and right heart failure. PAH encompasses several forms of the disease, including 
idiopathic PAH and PAH due to collagen vascular disease, congenital heart disease and 
portopulmonary hypertension (1). All of these forms of PAH are characterized by similar 
histological features, including intimal and medial hypertrophy and plexiform lesions. 
In severe pulmonary hypertension, atherosclerotic lesions might also be present (2).
In recent years, PAH has been recognized as a disorder with pronounced systemic 
and metabolic consequences, including systemic hypotension, renal impairment, 
hyperuricemia, hyponatremia and hypocapnia (3-6). 
Impaired glucose metabolism has been noted in pulmonary hypertension. The loss-of-
function mutations in bone morphogenetic protein receptor II (BMPR2) associated with 
the development of PAH may affect downstream targets of BMPR2 signalling, such as 
peroxisome proliferator-activated receptor gamma (PPARγ) and apolipoprotein E 
(apoE). Both PPARγ and apoE are involved in glucose metabolism. Animal studies have 
demonstrated that insulin resistance in apoE-deficient mice and deficiency of PPARγ in 
smooth muscle cells of transgenic mice lead to the development of a mouse pulmonary 
hypertension phenotype (7-11). 
In female PAH patients, insulin resistance appears to be more common than in the general 
population and has been associated with worse short-term survival (12). 
Increased glucose intolerance - assessed by the concentration of glycosylated hemoglobin 
A1c (HbA1c) - has been noted in patients with PAH, but without effect on 6 months event 
free survival (13).   
In the present study, we assessed HbA1c concentrations in patients newly diagnosed with 
PAH prior to commencement of therapy and correlated HbA1c values with the long-term 
survival of these patients.
Patients and Methods
In the Giessen Pulmonary Hypertension Center (Department of Internal Medicine, University 
Hospital Giessen, Germany), a specialized referral centre, patients with pulmonary 
hypertension (PH) were diagnosed and evaluated with respect to the underlying disease. 
Diagnosis of PAH was made according to current recommendations (1) by means of clinical 
examination, transthoracic echocardiography, pulmonary function tests, cardiopulmonary 
exercise testing, blood gas analyses, screening for HIV and collagen vascular diseases, 
coronary angiography or sleep studies, as clinically indicated. The presence of chronic 
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thromboembolic pulmonary hypertension  or parenchymal lung disease was excluded 
using thoracic computed tomography, computed tomographic pulmonary angiography 
and pulmonary perfusion scintigraphy. The diagnosis of precapillary PH was confirmed on 
initial right heart catheter investigation by a mean pulmonary arterial pressure (mPAP) of 
>25 mmHg, a pulmonary arterial wedge pressure (PAWP) of <15 mmHg and a pulmonary 
vascular resistance (PVR) of > 240 dyn.s.cm-5. The presence of right-to-left shunting 
had been excluded by transthoracic contrast echocardiography and standardised contrast 
enhanced transcranial Doppler sonography (14).  
In addition to routine laboratory values, brain natriuretic peptide (BNP), fasting blood 
glucose levels and HbA1c levels ( Dimension Vista® HbA1c Kit, Siemens Healthcare, 
Erlangen, Germany) were assessed. After diagnosis of PAH, patients were started 
on pulmonary vasoactive treatment with either endothelin receptor blockers, 
phosphodiesterase 5 inhibitors or prostanoids. When indicated, treatment with calcium 
channel blockers was initiated. Additionally, patients were started on oral anticoagulation 
if not contraindicated.  
Patients were further assessed by World Health Organization (WHO) functional 
classification, six-minute walking distance (6MWD), and if indicated, pulmonary 
hemodynamics, according to current guidelines (1).
The HbA1c levels were assessed with respect to clinical, functional and hemodynamic 
parameters at the time of presentation. Furthermore, long-term follow-up was undertaken, 
paying particular attention to survival while on pulmonary vasoactive treatment with 
respect to initial HbA1c levels. 
Clinical stabilization on initial treatment was assessed by measuring time to clinical 
worsening (TTCW), which has been defined by including time from start of specific 
medication to the beginning of an additional pulmonary vasoactive treatment compound 
or  all-cause-death. The decision of initiation of combination therapy has been based on 
criteria as outlined in the current PAH guideline (1). 
Follow-up data were retrieved from the local PAH database, review of patient histories and 
correspondence, or via telephone contact to the patient or family doctor, respectively.
Statistical analysis: Since the data exhibited a normal distribution, parameters are 
displayed as mean±standard deviation, otherwise median±interquartile range was used. 
To test for significant differences between groups, the two-tailed Student’s t- test was 
used. Correlations between two variables were analysed using the Pearson correlation 
coefficient. ANOVA was used to identify relevant covariates for survival. 
Kaplan-Meier analysis with log-rank test and multivariate Cox proportional hazard models 
correcting for demographic and clinical covariates were used to assess the difference in 
survival depending on the level of HbA1c at time of initial assessment.  




Univariate and multivariate Cox regression models were used to calculate hazard 
ratios and a multivariate survival analysis (also using Cox’s regression mode) was used 
to eliminate significant covariates and to assess independent predictors for long-term-
survival. A p-value of <0.05 was considered statistically significant. Statistical analysis was 
performed with SPSS 17.0 (SPSS, Chicago, IL, USA).
Patients gave written informed consent for entering the study. The study has been 
approved by the Ethics Committee of the Medical Division of the Justus Liebig University 
of Giessen (approval number 113/11). 
Results
Characteristics of PAH Patients 
Between June 1996 and July 2007, 529 patients were diagnosed with PAH in our centre. For 
the present study we excluded patients on treatment with corticosteroids (n=42), diagnosis 
of diabetes mellitus according to the new guidelines (n=53) (15), previous treatment with 
pulmonary vasoactive compounds (n=27), lack of available HbA1c measurement at time of 
initial presentation (n=194) or lack of follow up data (n=98). Survival data were collected 
until May 2010. 
Subsequently, 115 therapy-naïve patients newly diagnosed with PAH were included in the 
analysis, among them 79 women and 36 male with a mean age of 49.2 years and a mean 
HbA1c of 5.73±0.75% prior to commencement of pulmonary vasoactive treatment. The 
demographic, hemodynamic, clinical and laboratory characteristics of the study subjects 
are summarized in Table 1. Baseline criteria of the patients excluded from analysis were 
similar and are also shown in this table.
A moderate but statistically significant positive correlation was observed between 
HbA1clevels and BNP (rp=0.41, p=0.014) and NYHA functional class (rp=0.32, p=0.001), 
respectively. No correlation was found between hemodynamic parameters, 6MWD, body 
mass index, age, uric acid, creatinine, pO2 or pCO2. 
For further analysis the patient population was separated by initial HbA1c and dichotomized 
at a value equal to or greater than 5.7%, selecting a cutoff with a clinical basis according 
to current guidelines (15). Dose-related effects on survival have been shown by also 
stratifying into quartiles and by using glycosylated hemoglobin as a continuous variable. 
Baseline data are shown in table 2.
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Table 1. Baseline characteristics and hemodynamics, dichotomized for HbA1c values. 
HbA1c (%) total < 5.7 ≥ 5.7 % p excluded         p
Subjects (n) 115 50 65 414                  
Male / female 36 / 79 17 / 33 19 / 46  132 / 282          
Age (yrs) 49.2 ± 15.9 46.6 ± 15.5 51.1 ± 16.0 0.13 51.3 ± 16.0   0.27
BMI (kg/m2) 25.6 ± 5.2 25.1 ± 5.0 25.9 ± 5.3 0.46 25.9 ± 4.3     0.63
BNP (pg/ml) 342 ± 461 101 ± 87 467 ± 527 0.02 275 ± 342     0.24
Blood glucose 
(non-fasting, mg%) 103 ± 26 101 ± 28 105 ± 23 0.48 109 ± 37       0.43
Hemoglobin (g/dl) 15.5 ± 2.0 15.4 ± 1.8 15.6 ± 2.1 0.66 14.7 ± 2.2     0.17
NYHA 3.0 ± 0.7 2.8 ± 0.8 3.1 ± 0.6 0.06 3.0 ± 0.6       0.78
mPAP (mmHg) 53 ± 18 50 ± 16 55 ± 19 0.25 50 ± 16         0.14
PVR (dyn.s.cm-5) 1014 ± 657 843 ± 672 1101 ± 639 0.12 967 ± 572     0.32












131 ± 23       0.34
75 ± 14         0.17
6MWD (metres) 337 ± 123 346 ± 124 330 ± 123 0.61 325 ± 126     0.55
For comparison, characteristics of the excluded patients without HbA1c value are presented. Data are presented as 
mean ± SD or n (%), unless otherwise stated. For abbreviations, see text.
Table 2. Baseline characteristics, hemodynamics and etiology, divided into quartiles according to the 
HbA1c value. Data are presented as mean ± SD or n (%), unless otherwise stated. For abbreviations, 
see text.
HbA1c (%) ≤ 5.3 5.31-5.79 5.8-6.19 ≥ 6.2 p 
Subjects (n) 30 29 31 25
Male / female 8 / 22 13 / 16 9 / 22 6 / 19
Age (yrs) 46.9 ± 15.6 48.2 ± 15.4 50.2 ± 16.1 51.6 ± 16.8 0.70
BNP (pg/ml) 78 ± 53 280 ± 519 430 ± 562 533 ± 348 0.26
NYHA 2.7 ± 0.9 3.0 ± 0.6 3.0 ± 0.6 3.2 ± 0.7 0.14
mPAP (mmHg) 47 ± 14 52 ± 20 53 ± 19 59 ± 18 0.30
PVR (dyn.s.cm-5) 671 ± 436 1030 ± 770 1062 ± 712 1224 ± 566 0.11














6MWD (metres) 341 ± 123 369 ± 126 351 ± 93 279 ± 146 0.23































Clinical, functional and hemodynamic parameters did not differ between both patient 
groups at the time of initial assessment, apart from BNP and systolic blood pressure (Table 1).
There was no statistical significance difference in HbA1c, brain natriuretic peptide, 
clinical, functional and hemodynamic parameters between male and female patients at 
the time of initial assessment (data not shown). 
Survival rates and factors affecting survival
The overall 1-, 3-, and 5-year survival rates were 94.6%, 80.6% and 68.2%, respectively. 
(Table 3). Four patients developed diabetes mellitus requiring antidiabetic medication 
during the follow up. Seven patients suffered from acute myocardial infarction and 3 
patients suffered from stroke.
A total of 40 deaths occurred during follow-up, in 25 patients due to right heart failure in 
progressive PAH (62.5%).
Patients presenting with a baseline HbA1c <5.7% had a significantly better 5 year survival 
compared to patients with an initial HbA1c ≥5.7% (85.1% vs. 55.9%, log rank p=0.002). 
(Figure 1 and Table 3). This statistical significant difference was consistent after correction 
for PH related death (log rank p=0.03).
Table 3. Comparison of survival rate and number of deaths in pulmonary arterial hypertension 
patients based on initial HbA1c levels and dichotomized at a level of 5.7%. 
HbA1c (%) total < 5,7% ≥ 5,7%             log-rank p

















Deaths 40 (34.8%) 8 (16.0%) 32 (49.2%)
PH related 25 (62.5%) 3 (37.5%) 22 (68.8%)
non-PH related 15 (37.5%) 5 (62.5%) 10 (31.2%)
Data are presented as n (%), unless otherwise stated. For abbreviations, see text.   
A Cox regression model was built for evaluation of predictive value of HbA1c. After 
adjustment for the plausible covariates age, gender, 6MWD, NYHA functional class and 
PVR, HbA1c was a predictor of all-cause mortality with a hazard ratio (HR) of 2.23 (95% 
CI, 1.06 to 4.70; p= 0.034) per 1 Unit increase of HbA1c. 
For the patient group with HbA1c ≥5.7% the adjusted HR for all-cause mortality was 3.91 
(95% CI, 0.97-12.03; p=0.056, unadjusted p <0.05). 
The adjusted all-cause mortality increased per quartile increase in HbA1c, with a HR 
ratio of 1,21 (95% CI 0,39-3,78) between quartile 1 and 2, a HR of 1,27 (95% CI 0,41-3,93) 
13106_Gall_BW.indd   97 22-01-16   15:11
Chapter 3.3
98
between quartile 2 and 3, and a HR of 2,52 (95% CI 0,87-7,30) between quartile 3 and 4 
(overall p = 0.04) (Figure 2 and table 4). After correction for PH related death this misses 
statistical significance (log rank p = 0.11).
There was, however, no difference in time to clinical worsening between HbA1c quartiles 









Number at risk       
50 45 43 43 36 30 --- 
65 59 50 40 35 30 --- 
Figure 1. Kaplan-Meier 5-year survival curve in pulmonary arterial hypertension patients. Patients 
presenting with HbA1c levels below 5.7% (---) had a significantly better survival rate compared with 
their counterparts with an HbA1c of greater than or equal 5.7% (---). 
(85.1% versus 55.9%; overall log-rank p=0.002; n=115)
Table 4. Comparison of survival rate and number of deaths in pulmonary arterial hypertension patients 
based on initial HbA1c levels and divided into four groups (quartiles). 
HbA1c (%) ≤ 5.3 5.31-5.79 5.8-6.19 ≥ 6.2 log-rank p 




















Deaths 5 (16.6%) 9 (31.0%) 11 (35.4%) 15 (60.0%)
Data are presented as n (%), unless otherwise stated. For abbreviations, see text.   








 Number at risk       
30 25 23 23 21 17 --- 
29 29 26 23 18 15 --- 
31 28 25 21 20 18 --- 
25 22 19 16 12 11 --- 
Figure 2. Cumulative 5-year mortality from all causes stratified in quartiles of HbA1c.
First: HbA1c < 5.3% ´; Second: HbA1c 5.31-5.79% ´; Third: HbA1c 5.8-6.19% ´; Fourth:  HbA1c ≥ 6.2 ´ (83.6% versus 
73.3% versus 68.5% versus 50.6%; overall log-rank p=0.04; n=115)
Discussion
Impaired glucose metabolism has been noted in PAH, and animal and clinical studies 
describe a higher rate of insulin resistance associated with this disease.   
In the present study, we measured HbA1c levels in non-diabetic PAH patients prior to 
initiation of pulmonary vasoactive treatment. In the whole study population, the mean 
HbA1c level was  5.73±0.75% at a mean age of 49.2±15.9 years. This is higher than the 
normal HbA1c in non-diabetic subjects within this age-group (between 4.9-5.5% at age 
of 40 to 70 years) according to large epidemiological studies (16). We excluded patients 
with manifest diabetes mellitus according to recent, revised guidelines (15) and indeed, 
all patients included in the study exhibited HbA1c levels of <6.5% or a non-fasting random 
blood glucose concentration <200mg%.  
In patients with heart failure, impaired glucose metabolism has been associated with 
worse clinical parameters and outcome (17, 18). In PAH, a previous study connected 
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insulin resistance with short term event-free survival (12). In contrary, HbA1c level has 
not been connected to short term event free survival in PAH (13).  
In our PAH patient group, no association between HbA1c level and anthromorphometric 
parameters, gender, hemodynamic or functional parameters was observed. This is in 
accordance with the recent findings of Pugh et al. (13). Importantly, we could show that 
PAH patients with a HbA1c levels <5.7% had a significantly better prognosis in long term 
follow up at 1, 3 and 5 years compared to patients presenting with initial HbA1c levels 
of ≥5.7% (Figure 1) even after correction for PH related death. The long-term outcome 
was associated with HbA1c levels in a dose-dependent manner. We calculated a 2.2-fold 
increase in hazard of all-cause mortality in PAH patients per 1 Unit increase in HbA1c 
levels after adjustment for age, gender, 6MWD, NYHA functional class and PVR. These 
data identify HbA1c as an indicator of impaired glucose metabolism, and connect HbA1c 
levels with long-term prognosis of patients with PAH. We suggest that HbA1c concentration 
might serve as a novel biomarker of long-term prognosis of patients classified as having 
PAH according to recently described criteria (19).
What could be the causes of impaired glucose metabolism in PAH? Possible explanations 
involve inactivity due to exercise impairment with a subsequent change in metabolism, 
impaired PPARγ activity due to impaired BMP signalling, but also an impairment of 
pancreatic-hepatic interaction due to venous congestion (11, 12). Furthermore, impaired 
gas exchange with hypoxaemia might impact glucose metabolism (20). However, in the 
present study, there was no demonstrable association between pO2, pCO2 and HbA1c 
levels. Studies in animal models of PAH indicate that insulin resistance is involved in 
structural changes to the pulmonary vasculature (9-11). Our retrospective study points to 
a long-term consequence of altered glucose metabolism in PAH which is reﬂected in the 
impact on survival. Certainly, a longterm prospective study on HbA1c in PAH is warranted, 
the importance and usefulness of such a study is underlined by our data.
In our study population there was a moderate correlation between HbA1c levels and BNP 
levels. Previous studies in diabetic heart failure patients connect insuline resistance to 
an increase in neurohormones such as BNP, however a causative impact of BNP on HbA1c 
concentration is not reported (21, 22). In our study the mid- and long-term survival was 
better than recently reported from the French and the US registry for PAH. We consider 
this as a result of the inclusion criteria. In our study we intentionally excluded patients 
with significant comorbidities, such as diabetes mellitus or steroid treatment. Furthermore 
there were less patients included with PAH due to connective tissue disease, a subset of 
PAH with a known worse prognosis (23, 24).
Our study has several limitations. Firstly, it is the result of a retrospective data analysis. 
Secondly, we cannot exclude a selection bias, as HbA1c was missing at baseline in 
many patients. Thirdly, we did not perform serial HbA1c measurements during active 




pharmacological treatment or other interventions such as exercise training. Prospective 
evaluation of HbA1c levels with respect to treatment in a larger cohort of PAH patients is 
required for further validation of HbA1c as a prognostic parameter in PAH. 
In conclusion, non-diabetic therapy-naïve PAH patients have higher HbA1c levels compared 
to the normal population. Levels of ≥5.7% are associated with a worse long-term outcome. 
HbA1c levels in patients with PAH might serve as an independent prognostic factor of long 
term prognosis with a hazard ratio of 2.2 per Unit increase in HbA1c.  
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Background: This study sought to analyze a new approach to assess exercise-induced 
systolic pulmonary artery pressure (PASP) increase by means of stress-Doppler 
echocardiography as a possible measure of right ventricular (RV) contractile reserve in 
patients with severe pulmonary hypertension (PH) and right heart failure. 
Methods: In this prospective study, patients with invasively diagnosed pulmonary arterial 
hypertension or inoperable chronic thromboembolic PH and impaired right ventricular 
pump function despite a stable targeted PAH medication underwent a broad panel of 
non-invasive assessments including stress echocardiography and cardiopulmonary 
exercise testing. Based on the assumption that exercise-induced PASP is a measure of 
right ventricular contractile reserve patients were classified into 2 groups according 
to an exercise-induced PASP increase above or below median. Patients were followed 
for 3.0±1.8 years. Uni- and multivariate analysis were employed for analysis of factors 
predicting survival.    
Results: Of 124 patients, 66 were below the median exercise-induced PASP increase of 
30 mmHg (low PASP), and 58 patients were above (high PASP). These groups were not 
significantly different concerning medication and resting hemodynamics. Low PASP was 
associated with a significantly lower 6-minute walking distance, peak VO2/kg and 1-, 3-, 
and 4-year survival rate (92%, 69% and 48% respectively vs. 96%, 92% and 89%). In the 
stepwise forward selection multivariate analysis, only peak VO2/kg and exercise-induced 
PASP-increase remained independent prognostic markers (hazard ratio 2.51 for peak VO2/
kg and 2.99 for PASP increase).
Conclusion: Exercise-induced PASP-increase is of high clinical and prognostic relevance 
in PH-patients and may indicate right ventricular contractile reserve. Stress Doppler 
echocardiography may be a useful tool for prognostic assessment in PH-patients.
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Introduction
Right ventricular (RV) pump function is of essential clinical and prognostic importance in 
a variety of heart and lung diseases, and in pulmonary arterial hypertension (PAH).1-5 The 
survival in PH patients depends on the capability of the RV to adapt to chronically elevated 
pulmonary artery pressures.6 Therefore, an accurate evaluation of RV pump function 
would be crucial for screening, diagnosis and follow-up assessment in PH.7 However, it is 
difficult to assess RV function due to its complex geometry and load-dependence and due 
to an inadequate standardization of the assessment.8 This is true for both non-invasive and 
invasive techniques. Evaluation of RV performance in PH patients has been recommended 
to be obtained at rest.9 It is unknown if assessment of RV function during exercise may be of 
additional benefit or even preferable. According to clinical experience, some PH patients 
with severely enlarged right heart and impaired RV pump function at rest do much better 
in their exercise capacity, WHO functional class and quality of life than others. They 
might differ in their RV reserve defined as the ability of the ventricle to increase ejection 
fraction and stroke volume during exercise or pharmacological stress.10,11 RV and left 
ventricular contractile reserve refers to changes in systolic function11 and has not been 
assessed in patients with pulmonary arterial hypertension (PAH) or inoperable chronic 
thromboembolic PH (CTEPH). In small studies, RV contractile reserve has been estimated 
during dobutamine stress echocardiography and had a prognostic impact in patients with 
mitral valve disease using RV tissue Doppler indices (isovolumic contraction)12 and in left 
heart failure using plots with RV pressure-area relations1 but there are no established 
methods to assess RV contractile reserve.11 Exercise-induced changes in radionuclide RV 
ejection fraction seemed to be inversely related to pulmonary artery pressure changes in 
patients with valvular left heart disease.3 
The objective of this study was to prospectively assess exercise-induced increase of 
systolic pulmonary arterial pressure (PASP) as a possible measure of the RV contractile 
reserve using exercise stress echocardiography in patients with invasively confirmed 
manifest PH and to analyze the prognostic impact of exercise-induced PASP increase in 
context with other prognostically relevant parameters. 




Study Population and Design
This prospective study investigated patients with severe chronic PAH or inoperable CTEPH 
and right heart failure, WHO functional class II-IV. For safety reasons only patients between 
18 and 80 years, and those who received an optimized medical PAH-targeted therapy (as 
endothelin-antagonists, inhaled or parenteral prostanoids, phosphodiesterase-inhibitors, 
anticoagulants, diuretics, and supplemental oxygen) for at least 2 months before 
entering the study were included. Patients had to be able to participate to standard 
echocardiography and cardiopulmonary exercise testing (CPET). The maximal PASP-value 
during exercise was obtained as mean value of at least 3 measurements. To avoid the 
inclusion of patients with only mild impairment of RV pump function and to make both groups 
comparable, patients with a workload of >75 Watt during stress Doppler echocardiography 
were excluded, Thus, PASP-increase has been compared in low workloads only. Patients 
were then assigned to a “high” or “low PASP increase” group according to the median 
of the obtained maximal increase of PASP reached during exercise. The diagnosis was 
established at the participating PH centers according to current guidelines.7,9 
The patients were referred to Heidelberg from several PH centers. All patients 
underwent a detailed clinical work-up including medical history, physical examination, 
electrocardiogram, 2-D-echocardiography at rest and during exercise, lung function 
test, arterial blood gases, CPET, 6-minute walking distance (6MWD) under standardized 
conditions,13 quality of life questionnaire (SF-36), laboratory testing including NTpro-
BNP levels, was performed in Heidelberg and set as baseline assessment. Left heart 
catheterization and/or computed tomography of the lungs were performed in all patients 
with suspected left heart or respiratory diseases and when clinically indicated. Exercise-
induced PASP and peak VO2 were assessed by an experienced team at the Thoraxclinic in 
Heidelberg in all patients. All patients gave written informed consent for this study, which 
was approved by the Ethics Committee of the University of Heidelberg.
                                               
Echocardiography: Two-dimensional and colour-ﬂow guided Continuous-wave-Doppler-
echocardiographic recordings were ob tained by experienced cardiac sonographers 
(EG, CN) using 2.5 MHz Duplex probes and conventional equipment (Vivid 7, GE 
Healthcare, Milwaukee, Wisconsin) on two occasions: 1) at rest; 2) during stress Doppler 
echocardiography as described previously.14 PASP was estimated from peak tricuspid 
regurgitation jet velocities (TRV) according to the equation: PASP= 4 (V)2 + right atrial 
pressure, where V is the peak velocity (in m/s) of tricuspid regurgitation jet (TRV).15 
For all calculations the mean value of at least 3 TRV measurements was used. Right 
atrial pressure was estimated from characteristics of the inferior vena cava.16 If it was 
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< 20 mm in diameter and decreased during inspiration we added 5 mmHg, ≥20 mm we 
added 10mmHg and 15 mmHg if no decrease of diameter during inspiration occurred. 
Echocardiographic assessments were performed according to current guidelines.8
Stress-Doppler-Echocardiography and cardiopulmonary exercise testing: Patients 
were examined on a variable load supine bicycle ergometer (model 8420; KHL Corp., 
Kirkland, Washington) in Heidelberg as described previously.14 Workload was increased 
by 25 Watt every 2 minutes to an exercise capacity or symptom limited maximum. TRV, 
heart rate, oxygen saturation and systemic blood pressure were analyzed at each stage. 
Echocardiographic assessment was stored in DICOM format. The anaerobic threshold was 
determined using the V-Slope method.17 Peak VO2 was defined as the highest 30-second 
average value of oxygen uptake during the last minute of the exercise test. Borg 
dyspnea index (with 6 representing no exertion and 20 maximal exertion)18 was inquired 
immediately after the test.
Follow-up Assessment 
In 2012 all participating patients were interviewed either by phone or at a control visit in 
the Thoraxclinic Heidelberg evaluating symptoms, WHO functional classification, current 
medication, any cardio-pulmonary events that might have occurred since last observation. 
Furthermore, medical records were reviewed to document among others potential 
worsening events and current medication. In the case where a patient deceased, date of 
death was recorded and treating physicians and/or relatives were asked for the cause and 
circumstances of death. The PASP-increase during exercise as well as cardiopulmonary 
exercise parameters, echocardiographic parameters and 6-minute walking distance were 
analyzed for their predictive value on survival.
Statistical Methods
Statistical analyses were conducted by a statistician (CF). Data are desribed as means ± 
standard deviations. For follow-up assessments baseline was defined as the day when the 
patient underwent the cardiopulmonary exercise test. Survival time was estimated from 
baseline until June 2012 (end of follow-up in this study). All quantitative characteristics 
between the two groups at baseline and during follow up were compared by t-tests. For 
comparison of categorical variables between groups chi-square test was used. In case of 
sparse cell counts with less than 5 rows and columns Craddock-Flood tests and Haldane-
Dawson test for larger sparse tables were used. 
For analysis of survival, death was the endpoint and one case of lung transplantation was 
added to the deaths.
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No patient died of non-cardiopulmonary causes. Three patients were lost to follow-up and 
described but not included in the survival analysis.
For analysis of predictive parameters for probability of death we performed a univariate 
analysis and a multivariate analysis. In all quantitative variables we used the median 
value to divide the cohort into two groups and used the dichotomous variable for analysis 
of their inﬂuence on survival. The univariate analyses were performed using log-rank tests 
for comparing Kaplan-Meier survival curves.19 
All variables identified within the univariate analysis as being significantly associated with 
survival (p<0.05) and being measured in more than 95% of the patients were selected 
for the multivariate analysis. For the multivariate analyses, variables were chosen for 
the model by stepwise forward selection within the Cox model based on likelihood ratio 
tests with p<0.05 for inclusion and p<0.10 for exclusion. Effect sizes are given as hazard 
ratios point estimates with 95% confidence intervals (CI) within Cox proportional hazard 
model.20 For uni- and multivariate analysis we performed a sensitivity analysis including 
only patients with PAH. All analyses were performed using IBM SPSS 20 (SPSS Statistics 
V20, IBM Corporation, Somers, New York).
Results
Study population (Table 1)
We prospectively included 153 patients diagnosed with severe PH and right heart failure, 
7 patients were excluded because TRV could not be obtained during exercise, 21 because 
they reached higher workloads than 75 Watt during stress Doppler echocardiography, 
suggesting an only mild impaired RV pump function. Thus, the final study group consisted 
of 124 patients with invasively confirmed manifest PH and severely impaired RV pump 
function (37 males and 87 females, mean age 54±16 years; 104 with pulmonary arterial 
hypertension (PAH) and 20 with inoperable CTEPH (Table 1, figure 1)). The exclusion of the 
21 patients who reached higher workloads made the assessment of PASP-increase during 
exercise better comparable between groups and did not significantly change the results 
of univariate and multivariate analysis or the estimated survival rates. 
Subgroups with different exercise-induced PASP-increase suggesting different RV 
contractile reserve: According to the median exercise-induced PASP increase of 30mmHg 
we defined two subgroups: Group A “low PASP” (PASP ≤30mmHg, suggesting reduced or 
low RV contractile reserve) included 66 patients (24 males, 42 females, mean age 57±15 
years) and Group B “high PASP” (PASP >30mmHg, suggesting preserved RV contractile 
reserve) included 58 patients (13 males, 45 females, mean age 50±17 years) (Table 1).
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Table 1.
Increase of systolic pulmonary 
arterial pressure
A B  
All patients  ≤ 30mmHg  > 30mmHg p-Value
Patients, n  124   66   58   
Gender male/female 37 / 87 24 / 42 13 / 45 0.09
Age, years 54 ± 16 57 ± 15 50 ± 17 0.018
Height, cm 167 ± 7 168 ± 8 166 ± 7 0.071
Weight, kg 74 ± 17 77 ± 16 71 ± 18 0.012
WHO Functional Class - No. (%)           
 II 10 (8%) 5 (8%) 5 (9%) 0.052*
 III 104 (84%) 52 (79%) 52 (90%)  
 IV 10 (8%) 9 (14%) 1 (2%)  
Diagnosis           
 Pulmonary artery hypertension  (79.0%) 51 (81.8%) 47 (81%) 0.89*
 Chronic thromboembolic pulmonary hypertension  (21.0%) 12 (18.2%) 8 (19%)  
NTproBNP, pg/ml           
  1578 ± 2192 1973 ± 2419 1156 ± 1849 0.006
Cardiac Catherization:           
 Pulmonary artery pressure [mmHg] 50 ± 15 47 ± 15 52 ± 14 0.070
 Pulmonary Vascular Resistance [dyn×sec×cm-5] 861 ± 430 800 ± 423 935 ± 430 0.079
 Right Atrium Pressure [mmHg] 8 ± 4 8 ± 3 8 ± 4 0.88
 Pulmonary Artery Oxygen Saturation [%] 92 ± 6 91 ± 6 92 ± 5 0.63
 Pulmonary capillary wedge pressure [mmHg] 9 ± 4 9 ± 5 9 ± 4 0.83
 Cardiac Index [l×min×m-2] 2.4 ± 0.7 2,3 ± 0,7 2,4 ± 0,7 0.64
PAH-targeted medication           
 Endothelin Receptor Antagonists 86 (69.4%) 48 (72.7%) 38 (65.5%) 0.29**
 Phosphodiesterase-5-Inhibitors 88 (71%) 49 (74.2%) 39 (67.2%)  
 Prostanoids inhaled 10 (8.1%) 4 (6.1%) 6 (10.3%)  
 Prostanoids intravenous 4 (3.2%) 3 (4.5%) 1 (1.7%)  
 Calcium Channel Blockers 18 (14.5%) 8 (12.1%) 10 (17.2%)  
 Soluble guanyl cyclase-Stimulator 3 (2.4%) 0 (0.0%) 3 (5.2%)  
Combination Therapy           
 Monotherapy 47 (37.9%) 24 (36.4%) 23 (39.7%) 0.71***
 Dualtherapy 60 (48.4%) 33 (50%) 27 (46.6%)  
 Tripletherapy 16 (12.9%) 9 (13.6%) 7 (12.1%)  
 Quadrupletherapy 1 (0.8%) 0 (0%) 1 (1.7%)  
Oxygen Therapy y/n 68 / 56 39 / 27 29 / 29 0.31
y = yes, n = no
Values are mean ± standard deviation; p-values refer to two-sided tests,  t-tests incase of quantitative variables, 
Chi square tests* for 2by2 contingency tables
Haldane-Dawson** and  Craddock-Flood test*** in tables; monotherapy compared to combination therapy







Figure 1: S tudy ﬂow-chart
Illustration of the entire study from the enrollment process until the end of follow-up.
Both groups did not significantly differ concerning their hemodynamic values measured 
by right heart catheterization or targeted PAH medication at baseline (Tables 1 and 2). 
According to right heart catheterization, at rest both groups had markedly reduced 
cardiac output and cardiac index, elevated pulmonary vascular resistance and mean 
pulmonary arterial pressures (Table 1). Echocardiography showed markedly enlarged RV 
area, reduced tricuspid annular plane systolic excursion (TAPSE), severely elevated left 
ventricular excentricity index (LVEI) due to impressed LV by the enlarged RV (Table 2). LVEF 
did not significantly differ between groups (PASP increase < 30mmHg 82.6±16.8 vs. PASP 
increase > 30mmHg 85.8±17.7; p=0.356). Patients with impaired left ventricular function/
PH due to left heart disease were not included into the study. In Subgroup A (PASP increase 
<30mmHg) were 5 patients with atrial fibrillation, in subgroup B 3 patients, respectively. 
In group A, patients were older (p=0.018), had higher mean NTproBNP-levels (p=0.006), 
mean heart rate at rest (p=0.033) and mean right atrial area (p=0.011) compared to 
group B. Apart from these resting parameters, the patients of both subgroups did not 
significantly differ concerning right heart catheterization and echocardiography measures 
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(table 1). Patients with high PASP-response (group B) had similar echo findings at rest 
with severely enlarged RV- compared with patients in group A (figure 2). Right atrial area 
significantly differed between groups (26.0±10.2 group A vs. 20.0±5.7 group B, p=0.005).
Table 2
      Increase of systolic pulmonary arterial pressure  
     A B  
Characteristic Total  ≤30mmHg  >30mmHg p-value
Mean 6-Minute-Walking Distance, meter
  420 ± 83 400 ± 89 443 ± 70 0.011
Echocardiography
 Right Ventricular Area, cm2 25.4 ± 7.4 26.9 ± 7.4 24.3 ± 7.2 0.13
 Right Atrial Area, cm2 23.1 ± 8.8 26.0 ± 10.2 20.0 ± 5.7 0.005
 LVEI 1.5 ± 0.4 1.5 ± 0.4 1.4 ± 0.3 0.18
 TAPSE 1.86 ± 0.42 1.85 ± 0.36 1.87 ± 0.49 0.89
 TDI s 10.6 ± 3.3 9.9 ± 2.6 11.5 ± 3.8 0.14
Cardiopulmonary exercise testing
 peak VO2/kg, mL/Min/kg 11.5 ± 2.52 11.0 ± 2.4 12.0 ± 2.6 0.025
 peak VO2, ml/min 832 ± 192 829 ± 202 835 ± 184 0.39
 EqCO2 at AT, ml/min 48.4 ± 10.0 47.8 ± 9.8 49.1 ± 10.2 0.67
 VO2 at AT, ml/min 603 ± 165 635 ± 174 564 ± 147 0.11
 Oxygen pulse, (mL/min)/min-1 6.9 ± 1.7 7.1 ± 1.9 6.7 ± 1.6 0.29
 HR rest, min-1 79 ± 12 81 ± 11 77 ± 13 0.033
 HR max, min-1 123 ± 18 120 ± 19 126 ± 16 0.047
 RR sys rest, mmHg 116 ± 18 114 ± 19 117 ± 17 0.19
 RR dia rest, mmHg 76 ± 16 77 ± 20 76 ± 11 0.64
 RR sys max, mmHg 144 ± 25 141 ± 24 148 ± 27 0.12
 RR dia max, mmHg 84 ± 14 82 ± 15 86 ± 13 0.072
 Oxygen saturation rest, % 94 ± 5 94 ± 4 94 ± 6 0.41
 Oxygen saturation max, % 87 ± 10 87 ± 11 87 ± 8 0.84
 sPAP rest, mmHg 64 ± 17 65 ± 18 63 ± 17 0.63
 sPAP max, mmHg 98 ± 25 85 ± 20 111 ± 23 <0.001
 Workload max, W 60 ± 12 58 ± 12 62 ± 13 0.12
 Respiratory quotient 0.97 ± 0.12 0.99 ± 0.12 0.96 ± 0.10 0.19
 Left ventricular ejection fraction, % 84.1 ± 17.2 82.7 ± 16.8 85.8 ± 17.7 0.36
 Increase in sPAP, mmHg 34 ± 19 21 ± 8 49 ± 17  
Values are mean ± standard deviation; two-sidel t-test pvalues are given 
6MWD=6-minute walking distance, VO2/kg=max. oxygen consumption/kg, HR=heart rate, 
RR=Blood pressure, sys=systolic, dia=diastolic, sPAP=systolic Pulmonary arterial pressure, W=Watt.
LVEI=left ventricular ejection index, TAPSE=tricuspid annular plane systolic excursion, TDI_s=Strain tissue doppler 
imaging












Figure 2: Illustration of two groups with low (group A) and high (group B) PASP-increase during 
exercise.
PASP changes that occur during cardiopulmonary exercise testing among PH patients with medium to severe 
impairment of right ventricular pump function. In some of the patients a significant increase in PASP can be 
observed during exercise whilst in others the change is minimal, though echocardiographic parameters as right 
heart size were not significantly different.
Clinical-technical observations during exercise stress echocardiography
In almost all patients TRV could be assessed by echocardiography at rest and during 
exercise due to the presence of tricuspid regurgitation in the enlarged right hearts. Stress 
echocardiography and CPET was safe and could be performed without complications in 
all patients. 
Correlation of peak VO2/kg and 6MWD in groups with low and high exercise-induced 
PASP-increase: There was a significant, but weak correlation of the PASP-increase during 
exercise with 6MWD and peak VO2/kg (Figure 3a and 3b). Patients with high exercise-
induced PASP-increase also showed higher values for peak VO2/kg and 6MWD than patients 
with a low PASP-increase. 
Follow-up and survival analyses (Figure 4a, 4b)
During a mean follow-up period of 3.0±1.8 years (median 2.9 years; interquartile range 
2.0-3.9 years) 31 patients died due to PH and/or right heart failure, and 3 patients were 
lost to follow-up. Within follow-up, significantly more patients died in group A compared 
to group B (24 vs. 7 patients). Patients in group A revealed significantly lower 1-, 3-, and 
4-year survival rates of 92%, 69% and 48% than patients of group 2 with 96%, 92% and 89% 
(p=0.002, figure 4a). The 1-, 3-, and 4-year survival rates for all patients were 94%, 80% 
and 67%, respectively (Figure 4a). As a further prognostic factor, the median of peak VO2/
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kg (11.4ml/min/kg) was used to split the patients into two groups. Patients with a peak 
VO2/kg >11.4ml/min/kg had significantly higher survival rates (98%, 93% and 80%) than 
patients with peak VO2/kg ≤11.4ml/min/kg (90%, 67% and 56%) for the 1-, 3- and 4-year 
survival rates (figure 4b).















Figure 3a: Correlati on of peak VO2/kg and PASP-increase during exercise















Figure 3b: Correlation of 6MWD and PASP-increase during exercise
The correlation between PASP-increase and peak VO2/kg  (r=0.245) and 6MWD (r=0.337) was significant. There was 
a significant difference (p=0.006 for peak VO2/kg and p<0.001 for 6MWD) but weak correlation between the two 
subgroups in relation to the median peak oxygen consumption of 11.4mL/min/kg and walking  distance of 428m. 
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Figure 4a: Survival rate of PH patients in relation to right ventricular contractile reserve obtained 
by PASP-increase during exercise 
The 1-, 3-, and 4-year survival rate amongst the patients with PASP-increase ≤30mmHg were 92%, 69% and 48% 
respectively and 96%, 92% and 89% amongst group B with high PASP >30mmHg. 
Figure 4b: Survival amongst patients in relation to peak VO2/kg. 
The median of peak VO2/kg (11.4ml/min/kg) was used to split the patients into two groups. Patients with a peak 
VO2/kg >11.4ml/min/kg had significantly higher survival (98%, 93% and 80%) rates than patients with peak VO2/kg ≤ 
11.4ml/min/kg (90%, 67% and 56%) for the 1-, 3- and 4-year survival rates.
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Prognostic factors in the univariate and multivariate analysis (Table 3)
Clinical parameters were analysed using univariate and multivariate methods. Table 
3 shows the results of the univariate log-rank test. Baseline parameters predictive of 
survival in univariate analysis (log-rank test) were gender (p=0.032), WHO functional class 
(p=0.004), trough oxygen saturation (p=0.047), NTproBNP (p=0.043), 6MWD (p=0.023), 
heart rate at rest (p=0.038), peak VO2 (p=0.046), peak VO2/kg (p=0.004, figure 4b), peak 
PASP (p=0.005), right ventricular area (p=0.005), TAPSE (p=0.015) and right atrial area 
(p=0.006). Hazard ratios define the ratio of death probability. The value for increased 
death probability is given in table three. In patients with pericardial effusion (PE) and in 
patients without PE, the total amount of deaths was 25%. Thus, in the univariate analysis 
pericardial effusion was no significant prognostic factor (p=0.745). Distribution of patients 
with pericardial effusion in the two subgroups (PASP increase above and below 30mmHg) 
was similar with 8 patients in each group (12.1 vs. 13.8%).
Table 3
Parameters Predictive of Survival
Variable 
(cut-off for higher probability of death) N Median p-value HR 95% CI 
Univariate Analysis
Sex (male) 121  0.032 2.15 1.05 - 4.41
Who Functional Class (III/IV) 121  0.004 5.75 (III:II) 1.23 - 29.41
    3.91 (IV:II) 1.56 - 9.80
Peak Oxygen saturation, % (≤ 89) 111 89 0.047 2.14 0.99 - 4.64
NTproBNP, pg/ml (> 619) 117 2192 0.043 2.15 1.00 - 4.63
6MWD, meter (≤ 428) 119 428 0.023 2.33 1.10 - 4.96
HR rest, bpm (> 77) 121 77 0.038 2.15 1.02 - 4.53
Workload, W (≤ 50) 121 50 0.021 2.60 1.11 - 6.06
Peak VO₂, mL/min (≤ 812) 121 812 0.046 2.08 0.99 - 4.26
Peak VO₂/kg, mL/min/kg (≤ 11.4) 121 11.40 0.004 2.98 1.36 - 6.49
Peak PASP, mmHg (≤ 95) 121 95 0.005 2.95 1.34 - 6.50
Δ Systolic pulmonary arterial pressure, 
mmHg (≤ 30) 121 30 0.002 3.49 1.50 - 8.12
Right ventricular Area, cm² (> 24) 64 24 0.005 10.75 1.36 - 83.33
TAPSE, cm (≤ 1.88) 95 1.88 0.015 2.83 1.17 - 6.85
Right atrial Area, cm² (> 20.5) 65 20.5 0.006 10.20 1.30 - 76.92
Multivariate Analysis        
Peak VO₂/kg, mL/min/kg (≤ 11.4) 121 11.40 0.022 2.51 1.14  5.52
Δ Systolic pulmonary arterial pressure,
mmHg (≤ 30) 121 30 0.012 2.99 1.28  7.04
logrank test P values, continuous variables were classified in low  ≤ median, and high > median 
Hazard ratios and their 95% confidence intervals (95% CI) were estimated with Cox regression models, 
showing probability of death. The value with higher probability of death is defined in brackets after the 
variable name.
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 The ability to increase PASP >30mmHg during exercise, was predictive for survival and 
had the highest hazard ratio (3.48) of all variables. In the multivariate analysis only 
peak VO2/kg and PASP-increase during exercise remained as independent predictors of 
survival (Table 3, figure 5). Patients who were positive for both independent risk factors 
at baseline (peak VO2/kg ≤11.4ml/min/kg and exercise-induced PASP-increase ≤30mmHg) 
had the worst survival rate of 84%, 54% and 42% for the 1-, 3- and 4-year survival rate, 
respectively (figure 5). In contrast, patients with high exercise-induced PASP-increase and 
peak VO2/kg >11.4ml/min/kg had a 3-year survival rate of 97% (figure 5).
 







Figure 5: Kaplan Meier survival curves of patients with up to two risk factors (low PASP increase and 
low peak VO2/kg). 
The number at risk increased with the number of risk factors present. The survival rates when both risk factors were 
present were 84%, 54% and 42% for the 1-, 3- and 4-year survival.
Sensitivity analysis excluding patients with CTEPH led to similar results with a median value of PASP increase of 
30mmHg and significant results for uni- and multivariate analysis. The multivariate analysis for the cohort excluding 
CTEPH patients defines peak VO2 below 11.45mL/min/kg (HR 4.63), peak oxygen saturation below 89% (HR 3.66) 
and PASP increase during exercise below 30mmHg (HR 3.31) to be of higher probability of death.
Discussion
This is the first study to evaluate exercise-induced PASP-increase using stress 
echocardiography in a large cohort of patients with severe PAH or inoperable CTEPH and 
right heart failure. The group of patients who revealed a high exercise-induced PASP 
increase i.e. a response above the median value of 30mmHg, had a significantly higher 
mean 6MWD, mean peak VO2/kg, lower mean heart rate, NTproBNP, right atrial area and 
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a better 1-, 3,- and 4-year survival rate. The study revealed that PASP-increase during 
low workload exercise assessed by echocardiography is an independent prognostic factor. 
Exercise-induced PASP-increase could be an estimate of right ventricular contractile 
reserve. Therefore, stress echocardiography may be instrumental for follow-up assessment 
especially to identify PH-patients at high mortality risk.
Measurements of contractile reserve in heart failure
Contractile reserve of the right and left ventricle (LV) have been defined by the change 
in ejection fraction (EF) or stroke volume during exercise or dopamine/norepinephrine-
infusion.10,11 An increase of LV and RV radionuclide ejection fraction ≥5% during exercise 
was found in healthy volunteers with significantly higher levels of LVEF-increase in males 
vs. females (+10.5% vs. +5.3).21 
LV contractile reserve has been shown to be a strong prognostic predictor in patients with 
left heart failure due to idiopathic dilated cardiomyopathy,22-26 valvular heart disease12,27 
and coronary artery disease.28,29 There are only few data on RV contractile reserve and no 
standardized methods how to measure it. LV contractile reserve has been estimated by 
invasively28,30 or non-invasively measured changes in LV- ejection fraction,31 radionuclide 
stroke volume,24 cardiac power (aortic pressure x aortic ﬂow)23 or by echocardiographic 
parameters of LV function including wall thickness.25,26 There have been no studies on 
RV contractile reserve in patients with right heart failure due to PAH or CTEPH. The 
concept to estimate RV contractile reserve by PASP-increase during exercise has not been 
used in PH-patients previously. Patients with severe tricuspid regurgitation have not been 
included in this patients cohort. However, it has to be noted, that measurement of PASP-
increase during exercise is limited in patients with severe TR as estimates of PASP (and RV 
cardiac output) are less accurate.
Rationale for choosing exercise-induced PASP-increase for estimation of RV 
contractile reserve
Exercise-induced PASP increase has been shown to be closely related to RV function. The 
ability of the RV to increase pressure depends on the maintenance of RV arterial coupling32 
and the ability to maintain or increase stroke volume during exercise without dilating.33 
Janicki et al. have shown that the exercise-induced pulmonary arterial pressure-ﬂow 
relationship in PH is very steep.34 Thus, a large increase in PASP implies the capacity of 
the RV to eject a large stroke volume despite high pressures reﬂecting a preserved RV 
contractile reserve. In our study patients of group A and B had similar workloads and no 
pulmonary stenosis. The slightly lower heart rate at rest in group B with better PASP-
increase reﬂects most likely the better contractile reserve. The lower peak heart rate 
during exercise in the group with inadequate PASP-increase may reﬂect a slightly lower 
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level of stress. It might also reﬂect a higher proportion of patients with chronotropic 
insufficiency, which is a common symptom in patients with pulmonary hypertension. Both 
patient groups did not differ in their respiratory quotient which also indicates a similar 
exercise capacity. Most patients with severely impaired RV pump function reached in the 
symptom limited supine exercise test workloads below 75 Watt. We excluded patients with 
higher work load in order to obtain comparable results between both groups (A and B) and 
to avoid that different PASP-response to exercise is due to different levels of stress. Thus, 
differences in PASP increase during exercise most likely represented different abilities of 
the RV to increase cardiac output and could therefore be used to assess the contractile 
reserve of the RV. For further hemodynamic assessment/prove of RV contractile reserve 
it would be useful to perform follow-up assessments using right heart catheterization not 
only at rest but also during exercise. However, this will be not suitable in every patient 
and even more dangerous than the non-invasive parameters. 
Apart from the physiologic rationale for choosing exercise-induced PASP-increase for 
estimation of RV contractile reserve there are technical advantages. Estimation of PASP 
by echocardiography is more easy and precise than the echocardiographic assessments of 
RV ejection fraction or cardiac output during exercise. Both parameters can be estimated 
by pulsed Doppler velocity-time integral measurements but are difficult to measure even 
at rest and not very reliable.35 The assessment becomes even more demanding during 
exercise, especially in PH-patients with enlarged right ventricle and complex geometry. 
Due to a high intra- and inter-observer variability, it would be difficult to establish these 
methods for routine follow-up in PH patients. In contrast, the measurement of TRV by 
means of stress Doppler echocardiography and CPET, is by far easier and accurate in 
patients with manifest PH and enlarged RV although this technique had many pitfalls in 
the screening for PH.36 Nearly all patients with PH and enlarged RV have at least a mild 
tricuspid regurgitation. Therefore, we were able to obtain the PASP-increase in ≈ 95% of 
our patients with clear-shaped Doppler-profiles. 
Stress echocardiography in manifest PH
The assessment during exercise with low workloads (50-75 Watt) remained without 
complications although all patients had a severely impaired RV pump function and severe 
PAH/CTEPH. As cut-off value for a high or low PASP-increase we used the median value 
of 30mmHg. In healthy subjects normal PASP increase during low-dose exercise (within 
75 Watt on supine bicycle ergometer test) was about 10 mmHg (from 20.4±5.3 to 29.8±5.
mmHg ≈ 46% increase).14 In the PH-patient cohort mean PASP at baseline was 70 mmHg, 
and an increase >30mmHg corresponds to a 45% increase. However, the true cut-off 
value can obviously not be obtained in healthy controls. It may even be more useful 
performing echocardiography together with cardiopulmonary exercise testing. Peak VO2/
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kg and PASP-increase were the only independent prognostic predictors and indicated a 
very poor prognosis if both parameters were reduced. Other signs of a severely reduced 
RV contractile reserve during stress Doppler echocardiography as the insufficient increase 
or even drop of systemic pressures should also be regarded.37 
Today, the only indication listed in international guidelines for evaluating PASP during 
exercise by stress echocardiography is in symptomatic patients with mild mitral valve 
stenosis or insufficiency. In these patients percutaneous valvotomy or valve surgery 
may be performed if the PASP during exercise exceeds 60 mmHg.38 In patients with left 
heart failure or with significant mitral regurgitation, PASP-increase during exercise has a 
different pathophysiology and also reﬂects an increase of left atrial pressure and impaired 
LV diastolic reserve and is a predictor of poorer prognosis.39
Prognostic parameters
So far, hemodynamic variables at baseline (such as elevated mean right atrial pressure, 
mean pulmonary artery pressure and reduced cardiac index) have shown to be prognostic 
predictors.4,37,40-41 Based on these parameters, an equation to predict a patient’s likelihood 
of survival has been created.4 However, this equation is based on patients with idiopathic 
and heritable PAH before PAH-targeted medication was available and therefore it may not 
reﬂect the wider PAH population in the modern treatment era.42 In addition to baseline 
hemodynamic parameters, the New York Heart Association functional class,43 heart rate,44 
6MWD,45,46 echocardiographic predictors47 such as pericardial effusion, NTproBNP48 and 
platelet level49 have been found to correlate with the prognosis in PH patients.41,42 Peak 
oxygen uptake and peak systolic blood pressure (SBP) during cardiopulmonary exercise 
testing were also shown to be of major prognostic value in patients with IPAH.50 Recently, 
Nickel et al. described changes in World Health Organization functional class, cardiac 
index, mixed-venous oxygen saturation and NT-proBNP during follow-up visits as significant 
predictors of outcome.51 The here described non-invasive estimation of PASP-increase 
during exercise has been obtained in patients who were under optimized PAH-targeted 
treatment and may therefore also be useful in follow-up assessments of patients. Most 
recent findings confirmed that the RV pump function is a stronger predictor for prognosis 
than baseline PVR and may decrease despite a reduced PVR by PAH-targeted medical 
therapies.33 The results of our study may add to this finding that the assessment of PASP-
increase during exercise as estimate for right ventricular contractile reserve may be 
even more important than the resting hemodynamics for the follow-up and therapeutic 
management of PH-patients. Patients with high PASP-increase and peak oxygen consumption 
>11.4mL/min/kg, had a good long term survival and do probably not need an increase of 
treatment although they might have severely impaired resting hemodynamics. In contrast, 
patients with reduced PASP-increase during exercise and peak oxygen consumption 
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might need escalation of PAH-medication or even be listed for lung transplantation. 
Both patient-groups could be hardly distinguished by resting hemodynamics and clinical 
parameters alone. Estimation of right ventricular contractile reserve may be even more 
important than resting hemodynamics measured by echocardiography for the follow-up 
and therapeutical management of PH-patients. In contrast, patients with reduced PASP-
increase during exercise and peak oxygen consumption might be further evaluated if an 
escalation of PAH-medication is necessary.
In this study patients with moderate to severe impairment of right ventricular function 
were included, mostly WHO functional class III-IV. PASP increase during exercise might also 
be a feasible parameter in patients with less severe pulmonary hypertension; however 
the cut-off value for PASP increase might be different. Further studies are needed to 
investigate the effect on patients with less severe disease and in pre-defined workloads 
e.g. 50 Watts or workloads adjusted to the patients’ body weight.
Clinical Implications and Conclusion
Assessment of PASP-increase during exercise by stress echocardiography at low 
workloads may reﬂect right ventricular contractile reserve and can contribute to 
follow-up assessment and risk-stratification of PAH/CTEPH patients. The combination of 
stress Doppler echocardiography and cardiopulmonary exercise test revealed the most 
important independent prognostic factors as peak VO2 and low PASP increase and may be 
useful for therapeutic decision making by identifying patients of especially high risk and 
inadequate therapy. Estimation of right ventricular contractile reserve may be even more 
important than resting hemodynamics measured by echocardiography for the follow-up 
and therapeutical management of PH-patients.
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Vasoreactivity testing with inhaled nitric oxide (NO) is recommended for pulmonary 
arterial hypertension (PAH) because of its therapeutic and prognostic value. Sildenafil has 
acute pulmonary vasodilating properties, but its diagnostic and prognostic impact in PAH 
is unknown. Our objective was to compare acute vasodilating  responses to sildenafil vs. 
NO during right heart catheterisation and their prognostic values in patients with PAH.
99 patients with idiopathic PAH and 99 with associated PAH underwent vasoreactivity 
testing with NO and sildenafil. Only mild adverse effects of sildenafil in the form of 
hypotension were observed at a rate of 4.5%. The acute responder rate was 8.1% for NO 
and 11.6% for sildenafil. The NO-induced response in mean pulmonary arterial pressure 
and cardiac output correlated with the response to sildenafil. 13 patients were long-term 
responders to CCBs and three of them were correctly identified by acute vasoreactivity 
test with both drugs. The specificity of the vasoreactivity test for identifying long-term 
CCB responders was 88.9% for NO and 85.1% for sildenafil testing. A trend towards better 
survival was found in sildenafil and NO responders compared with non-responders.
Use of sildenafil for vasoreactivity testing is safe. Sildenafil may be useful as alternative 
vasoreactivity testing agent identifying the same number of long-term CCB responders 
as NO. However, NO seems to be a more ideal testing drug due to it’s pharmacologic 
properties. Moreover, sildenafil vasoreactivity testing might contribute to an improved 
estimate of prognosis among patients with PAH. 
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Introduction
Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary 
arterial pressure leading to progressive right ventricular dysfunction and failure. Invasive 
hemodynamic measurement by right heart catheterization (RHC) is necessary to establish 
the diagnosis. In order to choose appropriate therapy, acute vasodilator testing during 
RHC is recommended in patients with idiopathic PAH. A ‘positive acute vasodilator 
response’ predicts the long-term response to high-dose oral calcium channel blockers 
(CCBs) 1,2 and is currently defined as a reduction of mean pulmonary arterial pressure 
(mPAP) > 10 mm Hg leading to mPAP < 40 mm Hg and normal cardiac output (CO) upon 
acute pulmonary vasodilator challenge generally performed with inhaled nitric oxide 
(NO).3 A formerly used definition of vasoreactivity is decrease in mPAP and pulmonary 
vascular resistance (PVR) by > 20% .4
IPAH patients with a significant acute response during vasoreactivity test are recommended 
for treatment with high-dose CCBs. Furthermore, they have a better prognosis than non-
responders, for whom treatment with CCB is not advisable.2,4high doses of oral calcium-
channel blockers (CCB However, despite an initial positive response, only one third of 
these patients show a long-term benefit from CCB, rendering re-evaluation of responders 
compulsory.1
Sildenafil is approved and widely used for the treatment of PAH.5–7 It targets the cyclic 
guanosine monophosphate (cGMP) pathway downstream of NO. Administration of sildenafil 
leads to an acute pulmonary vasodilation that can be tracked during hemodynamic 
measurements.8–11 It may thus be tempting to use sildenafil for acute vasoreactivity 
testing as it is cheaper, more stable and easier to handle than inhaled NO and intravenous 
epoprostenol. However, it is not yet known how similar the acute responses to sildenafil 
and NO and the long-term therapeutic and prognostic implications are.
Hence, we aimed to compare acute vasoreactivity in response to oral sildenafil vs inhaled 
NO in patients with PAH and to determine their prognostic values for long-term treatment.





In this retrospective, open-label, single-center study, we included consecutive patients 
who were admitted to our adult pulmonary hypertension unit from 2002 to 2011 and met 
the following criteria: 
1. Patients had PAH defined as mPAP > 25 mm Hg at rest and pulmonary capillary wedge 
pressure < 15 mm Hg with PVR > 240 dyn•sec/cm. 5, 12the practical implementation of 
the European Guidelines in Germany requires the consideration of several country-
specific issues and already existing novel data. This requires a detailed commentary 
to the guidelines, and in some aspects an update already appears necessary. In June 
2010, a Consensus Conference organized by the PH working groups of the German 
Society of Cardiology (DGK In case of congenital heart disease (CHD) only patients with 
repaired CHD and absence of shunts were included.  
2. Patients were treatment naïve. 
3. Patients had undergone vasoreactivity testing with both, NO and sildenafil during right 
heart catheterisation at initial assessment. 
Right heart catheterization and vasoreactivity testings were performed on clinical grounds 
solely. Patients’ written informed consent was obtained. Compassionate treatment of 
patients with Sildenafil in patients who received sildenafil during periods when the drug 
was not yet approved was done in agreement with the local IRB and in accordance with 
national legal requirement. 
The decision to apply sildenafil was made by the physician performing the right heart 
catheterization. Sildenafil was applied if the drug was considered as a treatment for the 
patient at hand, the systolic SAP was >90mmHg and the general condition of the patient 
during the catheterization allowed for this longer testing procedure.
Assessment of Pulmonary Hemodynamics and Vasoreactivity Testing
A pulmonary artery catheter (Edwards Swan-Ganz, 93A-754H 7.5-F; Baxter Healthcare, 
Irvine, California) was used to measure pulmonary hemodynamics. Cardiac output was 
measured by the Fick method. For patients receiving oxygen therapy, oxygen uptake was 
calculated using the formulas of LaFarge and Bergstra. 13 For the other patients oxygen 
uptake was measured using indirect calorimetry using the Fitmate device (COSMED, Rome, 
Italy). Patients received continuous nasal oxygen throughout the test procedure if initial 
arterial oxygen saturation was <90%. 
After evaluation of baseline parameters, acute vasoreactivity testing was performed using 
inhaled NO at a concentration of 20 ppm for 5 to 10 min (INO therapeutics AB, Lidingo, 
Sweden). After 30 min of washout, all patients received a single dose of 25 mg of oral 
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sildenafil. Pulmonary hemodynamics were registered every 15 min for 60 min after the 
administration of sildenafil. The values at the timepoint with the greatest decrease in 
mPAP were used for further analysis. A positive vasoreactivity test was defined as a drop 
in mPAP > 10 mm Hg leading to an absolute value of < 40 mm Hg and a normalization of 
cardiac index (CI) to a value of ≥ 2.4 L/min/m2.
Assessments and Long-Term Response to Calcium Channel Blockers
Patients underwent clinical examination, a 6-minute walk test, and measurement of brain 
natriuretic peptide at baseline and at each follow-up visit. The 6-minute walk test was 
performed according to the American Thoracic Society guidelines.14 Long-term responders 
to CCBs were defined as patients whose condition improved with CCB therapy according to 
clinical assessment of non-invasive parameters (functional class, 6minute walk test, BNP) 
and were still on CCB monotherapy after 1 year.
Statistical Analysis
Groups were compared using ttest or analysis of variance. The correlation coefficient r 
was computed using univariate linear regression, graphs were plotted with IBM® SPSS® 
Statistics 20 graph builder (IBM Corp, Armonk, NY, USA). Differences in survival between 




A total of 198 treatment-naïve, adult patients with PAH (group 1 of the Nizza classification)15 
underwent right heart catheterization and vasoreactivity testing with NO and oral 
sildenafil at the time of diagnosis. The patients had a mean age of 52.1 years and 64% 
were women (Table 1). Half of the patients (n = 99) were diagnosed with idiopathic PAH 
(IPAH). At the time of diagnosis, mean 6-minute walk distance was 320 m and the majority 
of patients were in functional class III.  Patients with IPAH showed a severe haemodynamic 
compromise (mPAP: 51.6 ± 13.9 mm Hg, PVR: 969 ± 458 dyn•sec/cm5, and CI: 2.1 ± 0.6 L/
min/m2). On average, those with APAH had slightly less severe hemodynamic impairment 
with elevated mPAP (49.3 ± 15.3 mm Hg) and PVR (830 ± 483 dyn•sec/cm5), while the CI 
(2.5 ± 0.8 L/min/m2) was well preserved (Table 2). 
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Table 1. Clinical characteristics of patients with pulmonary arterial hypertension
Characteristic Mean (SD) or n (%)
Age at RHC, yr* 52.1 (15.7)
Female sex 126 (63.6)
























* Data are presented as mean (SD).
APAH = associated pulmonary arterial hypertension; CHD = congenital heart defect; CTD = connective tissue disease; 
HIV = human immunodeficiency virus; IPAH = idiopathic pulmonary arterial hypertension; NYHA = New York Heart 
Association; PCH = pulmonary capillary hemangiomatosis; PoPH = portopulmonary hypertension; RHC = right heart 
catheterization; SD = standard deviation. 
Safety of vasoreactivity testing
No severe adverse events such as pulmonary edema were noted during vasoreactitvity 
testing with both drugs in the studied patients. Mild adverse effects were observed in 
response to sildenafil in form of systemic hypotension that could be managed by ﬂuid 
infusion. We defined symptomatic systemic hypotension if systolic SAP fell <90mmHg and 
ﬂuid infusion was applied and found this in 9 patients (4.5%). 
Vasoreactivity
Both patient groups showed a significant drop in mPAP and PVR in response to administration 
of each vasodilator compared with baseline (Table 2, P < 0.001, P values in comparison 
to baseline not shown in the table). The mean systemic arterial pressure (SAP) did not 
change in response to iNO, but a mild decrease was observed in response to sildenafil. In 
patients with IPAH, the mean response to sildenafil was significantly stronger than to NO in 
terms of right atrial pressure (RAP), CI, and PVR, whereas the changes in mPAP and heart 
rate did not show significant differences (Table 2). In the APAH group, the mean response 
to sildenafil was significantly stronger than that to NO for all hemodynamic parameters.
13106_Gall_BW.indd   132 22-01-16   15:11
4.2



















































































































































































































































































































































































































































































































































































































































13106_Gall_BW.indd   133 22-01-16   15:11
Chapter 4.2
134
8.1% of the patients met the responder criteria for NO and 11.6% for sildenafil (Table 3). It 
was noted that, of the 16 NO responders, 13 were also sildenafil responders. The highest 
frequency of NO responders (10.1%) was found among patients with IPAH (Table 4). In 
patients with APAH, a positive NO response was found less often (6.1%). Responder rates 
for sildenafil were comparable in IPAH (11.1%) and APAH (12.1%); the highest frequency 
(18.5%) was found in patients with congenital heart defects. 
Table 3. Response to nitric oxide and sildenafil
Sildenafil response
Total
Negative, n Positive, n
Nitric oxide 
response Negative, n 172 10 182
Positive, n 3 13 16
Total 175 23 198
A positive response to each drug was defined as a drop in mean pulmonary arterial pressure of ≥ 10 mm Hg from an 
absolute value of ≥ 40 mm Hg and normalization of the cardiac index to ≥ 2.4 L/min/m2.









Number of responders/patients 
treated with LT CCB (%)
IPAH 10/99 (10.1) 11/99 (11.1) 11/27 (40.7)
APAH 6/99 (6.1) 12/99 (12.1) 2/13 (15.4)
CTD 3/46 (6.5) 5/46 (10.9) 2/9 (22.2)
CHD 2/27 (7.4) 5/27 (18.5) 0/3 (0)
HIV 0/18 (0) 0/18 (0) 0/0 (0)
PCH 0/1 (0) 0/1 (0) 0/0 (0)
PoPH 1/17 (5.9) 2/17 (11.8) 0/1 (0)
APAH = associated pulmonary arterial hypertension; CHD = congenital heart defect; CTD = connective tissue 
disease; HIV = human immunodeficiency virus; IPAH = idiopathic pulmonary arterial hypertension; LT CCB = long-
term calcium channel blocker; PCH = pulmonary capillary hemangiomatosis; PoPH = portopulmonary hypertension.
Comparing the intra-individual responses to both drugs, we found that the NO-induced 
decrease in mPAP correlated with the decrease in mPAP after sildenafil administration 
(Figure 1A; r = 0.516, P < 0.001). The same was true for the increase in CO in response to 
both drugs (Figure 1B; r = 0.521, P < 0.001).
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Figure 1. Correlation of hemodynamic responses induced by sildenafil and nitric oxide administration. 
(A) For each patient, the change in mean pulmonary arterial pressure (mPAP) in response to 
sildenafil administration is plotted against the change in mPAP after nitric oxide (NO) inhalation. 
The correlation coefficient was r = 0.516 with P < 0.001. (B) For each patient, the change in cardiac 
output (CO) in response to sildenafil is plotted against the change in CO in response to NO. The 
correlation coefficient was r = 0.521 with P < 0.001. 
Nitric Oxide and Sildenafil Vasoreactivity and Long-term Calcium Channel 
Blocker Response 
Therapy with CCBs was started if the patient met the acute vasoreactivity response 
criteria for NO valid at that time (until 2004: decrease in mPAP and PVR > 20%; from 2005 
onwards: current criteria).16 Therefore, the number of patients starting CCB therapy was 
greater than the number of patients who met the current NO responder criteria.
Of the 40 patients who received CCBs, 13 (32.5%) were long-term responders (Table 4), 
the majority of whom (n = 11) had IPAH. Two patients with APAH with a positive long-
term response were noted, both of whom had connective tissue disease as the underlying 
disease.
We then looked at the initial response to vasoreactivity testing in those patients who 
received long-term CCB therapy, and differentiated between long-term responders or 
non-responders (according to the pre-defined criteria of treatment success described in 
the methods). Three of the 13 long-term responders to CCBs were correctly identified by 
acute vasoreactivity test with both drugs (sensitivity 23 % Table 5). The number of false 
positives – that is, patients who were responders in acute testing but non-responders to 
long-term CCBs – was 3 for NO and 4 for sildenafil testing, resulting in a specificity of 
88.9% for NO and 85.1% for sildenafil testing.
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Table 5. Cross-tabular comparison between long-term response to calcium channel blockers and 
acute response to nitric oxide and sildenafil
Nitric oxide response Sildenafil response
Negative Positive Total Negative Positive Total
Full group
Long-term CCB
Negative 24 3 27 23 4 27
Positive 10 3 13 10 3 13
Total 34 6 40 33 7 40
IPAH
Long-term CCB
Negative 13 3 16 14 2 16
Positive 8 3 11 8 3 11
Total 21 6 27 22 5 27
APAH
Long-term CCB
Negative 11 0 11 9 2 11
Positive 2 0 2 2 0 2
Total 13 0 13 11 2 13
CCB = calcium channel blocker.
APAH, IPAH
Table 6. Comparison of acute hemodynamic responses to nitric oxide and sildenafil of long-term 























ΔPAP −19.8 (7.7) −8.0 (5.8) < 0.001 -4.4 (5.9) <0.001
ΔPVR −460 (285) −200 (178) 0.001 -115 (163) <0.001
ΔRAP −2.3 (2.4) −1.7 (2.2) 0.412 -0.8 (1.9) 0.009
ΔCO 0.5 (0.4) 0.3 (0.5) 0.158 0.1 (0.5) 0.004
Acute sildenafil response
ΔPAP −10.4 (9.7) −8.3 (7.0) 0.451 -6.2 (5.4) 0.014
ΔPVR −321 (232) −226 (184) 0.170 -191 (172) 0.012
ΔRAP −2.3 (3.4) −2.7 (3.3) 0.753 -2.0 (2.6) 0.719
ΔCO 1.0 (0.9) 0.6 (0.7) 0.142 0.4 (0.6) 0.002
The results of the vasoreactivity tests are shown as change from baseline, all values mean (SD). PAP and RAP in 
mmHg, PVR in dynes, CO in L/min.
P value was calculated by t-test.
CCB = calcium channel blocker; CI = cardiac index; NO = nitric oxide; PAP = pulmonary arterial pressure; PVR = 
pulmonary vascular resistance; RAP = right atrial pressure; SD = standard deviation, LT = long-term
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We next looked at the potential of NO and sildenafil administration to predict long-term 
CCB response by the absolute changes in hemodynamic parameters (Table 6). Responders 
to long-term CCBs exhibited a significantly stronger decrease in mPAP and PVR after NO 
administration than non-responders to long-term CCBs (PmPAP < 0.001, PPVR = 0.001). In 
sildenafil testing this difference was smaller and non-significant.
The receiver operating characteristic curves in supplemental Figures S1 and S2 confirm 
that the changes in mPAP and PVR in response to NO are suitable parameters to identify 
long-term responders to CCBs (AUC 0.763 and 0.713 for mPAP and PVR, respectively). 
Logistic regression analysis showed that the decrease of mPAP and the increase of CO after 
sildenafil and NO administration are independent predictors for long-term CCB response 
(Table S1). After dividing the patient sample according to the diagnosis, a stable logistic 

















mPAP response to NO
PVR response to NO
RAP response to NO
CO response to NO
    Asymptotic
    95% Confidence    
    Interval
Test Result   Standard Asymptotic Lower Upper 
Variable(s) Area  Error* Significance† Bound Bound
mPAP response  0.237 0.042 0.000 0.155 0.319
to NO
PVR response  0.287 0.044 0.000 0.201 0.372
to NO
RAP response 0.371 0.053 0.012 0.268 0.474
to NO
CO response  0.636 0.052 0.008 0.534 0.737
to NO
Area Under the Curve
Figure S1. Receiver operating 
characteristic curve for the prediction of 
the long-term response to calcium-channel 
blockers by the acute nitric oxide response. 
To correctly display all the parameters in 
one Figure, the curves for mean pulmonary 
arterial pressure (mPAP; blue), pulmonary 
vascular resistance (PVR; green) and right 
atrial pressure (RAP; black) are displayed 
below the diagonal. They are based on 
negative values since all these parameters 
decrease upon vasoreactivity testing. The 
red line shows the curve for cardiac output 
(CO). Diagonal segments in the figure are 
produced by ties.



















mPAP response to sildenafil
PVR response to sildenafil
RAP response to sildenafil
CO response to sildenafil
    Asymptotic
    95% Confidence    
    Interval
Test Result   Standard Asymptotic Lower Upper 
Variable(s) Area  Error* Significance† Bound Bound
mPAP response  0.432 0.053 0.186 0.329 0.535
to sildenafil
PVR response  0.417 0.050 0.107 0.319 0.516
to sildenafil
RAP response  0.469 0.055 0.549 0.361 0.577
to sildenafil
CO response  0.618 0.053 0.021 0.515 0.721
to sildenafil
Area Under the Curve Figure S2. Receiver operating 
characteristic curve for the prediction of 
the long-term response to calcium-channel 
blockers by the acute sildenafil response. 
In order to correctly display all the 
parameters in one Figure, the curves for 
mean pulmonary arterial pressure (blue), 
pulmonary vascular resistance (green) and 
right atrial pressure (black) are displayed 
below the diagonal. They are based on 
negative values since all these parameters 
decrease upon vasoreactivity testing. The 
red line shows the curve for cardiac output 
(CO). 
Table s1. Logistic regression analysis for long-term response to calcium channel blockers in the full 
patient cohort*
Nitric oxide response Sildenafil response
 OR P value OR P value
ΔmPAP 0.85 0.001 0.912 0.014
ΔPVR 1.001 0.47 1.001 0.385
ΔRAP 0.929 0.479 0.975 0.725
ΔCO 3.086 0.041 2.269 0.01
* After grouping the patients by diagnosis (idiopathic or associated pulmonary arterial hypertension), a stable 
logistic regression model could no longer be built.
Multivariate logistic regression analysis was performed to evaluate the predictive power of acute hemodyamic 
response to NO and sildenafil for long-term CCB response using the following parameters: NO_response_PAP, 
NO_response_PVR, NO_response_RAP, NO_response_CO, SIL_response_PAP, SIL_response_PVR, SIL_response_RAP, 
SIL_response_CO.CO = cardiac output; PAP = pulmonary arterial pressure; PVR = pulmonary vascular resistance; OR 
= odds ratio; RAP = right atrial pressure; SD = standard deviation.
13106_Gall_BW.indd   138 22-01-16   15:11
4.2
Sildenafi l vs Nitric Oxide for Acute Vasodilator Testing in Pulmonary Arterial Hypertension
139
Nitric Oxide and Sildenafil Vasoreactivity and Survival 
A tendency towards better survival was noted for NO responders and sildenafil responders 
in comparison with non-responders in the PAH patient sample but the differences were 
not statistically significant, irrespective of long-term treatment. The five year survival 
rate was 75% for NO responders versus 63% for non-responders. For sildenafil responders 
the five year survival rate was 77% while it was 62% for non-responders (Supplemental 













































Figure S3. Nitric oxide and sildenafil vasoreactivity and survival in pulmonary arterial hypertension. 
(A) Kaplan-Meier survival curves for patients with pulmonary arterial hypertension stratified by 
vasoreactivity to nitric oxide (as defined by current guideline criteria, P = 0.151). (B) Kaplan–Meier 
survival curves for patients with pulmonary arterial hypertension stratified by vasoreactivity to 
sildenafil (P = 0.083). The vertical ticks indicate censoring, which refers to patients reaching the end 
of observation period alive.
 Discussion
PAH is a severe disease requiring costly and complicated care and treatment. A positive 
response to acute vasodilator challenge identifies a subgroup of patients in whom 
mortality is lower compared to the general PAH group and long-term treatment with 
calcium channel blockers, a relatively cheap drug without significant toxicity, is effective. 
Performing acute vasodilator challenge involves expensive and difficult to manage drugs 
such as iNO or epoprostenol and is therefore currently limited to specialized centers in 
developed countries. With PAH increasingly recognized as a disease that is common in 
developing countries where resources are scarce, a less complex and costly vasoreactivity 
testing is needed.
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We compared acute vasoresponse to inhaled NO and oral sildenafil in a large cohort of 
patients with IPAH and APAH, and assessed the related prognostic value for prediction of 
long-term outcomes in this population. 
As sildenafil also causes systemic vasodilation and has a half-life of four hours, it might 
induce a higher number or increased severity of adverse effects compared to iNO. In the 
present study, administration of sildenafil was safe as no severe adverse effects were 
observed using 25mg of sildenafil. The rate of mild adverse events, namely hypotension 
that was managed by ﬂuid infusion, was moderate. However, sildenafil was not applied if 
the patients’ systolic SAP was already < 90mmHg.
Our patient cohort is comparable to other cohorts of patients with IPAH and APAH in terms 
of age, female predominance, and severity of elevation of pulmonary arterial pressure.1,17
The previous definition of a positive vasoractivity test (relative drop in mPAP and PVR by 
at least 20%) has been replaced by the current criteria of a drop in mPAP of > 10 mm Hg to 
an absolute value < 40 mm Hg and a normalization of CI to a value ≥ 2.4 L/min/m2. Using 
these criteria, the rate of positive acute vasoreactivity to NO in patients with IPAH in our 
study was 10.1%, which is slightly less than the rate reported in previous studies.4high 
doses of oral calcium-channel blockers (CCB This could be due, at least in part, to the 
application of the more recent response criteria as opposed to the less strict criteria used 
in former studies. As shown previously, and also in our study, positive vasoreactivity to NO 
was less frequent in patients with APAH than in patients with IPAH.17
Our data suggest that sildenafil may also be used for vasoreactivity testing in patients 
with IPAH identifying the same number of long-term responders to CCBs as the gold-
standard iNO when current criteria are used. Moreover, the intra-individual responses to 
both drugs were highly correlated and the specificity to identify long-term CCB responders 
by vasoreactivity testing was similar with both drugs. 
Recently, the intravenous formulation of sildenafil has become available, with the 
potential of shortening the vasoreactivity testing procedure due to a more rapid onset of 
action and more reproducible bioavailability than the oral formulation.
Nevertheless, iNO seems more discriminative, as the difference in the acute vasoresponse 
between long-term CCB responders and non-responders were larger than with sildenafil 
(19.8 vs. 8.0 mmHg for iNO, 10.4 vs. 8.3 mmHg for sildenafil).
The rate of positive vasoreactivity was higher for sildenafil than for iNO (11.6% vs. 8.0% for 
sildenafil vs iNO, respectively). This difference was largely observed in the patients with 
APAH who exhibited a clinically significant response to sildenafil but not to iNO. Comparing 
the intra-individual responses to both drugs, we have shown that 25mg of sildenafil exerts 
a stronger acute effect on all hemodynamic parameters than iNO in patients with APAH. 
Similar observations with a more pronounced acute response to sildenafil compared to 
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iNO were made in previous studies using higher doses of iNO and oral sildenafil in patients 
with PAH 10,11 or intravenous sildenafil in patients with chronic thromboembolic pulmonary 
hypertension.18 In contrast to the present study, these studies were conducted on small 
numbers of patients and did not evaluate the prognostic value of the vasoreactivity 
testing. In patients with IPAH, the drop in mPAP was equivalent in response to both drugs, 
but a significantly stronger response to sildenafil was noted for RAP, PVR and CI. The 
reasons for these differences may be found in the pharmacodynamic profiles of the drugs, 
but may also reﬂect a different pathogenesis or state of the underlying disease.
NO is a physiologically produced gas with an extremely short half-life. When inhaled, 
it is almost 100% pulmonary selective and, through an increase in wedge-pressure, may 
additionally unmask left heart disease as a cause of pulmonary hypertension. 4
The phosphodiesterase-5 inhibitor sildenafil targets the NO pathway downstream of NO. 
Sildenafil exhibits systemic vasodilatory effects and animal studies suggest it might have 
additional, long-term effects beyond vasodilation that counteract remodeling processes 
in the heart and vasculature. 19,20 Further, there is evidence that phosphodiesterase type 
5 inhibitors may directly enhance right ventricular contractility through cyclic guanosine 
monophosphate–mediated inhibition of phosphodiesterase type 3. 21,22
Systemic hypotensive effects of sildenafil might have secondary effects on pulmonary 
hemodynamics. However, these secondary effects can be recognized by a reﬂectory 
increase in heart rate. As heart rate did not increase in response to sildenafil in our study, 
this does not seem to be a major contributor here.
Even though NO and phosphodiesterase-5 inhibitors target the same pathway, different 
responses to both substances may be observed within one patient due to the different 
endogenous activities of NO-synthase and phosphodiesterase-5. It can be speculated, 
for instance, that in a patient with high basal phosphodiesterase-5 activity and normal 
endogenous NO-production, a strong response to phosphodiesterase-5 inhibitors can 
be observed, while exogenous NO-inhalation is hardly effective. On the other hand, 
patients with low endogenous phosphodiesterase-5 activity may not respond well to 
phosphodiesterase-5 inhibitors, whereas they may show a good response to inhaled NO. 
The down-regulation of NO synthase found in some patients with IPAH reported by Giaid et 
al 23 could provide a clue to this differential responsiveness to agents targeting the same 
signaling pathways on different levels.
Of note, only one in every three patients receiving CCB therapy was a long-term responder. 
In accordance with previous studies,17 we found that long-term responders to CCBs were 
almost exclusively patients with IPAH, suggesting that CCB therapy should only be started 
in these patients. Surprisingly, sensitivity for detection of long-term responders to CCBs 
both by iNO vasoreactivity testing and by sildenafil vasoreactivity testing with the current 
criteria was low (23 % for both substances). Several of the long-term responders to CCBs 
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fulfilled the old, but not the new criteria or just barely missed them. The current criteria 
were defined after retrospective analysis of one large, single-center IPAH cohort,1 but 
have not been prospectively evaluated. Hence, the reasons for the low sensitivity of these 
criteria in our cohort may be diverse. Differences in patients’ characteristics compared 
with the defining cohort could be an explanation for the unsatisfying transferability. 
Previous studies have found large differences in the positive predictive value of acute 
vasoreactivity testing for long-term response to CCB therapy. Jing et al 24 recently found 
that acute responsiveness to adenosine infusion and iloprost inhalation successfully 
predicted long-term CCB response in nine young patients with IPAH. On the other hand, 
Barst et al 25 found that 15 of 31 children who were acute responders did not improve 
with long-term CCB therapy. From a practical point of view, we suggest that patients with 
IPAH who fulfill the old or new responder criteria for iNO or sildenafil testing should start 
CCB therapy with close monitoring. The ability to closely monitor therapeutic response 
is prerequisite to initiating CCB therapy as, even in patients identified by vasoreactivity 
testing, the rate of long-term non-responders may be high. Moreover, vasoreactivity 
testing remains crucial to identifying non-responders and saving them from a potentially 
dangerous trial of CCB.
It has been suggested that patients with good initial vasoreactivity may identify patients 
in an earlier disease state or a more benign variant of the disease.2,26,27 Our data indicate 
that initial vasoreactivity to both iNO and sildenafil, irrespective of the modern specific 
treatments later applied in the non-responders, might be of prognostic value for the long-
term outcome. However, the difference was not statistically significant for both drugs, 
possibly due to the low number of patients in the responder group.
Limitations of the Study
The main limitation of this study is its retrospective design. A prospective study to 
confirm the value of the current vasoreactivity criteria for the prediction of long-term 
CCB response has not yet been conducted and would be desirable. However, with the 
retrospective data and other treatment options for this fatal disease available, such a 
study could not be performed for ethical reasons.
Moreover, selection bias cannot be excluded as only treatment-naïve patients who 
underwent vasoreactivity testing with both, iNO and sildenafil, were studied. Another 
limitation of the study, which is due to the low rate of positive vasoreactivity, is the low 
number of patients in the long-term CCB analyses.
Finally, a systematic bias was inherent to this analysis, as the decision to start long-term 
CCB treatment was solely based on the hemodynamic criteria achieved with inhaled NO 
and not with sildenafil. Therefore, we cannot provide data on the long-term CCB response 
of patients that responded to sildenafil, but not to iNO. 
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Conclusion
We conclude that sildenafil may serve as a vasoreactivity testing agent in patients 
with IPAH, even though iNO might be more discriminative and should be preferred due 
to its pulmonary selectivity and short half-life. Therefore, when sildenafil is used for 
vasoreactivity testing, the positive predictive value to identify long-term CCB responders 
should be assessed to provide more evidence for this approach. Given the low number of 
positive acute responders to NO and the even lower rate of long-term CCB response in 
patients with APAH, vasoreactivity testing may be dispensable for these patients in terms 
of CCB trial. Interestingly, our data suggest that acute vasoresponsiveness to sildenafil 
might be of prognostic value for both IPAH and APAH patients regardless of the type of 
PAH-specific treatment.
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Background: Combination therapy is frequently used to treat patients with pulmonary 
hypertension but few studies have compared treatment regimens. This study examined 
the long-term effect of different combination regimens of inhaled iloprost and oral 
sildenafil on survival and disease progression. 
Methods: This was a retrospective study of patients in the Giessen Pulmonary Hypertension 
Registry who received iloprost monotherapy followed by addition of sildenafil (iloprost/
sildenafil), sildenafil monotherapy followed by addition of iloprost (sildenafil/iloprost), or 
upfront combination therapy (iloprost + sildenafil). The primary outcome was transplant-
free survival (Kaplan–Meier analysis). When available, haemodynamic parameters and 
6-minute-walk distance were evaluated. 
Results: Overall, 148 patients were included. Baseline characteristics were similar across 
treatment groups; however, the iloprost + sildenafil cohort had higher mean pulmonary 
vascular resistance and pulmonary arterial pressure than the others. Transplant-free 
survival differed significantly between groups (P = 0.007, log-rank test). Cumulative 
transplant-free survival was highest for patients who received iloprost/sildenafil (1-year 
survival: iloprost/sildenafil, 95.1%; sildenafil/iloprost, 91.8%; iloprost + sildenafil, %62.9); 
this group also remained on monotherapy significantly longer than the sildenafil/iloprost 
group (median 17.0 months vs 7.0 months, respectively; P = 0.004). Compared with pre-
treatment values, mean 6-minute-walk distance increased significantly for all groups 
3 months after beginning combination therapy.
Conclusions: In this observational study of patients with pulmonary hypertension receiving 
combination therapy with iloprost and sildenafil, cumulative transplant-free survival was 
highest in those who received iloprost monotherapy initially. However, owing to the size 
and retrospective design of this study, further research is needed before making firm 
treatment recommendations.
Keywords: Combination therapy, Iloprost, Sildenafil, Pulmonary hypertension, Giessen 
Pulmonary Hypertension Registry
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Background
Pulmonary hypertension (PH) is a life-threatening disorder with a variety of aetiologies [1]. 
Because PH is a multifactorial condition, monotherapy focused on a single pathological 
pathway may be insufficient to halt disease progression. By acting on two or more 
biological pathways, combination therapies have the potential for increased efficacy 
over monotherapies. In patients with PH, two main approaches for combining treatments 
may be followed, with therapies introduced sequentially or concomitantly as ‘upfront’ 
combination therapy. Monotherapy is normally used initially, with additional therapy 
introduced if clinical deterioration occurs. Less frequently, combination treatment is used 
as first-line therapy to exploit the ‘hit hard and early’ model, which aims to use early and 
aggressive treatment to halt disease progression [2].
Treatment guidelines suggest combining established pharmacotherapies for patients with 
PH who do not respond adequately to monotherapy, but do not recommend particular 
combinations or regimens [3]. During a 3-year study employing pre-defined treatment 
goals to guide therapeutic decisions, combination therapy was eventually required by 
almost half of patients initially prescribed monotherapy [4]. Several studies have examined 
the combination of the prostanoid iloprost and the phosphodiesterase type 5 (PDE-5) 
inhibitor sildenafil in the treatment of patients with PH. In acute haemodynamic testing, 
combining these drugs led to a greater reduction in pulmonary vascular resistance (PVR) 
than each agent alone [5]. Furthermore, patients with pulmonary arterial hypertension 
(PAH) showed improved exercise capacity and haemodynamics when given sildenafil as an 
add-on to existing iloprost therapy [6]. Randomized controlled trials directly comparing 
the efficacy of iloprost and sildenafil have not been undertaken, although a meta-analysis 
found no significant difference in efficacy between these therapies [7]. The aim of this 
study was to examine the long-term effect of different combination regimens of inhaled 
iloprost and oral sildenafil on the survival and disease progression of patients with PH.
Methods
Study design
This was an observational study [8] of patients in the Giessen Pulmonary Hypertension 
Registry, a single-centre registry including more than 2500 patients. The first patient was 
enrolled in March 1993. Adult patients who received a combination of inhaled iloprost and 
oral sildenafil were eligible for inclusion. Patients who received intravenous iloprost or 
sildenafil, or who had begun treatment with therapies other than iloprost or sildenafil, were 
excluded. Each patient gave informed consent to participate. The study was approved by 
the Institutional Review Board and followed the principles of the Declaration of Helsinki.
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Three treatment regimens were studied: iloprost monotherapy followed by addition 
of sildenafil (iloprost/sildenafil); sildenafil monotherapy followed by addition of 
iloprost (sildenafil/iloprost); and upfront combination therapy of iloprost and sildenafil 
(iloprost + sildenafil). No pre-defined protocol was followed; treatment and doses were 
tailored to the individual patient’s needs and optimized by dose-titration.
Outcome measures
The primary outcome measure was transplant-free survival, as calculated by Kaplan–
Meier analysis. As this was a retrospective study of patient records, complete information 
could not be obtained in all cases. When available, 6-minute-walk distance (6MWD), 
New York Heart Association (NYHA) functional class, pulmonary arterial pressure (PAP), 
PVR, and cardiac output were analysed. Changes were compared using intra-individual 
paired analysis (i.e. including only patients with both baseline and post-treatment data 
available). Values were determined pre-treatment (baseline), 3 months after monotherapy 
initiation, before combination therapy initiation (post-monotherapy baseline), and 
3 months after combination therapy initiation. Patients lost to follow-up were classified 
as having withdrawn alive on the date of last contact.
Statistical methods
Data are presented as mean (standard deviation) or median (interquartile range), as 
applicable. The log-rank test was used to analyse differences in cumulative transplant-
free survival; analysis of variance was applied to test for differences between groups; 
and the paired t-test (two-tailed) was used to examine changes in response to therapy. 
Cox regression, defining iloprost as the reference, was applied to control for possible 
confounders in survival analysis, correcting for NYHA functional class, 6MWD, and cardiac 




In total, out of 685 patients assessed, 148 patients were eligible for the study. Similar 
numbers of patients initially received iloprost or sildenafil monotherapy (61 patients and 
63 patients, respectively), and 24 received upfront combination therapy (Table 1). In 
the iloprost/sildenafil group, idiopathic PAH and PAH associated with other conditions 
(Dana Point classification 1.4) [1] were the most frequent aetiologies (35.0% and 33.3%, 
respectively). Similarly, patients treated with sildenafil/iloprost were mainly those with 
idiopathic PAH or PAH associated with other conditions (25.0% and 43.3%, respectively). 
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Female sex, % 65.0 66.7 78.3
[n = 60] [n = 60] [n = 23]
Mean age at diagnosis, years (SD) 48.7 (14.9) 53.0 (15.2) 43.3 (17.1)
Classification of PH, n (%)
Idiopathic PAH 21 (35.0) 15 (25.0) 11 (47.8)
PAH associated with other conditionsb 20 (33.3) 26 (43.3) 6 (26.1)
Associated with lung diseases 4 (6.7) 9 (15.0) 1 (4.3)
CTEPH 14 (23.3) 10 (16.7) 3 (13.0)
Miscellaneous 1 (1.7) 0 (0.0) 2 (8.7)
[n = 60] [n = 60] [n = 23]
NYHA functional class, n (%)
II 3 (10.3) 4 (8.5) 0 (0)
III 13 (44.8) 18 (38.3) 5 (38.5)
IV 13 (44.8) 25 (53.2) 8 (61.5)
[n = 29] [n = 47] [n = 13]
Mean PAP, mmHg (95% CI) 55 (51–58) 57 (53–61) 73 (65–82)
[n = 50] [n = 51] [n = 21]
Mean cardiac output, L/min (95% CI) 3.4 (3.1–3.7) 3.6 (3.3–3.9) 3.1 (2.5–3.7)
[n = 49] [n = 51] [n = 21]
Mean PVR, dyn.s.cm−5 (95% CI) 1287 (1134–1440) 1143 (1016–1270) 1824 (1538–2109)
[n = 49] [n = 51] [n = 21]
Mean 6MWD, m (95% CI) 276 (232–319) 281 (245–317) 222 (179–265) 
[n = 38] [n = 48] [n = 16]
aThe treatment regimens were: iloprost/sildenafil (iloprost followed by addition of sildenafil), sildenafil/iloprost 
(sildenafil followed by addition of iloprost), or iloprost + sildenafil (combined iloprost and sildenafil as upfront 
therapy); bDana Point classification 1.4 [1].
6MWD, 6-minute-walk distance; CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue 
disease; CTEPH, chronic thromboembolic pulmonary hypertension; ILD, interstitial lung disease; NYHA, New York 
Heart Association; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PVR, pulmonary vascular 
resistance; SD, standard deviation.
The most common classification for patients who received upfront combination therapy 
was idiopathic PAH (47.8%). Baseline characteristics were broadly similar in the treatment 
groups (Table 1). The mean age at diagnosis of the sildenafil/iloprost group was significantly 
higher than that of the iloprost + sildenafil group (53.0 years vs 43.3 years, respectively; 
P = 0.029); otherwise, there were no significant differences between the mean ages of the 
groups. Patients who initially received iloprost monotherapy were admitted to the study 
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centre earlier (median date November 2000) than those beginning sildenafil monotherapy 
or combination therapy (median dates April and August 2003, respectively; P < 0.001). The 
mean baseline 6MWD was lower for patients who received upfront combination therapy 
than for the other groups (Table 1), but not significantly so (P = 0.227). 
Patients who received upfront combination therapy had significantly higher mean PAP 
than patients initially treated with iloprost or sildenafil monotherapy (P < 0.001 [Table 
1]). Between treatment groups, however, there was no significant difference in cardiac 
output (P = 0.264). Patients treated with upfront combination therapy had higher mean 
PVR than those who started on iloprost or sildenafil monotherapy (P < 0.001). Data for 
exercise capacity and haemodynamic parameters were not available for all patients. The 
proportions of patients who went on to receive additional therapy with an endothelin 
receptor antagonist, an intravenous prostanoid or both were 48.6%, 5.4%, and 13.5%, 
respectively. Patients were followed up for a mean of 60.9 months. 
Duration of monotherapy treatment 
Patients initially treated with iloprost remained on monotherapy significantly longer than 
those starting with sildenafil (P = 0.004; Figure 1). Median time on monotherapy was 
17.0 months (95% confidence interval: 10.4–23.6 months) with iloprost and 7.0 months 
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Figure 1 Kaplan–Meier plot of proportions of patients remaining on iloprost or sildenafil monotherapy 
over time.
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Cumulative transplant-free survival
In total, eight patients were lost to follow-up: three in the iloprost/sildenafil group, one 
in the sildenafil/iloprost group, and four in the iloprost + sildenafil group. There was a 
significant difference in transplant-free survival among groups (P = 0.007, log-rank test; 
Figure 2A). Cumulative transplant-free survival was highest in the iloprost/sildenafil group 
and lowest for those who received upfront combination therapy. In the iloprost/sildenafil 
group, survival rates were 95.1% at 1 year, 81.8% at 3 years, and 66.4% at 5 years. In the 
sildenafil/iloprost group, survival rates were 91.8% at 1 year, 68.1% at 3 years, and 54.5% 
at 5 years. Survival rates were 62.9% at 1 year, 57.7% at 3 years, and 50.5% at 5 years for 







































































Figure 2 Transplant-free survival. (A) 
Kaplan–Meier plot of cumulative transplant-
free survival and (B) Cox regression estimate 
of transplant-free survival after correction 
for possible confounders (New York Heart 
Association functional class, 6-minute-walk 
distance, and cardiac output). Patients 
were treated sequentially with iloprost 
and sildenafil (either iloprost followed by 
addition of sildenafil [iloprost/sildenafil] or 
sildenafil followed by addition of iloprost 
[sildenafil/iloprost]), or with upfront 
combination therapy (iloprost + sildenafil). 
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After Cox regression analysis, cumulative transplant-free survival was significantly higher 
in the iloprost/sildenafil group than in the sildenafil/iloprost group (P = 0.035; Figure 2B). 
Survival was also higher for patients treated with iloprost/sildenafil than for those treated 
with upfront combination therapy, but this difference was not statistically significant 
(P = 0.120).
Cumulative transplant-free survival based on the aetiology of pulmonary 
hypertension
For patients with PAH initially treated with iloprost or sildenafil, cumulative transplant-
free survival was analysed by PH classification (Additional file 1: Figure S1). For all groups 
assessed (PAH associated with collagen-vascular disease, idiopathic PAH, and PAH associated 
with systemic-to-pulmonary shunt), survival was higher in the iloprost/sildenafil group 
than in the sildenafil/iloprost group. No statistical analyses were conducted because the 
number of patients in these sub-analyses was small. 
Change in functional class 
The iloprost/sildenafil group had a lower proportion of patients in NYHA functional class 
IV at pre-treatment baseline than the sildenafil/iloprost group (Figure 3). The proportion 
of patients in NYHA functional class IV showed a more pronounced decrease with sildenafil 
than with iloprost. The lowest proportion of patients in NYHA functional class IV was 
observed after addition of the second therapy in both groups. 
Change in mean pulmonary arterial pressure 
There was no significant change in mean PAP measured 3 months after therapy initiation 
from pre-treatment baseline for patients initially treated with iloprost (Figure 4A). 
Following combination therapy, mean PAP was significantly reduced compared with post-
monotherapy baseline (P = 0.037). However, there was no significant change in mean PAP 
after 3 months of combination therapy compared with pre-treatment baseline. 
Mean PAP was significantly reduced from a pre-treatment baseline of 57 mmHg to 50 mmHg 
for patients who received sildenafil monotherapy (P = 0.001; Figure 4B). However, mean 
PAP was unchanged 3 months after beginning combination therapy compared with post-
monotherapy baseline. Compared with pre-treatment baseline, there was no significant 
change in mean PAP after combination therapy (P = 0.148).
For patients who began initial combination therapy, mean PAP was significantly reduced 
from a pre-treatment value of 79 mmHg to 69 mmHg after 3 months of treatment 
(P = 0.018; Figure 4C). 
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Figure S1. Kaplan–Meier plots of 
cumulative transplant-free survival 
in patients with pulmonary arterial 
hypertension associated with collagen-
vascular disease, idiopathic pulmonary 
arterial hypertension, and pulmonary 
arterial hypertension associated with 
systemic-to-pulmonary shunt. Data are 
shown for patients who were treated 
with iloprost followed by addition 
of sildenafil (iloprost/sildenafil) or 
sildenafil followed by addition of 
iloprost (sildenafil/iloprost).
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NYHA functional class IV
Figure 3 New York Heart Association 
(NYHA) functional class over the study. 
(A) Patients received iloprost followed 
by addition of sildenafil. (B) Patients 
received sildenafil followed by addition 
of iloprost. 
Change in mean cardiac output 
Mean cardiac output was unchanged 3 months after beginning iloprost therapy compared 
with pre-treatment values (Figure 4D). However, after combination therapy, mean cardiac 
output was increased compared with post-monotherapy baseline, from 2.9 L/min to 
3.4 L/min (P = 0.001). There was no significant difference between mean cardiac output 
pre-treatment and following combination therapy.
For patients initially treated with sildenafil, mean cardiac output increased from 3.5 L/min 
at pre-treatment baseline to 4.1 L/min 3 months after beginning treatment (P = 0.001; 
Figure 4E). Following iloprost addition, there was no significant change in mean cardiac 
output compared with post-monotherapy or pre-treatment baselines. Similarly, for 
patients treated with combination therapy initially, there was no significant change in 
mean cardiac output compared with pre-treatment baseline (Figure 4F).
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Figure 4 Changes in haemodynamic parameters and 6-minute-walk distance over the study (intra-
individual responses). (A–C) Pulmonary arterial pressure (PAP), (D–F) cardiac output, (G–I) pulmonary 
vascular resistance (PVR), and (J–L) 6-minute-walk distance (6MWD). Data are presented as means ± 
95% confidence interval. Patients were treated with iloprost followed by addition of sildenafil (iloprost/
sildenafil), sildenafil followed by addition of iloprost (sildenafil/iloprost), or upfront combination 
therapy with iloprost and sildenafil (iloprost + sildenafil). Values are shown pre-treatment (baseline), 
3 months after therapy initiation (monotherapy), before combination therapy (post-monotherapy 
baseline), and 3 months after starting combination therapy (combined therapy). *P < 0.05; **P < 0.01; 
***P < 0.001. Statistical analysis was conducted using the paired sample t-test (two-tailed).
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Change in mean pulmonary vascular resistance 
After 3 months of iloprost monotherapy, there was no significant change in mean PVR 
compared with pre-treatment baseline (Figure 4G). However, mean PVR was significantly 
reduced 3 months after initiating combination treatment compared with post-
monotherapy baseline, from 1455 dyn.s.cm–5 to 1143 dyn.s.cm–5 (P = 0.006). A significant 
reduction in mean PVR was also seen following combination therapy when compared with 
pre-treatment values (P = 0.006).
Mean PVR was significantly reduced from a pre-treatment baseline of 1161 dyn.s.cm–5 to 
909 dyn.s.cm–5 3 months after beginning sildenafil monotherapy (P < 0.001; Figure 4H). 
However, 3 months after beginning combination therapy there was no change in mean PVR 
compared with post-monotherapy or pre-treatment baselines.
For patients treated initially with combination therapy, there was no significant change in 
mean PVR compared with pre-treatment baseline (Figure 4I).
Change in 6-minute-walk distance
Compared with pre-treatment values, patients who received initial iloprost monotherapy 
showed significantly increased mean 6MWD, from 283 m to 346 m (P < 0.001; Figure 4J). 
Exercise capacity was also improved following add-on sildenafil therapy: compared with 
post-monotherapy baseline, mean 6MWD increased from 345 m to 374 m (P = 0.01). Mean 
6MWD increased from 283 m at pre-treatment baseline to 374 m 3 months after beginning 
combination therapy (P < 0.001).
For patients who received initial sildenafil monotherapy, mean 6MWD increased from 
278 m at pre-treatment baseline to 307 m 3 months after beginning treatment (P = 0.036; 
Figure 4K). Subsequently, patients treated with add-on iloprost therapy showed increased 
exercise capacity compared with post-monotherapy baseline, with mean 6MWD increased 
from 303 m to 328 m (P = 0.002). Compared with pre-treatment values, mean 6MWD 
increased from 280 m to 312 m for patients treated with combination therapy (P = 0.038). 
6MWD increased from 213 m to 305 m for patients treated with upfront combination 
therapy compared with pre-treatment baseline (P = 0.001; Figure 4L).
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Discussion
In the treatment of patients with PH, clinical studies have evaluated combinations of 
major pharmacological classes of medical therapies, i.e. endothelin receptor antagonists 
and prostanoids [9-12], endothelin receptor antagonists and PDE-5 inhibitors [13, 14], and 
prostanoids and PDE-5 inhibitors [6, 5, 15-19]. However, only one study, of administration 
of the prostanoid treprostinil for up to 2 years in patients receiving oral background PAH 
therapy, examined long-term outcomes (survival and clinical worsening [defined as addition 
of a new PAH therapy, discontinuation due to disease progression, or death]) [20]. A meta-
analysis of randomized controlled studies in patients with PAH found that, compared 
with monotherapy, combination therapy significantly reduced clinical deterioration, 
increased 6MWD, and improved haemodynamics [21]. However, no significant difference in 
mortality was observed between patients treated with monotherapy and those receiving 
combination therapy.
Iloprost and sildenafil act via different pathways (stimulating cyclic adenosine 
monophosphate [cAMP] production and preventing cyclic guanosine monophosphate 
[cGMP] breakdown, respectively), but there is evidence of cross-talk between these 
pathways. Raised cGMP levels inhibit cAMP breakdown, and pre-treatment of erythrocytes 
in vitro with PDE-5 inhibitors potentiated cAMP release in response to treprostinil [22]. 
In acute haemodynamic testing in patients with PH, the combination of sildenafil and 
iloprost produced a greater vasodilatory response than either agent alone [5]. There are 
limited data showing the long-term benefits of combining sildenafil and iloprost, but in 
a 16-week study the addition of sildenafil to long-term treatment with the prostacyclin 
epoprostenol improved exercise capacity and haemodynamics among patients with PAH 
compared with those receiving placebo [23].
In our study, cumulative transplant-free survival was lower for patients who received 
upfront combination therapy than for those treated with initial monotherapy. At 1 year, 
the survival rate was 62.9% for those who received combination therapy, compared with 
95.1% and 91.8% for those first treated with inhaled iloprost or oral sildenafil monotherapy, 
respectively. However, before therapy, patients treated with iloprost + sildenafil had 
higher mean PVR and mean PAP than those who began monotherapy. Therefore, patients 
with the most severe disease had been assigned to receive upfront combination therapy. 
This approach, of treating patients with severe PAH with upfront inhaled iloprost and 
oral sildenafil therapy, was taken in a separate study of eight patients of NYHA functional 
class IV who were unable to perform a 6MWD test. Following treatment, all patients had 
an improvement in their functional class and were able to complete a 6MWD test, though 
one patient later underwent lung transplantation and subsequently died [24]. Similarly, 
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for the small number of patients for whom measurements were recorded in our study 
(n = 16), 6MWD significantly increased following combination treatment.
Among patients treated initially with monotherapy, transplant-free survival was higher 
for those receiving iloprost/sildenafil than for those treated with sildenafil/iloprost. 
Patients treated with inhaled iloprost also remained on monotherapy longer than patients 
beginning oral sildenafil monotherapy. When paired recordings were available, the benefit 
of sequential therapy on exercise capacity was also observed for both drug regimens, 
with 6MWD significantly higher than pre-treatment values after 3 months of combination 
therapy. The results from this study suggest that when combining iloprost and sildenafil 
in a step-wise manner the optimal treatment regimen may be initial monotherapy with 
iloprost followed by add-on sildenafil if clinical deterioration occurs.
This study has limitations. Owing to the retrospective design, patients were not randomly 
assigned to each treatment, as highlighted by significant differences in baseline 
characteristics between the patient groups. Furthermore, complete data were not 
available for functional class, haemodynamic parameters, and exercise capacity, and 
there was the potential for selection bias. Unlike treatment with iloprost monotherapy, 
sildenafil monotherapy resulted in significant improvements in haemodynamics compared 
with pre-treatment values. Despite this, transplant-free survival was shorter in patients 
initially treated with sildenafil than among those who received iloprost therapy first. This 
is difficult to explain, and may reﬂect differences in the baseline characteristics between 
these patient groups or be the result of an unrecognized confounding factor. These 
outcomes also need to be viewed in the context of treatment practices over the course 
of this study, because patients who received initial iloprost therapy were admitted to the 
study centre before those first treated with sildenafil. In Europe, iloprost was approved 
for the treatment of PAH 2 years before sildenafil. Thus, in the early years of the study, 
inhaled iloprost was the only treatment available and patients may have remained on 
monotherapy because no other treatment options were available.
Conclusions
The sequence in which patients with PH received combination therapy with iloprost and 
sildenafil was independently associated with transplant-free survival rate. However, owing 
to the small size of the study and its retrospective design, further research is required to 
confirm the external validity of the results.
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Despite a large amount of research, pulmonary hypertension (PH) is still a disease which 
causes extensive morbidity and mortality, and which is difficult to diagnose and has a 
poor prognosis.1 Targeted therapy for PH is now available in some regions of the world to 
improve symptoms, but to date, for most of the patients there is no cure. 2
This thesis describes a comprehensive approach to evaluate various aspects of PH 
epidemiology including prevalence, risk factors, diagnosis, and prognosis, using data from 
both a large population-based study and an extensive patient registry. This work reports 
the prevalence of PH in the general elderly population and the associations of PH with 
common diseases, including COPD and left ventricular dysfunction. Furthermore, we 
present data on mortality and prognosis of patients diagnosed with PH. Using information 
from the large biobank that is linked to the Giessen patient registry, in this thesis we also 
present data on two biomarkers that were studied within the registry, one with diagnostic 
potential and one possible prognostic tool.
The findings presented in this thesis may help to improve the understanding of the disease 
by facilitating the diagnostic process, enabling more detailed information about prognosis, 
and by improving the possibility of personalizing treatment. Additionally, the findings give 
further insight into the disease in the pre-clinical stage, at the population level. 
This is the first epidemiological study to evaluate the prevalence of PH in an elderly 
population. 3 By studying both the general population and analyzing data from the largest 
single center PH registry we were able to integrate various aspects of PH: Significant 
PH is rare in asymptomatic elderly people. Presence of PH in the general population is 
associated with concomitant diseases. The PH registry includes sizable groups of WHO 
groups II+III, which are likely the most prevalent groups in the general population as well.
Discussion of key findings
Studies of Pulmonary Arterial Systolic Pressure in the General Population: 
The Rotterdam Study
Although previous studies have described the prevalence of the different subtypes of PH 
using patient registries, much less is known about the overall prevalence of PH in the 
general population. In daily clinical practice PH is under-diagnosed and undertreated 
since several years may pass between the first symptoms and the establishment of the 
diagnosis, which, in itself, is cumbersome and time consuming. 4 Part of the difficulty 
in diagnosing PH is due to the relatively unspecific early symptoms of PH, including 
shortness of breath and fatigue.4 A number of associated factors and underlying or co-
occurring morbidities related to PH may be associated with a subclinically increased PASP. 
Associated factors may precede the occurrence of overt PH, may modify disease severity, 
and may impact prognosis.5 
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To gain insight into the distribution of echocardiographically measured PASP (ePASP), the 
prevalence of echocardiographic PH (ePH), and the presence of co-morbidities in the 
general population, we studied the general elderly population of the Rotterdam Study. As 
described in chapter 2.1, we found a relatively low prevalence of 2.6% for ePH. Previous 
studies have found higher prevalences of up to 9.1%, mostly in younger populations. 6,7 The 
highest estimate of 9.1% was calculated in a population referred for echocardiography, 
so it might be an overestimation of the true prevalence in the general population. 7  A 
recent study in the population-based Jackson Heart Study used a slightly lower threshold 
for ePH (35 mmHg vs. 40 mmHg in our study) and excluded patients with absent tricuspid 
regurgitation from analysis whereas we included those as non-cases, which may, in part, 
explain the higher prevalence of 6.8% found in the Jackson Heart Study. 6 Our study 
population arguably represents the „healthier“, elderly population because  those too 
sick to come to the research center or to undergo echocardiography were not included in 
the measurements. Thus, the prevalence in the full population of elderly may be higher. 
Nevertheless, even in healthy elderly adults, we would not expect the prevalence of ePH 
to be lower than in healthy younger populations. As mentioned, a reason for the lower 
estimate may be that we included participants without tricuspid regurgitation or with 
a tricuspid regurgitation velocity that was too small to measure as non-cases, since we 
could not estimate the ePASP in these participants and we assumed that is was likely to 
be low. This may have deﬂated our estimates. An alternative approach could have been 
to exclude them from the analysis. Sensitivity analyses without these participants showed 
a slightly higher, but still relatively low, estimate of 3.4%, thus not completely explaining 
the differences with other studies. 
The European Society of Cardiology recommends that additional right heart characteristics 
should be used to estimate PASP on echocardiography. 8 We further estimated the 
prevalence of ePH using both estimated PASP and the dimensions of the right ventricle. 
This increased the prevalence from 2.6% to 4.5%, indicating that our prevalence estimate 
may indeed be an underestimation. 9 
In addition, we studied the associations of left heart measures and PASP in 2592 participants 
of the Rotterdam Study in chapter 2.2. In a large multivariable model E/A, E/E´, and left 
atrial diameter had the strongest associations with PASP (figure 3b in chapter 2.2). The 
strong associations of markers of diastolic function (E/A and E/E´) with PASP reﬂect the 
importance of diastolic dysfunction for the development of PH. The pathophysiology of 
PH due to heart failure with preserved ejection fraction (HFpEF-PH) includes increased 
LV filling pressures leading to pathologic remodeling of the pulmonary vasculature and 
involvement of the right ventricle (RV).10 Among patients with PH due to left heart failure, 
HFpEF is the most common pathology.10 One reason may be the increasing incidence and 




prevalence of HFpEF in the population. Oktay et al. describe factors that “are likely 
contributing to both the increasing overall prevalence of HFpEF and the increasing 
proportion of HF that is due to HFpEF”, listing the increased life expectancy and aging of 
the population, the epidemic of cardiac and non-cardiac comorbidities, and the increased 
clinical recognition of HFpEF as contributing factors. 11 Survival in patients with HFpEF is 
strongly associated with RV performance and PASP, underlining the importance of PASP in 
the prognosis of the underlying disease. 12
Prevalence of and hospitalizations due to HFpEF are increasing. 13 Physical activity and 
less sedentary time reduce the risk of developing heart failure, both heart failure with 
reduced ejection fraction (HFrEF) and HFpEF. 14 In the ARIC Study, the impact of potentially 
modifiable risk factors on the incidence of heart failure of any kind was analyzed. Among 
diabetes mellitus, current smoking, systemic arterial hypertension, obesity, and elevated 
LDL, diabetes mellitus had the highest incidence rate difference. 15 This is also important 
to consider for the development of PH. Especially as a reduction in the prevalence (or risk 
on the individual basis) of HF could lead to a reduction in PH due to left heart disease. 
Treatment of patients with group 2 PH (PH associated with left heart failure) is always 
recommended to start with optimized treatment of the left heart disease, irrespective of 
the specific disease. 8 In addition to optimized treatment of left heart disease, treatment 
with PH-specific drugs should be considered on an individual basis. However, published 
trials show disappointing results, albeit in small populations. 16–21 Further studies in larger 
populations are needed to give further insight into the usefulness and feasibility of PH-
specific drugs in patients with left heart failure.
The Giessen Pulmonary Hypertension Registry and biobank: prognosis and 
diagnosis
By design, population-based studies are best suited to study diseases with the highest 
prevalence in the population. Conversely, patient registries capture the full spectrum 
of patients with a particular disease, enabling more detailed assessment of clinical 
presentation, diagnosis, treatment and prognosis. For PH in particular, these aspects can 
also be studied for the different etiological subgroups. The Giessen registry is such a 
patient registry. It includes more than 2500 patients with PH of all etiological groups 
with deep phenotyping. Additionally, the registry is linked to a biobank with more than 
4000 blood and urine samples. Samples are taken from all patients at baseline and during 
follow-up. Below, we discuss the results of our studies including patients from the Giessen 
registry, the largest single-center PH registry to date.
In chapter 3.1, we present survival data from the Giessen registry. In contrast to most 
other registries established so far, all etiologic groups are included in the registry and we 
report differences in survival between the distinct etiologic groups. Prognostic factors 
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perform differentially between the etiologic groups. The main causes of death among all 
etiologic groups were right heart failure or respiratory insufficiency, accounting for half 
of the known causes of death. 
Patients in our registry had similar baseline characteristics to those in other national 
registries in terms of age, six-minute walking test (6MWT), New York Heart Association 
functional class (NYHA FC), female-to-male-ratio, and hemodynamic parameters. Only 
minor differences could be detected between the Giessen registry and other registries 
in terms of survival of PH due to lung disease (LD-PH) and PH due to left heart disease 
(PVH). 22–25 Within the pulmonary arterial hypertension (PAH) group, patients with PH due 
to congenital heart disease (CHD) had the best survival. This finding is in agreement with 
those identified in previous publications, showing good long-term survival in patients with 
CHD/Eisenmenger syndrome 26. The survival of patients with idiopathic PAH (IPAH) is very 
similar to with outcomes from registries in France, UK/Ireland, and the US. 27
The PH biomarkers identified to date can serve as prognostic tools or are associated with 
disease severity or progression.  Biomarkers can be grouped into markers of endothelial 
damage, inﬂammation, right ventricular maladaptation, tissue hypoxia, and end organ 
failure.28 There are no established biomarkers to diagnose or exclude PH. To address 
this lack of established biomarkers, the vascular endothelial growth factor (VEGF) family 
members placental growth factor (PlGF) and soluble VEGF receptor 1 (sFlt-1) were tested 
as potential diagnostic biomarkers for PH in chapter 3.2. VEGF and its family members are 
involved in the pathophysiology of PH, as shown in rodent models, and expression studies 
in human lungs and blood. 29,30 In a relatively large patient cohort of 247 patients with 
invasively proven or excluded PH of different etiologies, we measured PlGF and sFlt-1 in 
plasma. Sensitivity and specificity for diagnosis of PH were 62% and 100%, respectively, 
when both markers were combined. The fact that we did not find a correlation of sFlt-1 
and PlGF and invasive pulmonary hemodynamics and other clinical parameters suggests 
a pathophysiological association not directly linked to increased pulmonary arterial 
pressure (PAP) or resulting changes of the RV. Immunohistochemical stainings of human 
lungs from PAH patients compared to healthy donor lungs indicated a pathophysiological 
link of sFlt-1 and PlGF with the remodeling process. 31 Though these markers seem useful 
for diagnosis but show no association with hemodynamics, we can speculate that they 
might reﬂect an initial disease trigger or even a cause of disease, rather than a signal that 
drives and worsens the disease.




Screening for a rare disease requires tests with high sensitivity and reasonable specificity 
as a first step, so, PlGF and sFlt-1 with the cut-offs we chose are not optimal screening 
tools. After a positive test result and other signs or symptoms suggestive of PH, the 
patient could undergo RHC sooner, potentially leading to an earlier diagnosis. As such, 
these measurements may not be used alone as a diagnostic test, but could be part of a 
diagnostic workup in patients suspected of PH.
On a population level, the test with the cut-off we chose does not seem appropriate 
to answer epidemiological questions because the moderate sensitivity would miss too 
many diseased persons. In addition, the test is very costly. In a clinical setting, with 
their moderate sensitivity and their high specificity for PH (and PAH), sFlt-1 and PlGF 
are reasonably suitable screening tools, however their main strength lies in their almost 
unfailing specificity. Therefore, in the decision-making tree of diagnostic workup of 
patients with suspected PH, in cases of a negative test, confirmation by means of invasive 
hemodynamic assessment remains obligatory provided other non-invasive tests (e.g. 
echocardiography) are suggestive of PH. In case of a positive test, sFlt-1 and PlGF are 
novel tools that confirm PH with high certainty at an early stage of diagnostic evaluation. 
Nevertheless, a confirmation by right heart catheterization is always needed.
Previous studies have also examined various potential diagnostic markers, including BNP, 
echocardiography, diffusion capacity of the lung for carbon monoxide (DLCO), computed 
tomography, oxygen saturation, lung function tests, and ECG and have been reviewed by 
Bonderman et al. 32 
BNP has been shown to be valuable for diagnosis of acute decompensation of left and 
right heart failure. 33,34 The potential for BNP alone as a diagnostic marker for stable PH 
remains poor, but BNP could be utilized in combination with other potential markers as 
it has a high negative predictive value. 32 In a meta-analysis by Taleb et al. published in 
2013, the pooled sensitivity and specificity of using echocardiographically estimated PASP 
for the diagnosis of PH were 88% and 56%, respectively, using RHC as the gold standard.35 
Bonderman et al. evaluated a combination of ECG, NT-proBNP, and echocardiography 
as a diagnostic tool for PH. This study investigated the diagnostic accuracy for the 
differentiation of precapillary PH vs. non-precapillary PH, using a methodologically 
elaborate approach including a retrospective evaluation cohort, an internal validation 
with bootstrapping, and a second validation within a prospective cohort. In the prospective 
cohort, the reported sensitivity was 100%, and specificity was 19%. 36 This reported high 
sensitivity and the associated low number of false negatives makes it an appropriate tool 
to detect PH in patients. The low specificity could pose a problem, as low specificity is 
associated with a high number of false positive results. False positive screening results 
lead to unnecessary right heart catheterizations with the associated risks and costs.
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Translating these findings from a patient registry to the population level is challenging. 
As the invasive diagnosis or exclusion of PH by RHC in population studies is not feasible 
and, hence, not available in the Rotterdam Study, a new diagnostic tool or algorithm 
should be evaluated in a patient registry instead. But for future analysis, ECG data 
could be combined with echocardiography data and BNP plasma levels to estimate the 
true prevalence of PH in the general population more accurately. The combination of 
these diagnostic tools could increase the sensitivity and specificity for detection of PH 
in the general population. Of course, the accuracy of such a combination of markers 
for estimating the prevalence of PH in the general population would have to be further 
evaluated.
Altered glucose metabolism and PAH
To study the association of glucose metabolism and long-term survival, we tested the 
prognostic relevance of HbA1c at the time of diagnosis for all-cause mortality in patients 
with PAH. HbA1c was a predictor of all-cause mortality with a hazard ratio of 2.2 per 
1-unit increase of HbA1c. The hazard ratio for all-cause mortality was 3.9 for presence 
of altered glucose metabolism defined as an HbA1c above the median. We found no 
association of HbA1c with disease severity. 37
In patients with heart failure, impaired glucose metabolism has been associated with 
worse clinical parameters and outcomes. 38 For PAH, no long-term prognostic relevance 
has been shown for HbA1c so far. One study associated glucose metabolism with short-
term outcomes and a worse prognosis for female PAH patients with increased insulin 
resistance was found. 39
Besides our finding of an association of impaired glucose metabolism with mortality in 
patients with PAH, in chapter 2.1, we also found a borderline-significant association of 
PASP prevalence with manifest diabetes mellitus. The risk ratio was 1.7 for presence of 
ePH in patients with diabetes mellitus when compared to non-diabetic persons; however 
only borderline statistical significance was reached (p=0.07). 3,37 Mechanisms to explain 
the potential pathophysiological link between PH and altered glucose metabolism speak 
in favor of PH as the cause rather than the consequence of altered glucose metabolism 
(AGM).37 Nevertheless, the association of AGM with increased mortality could lead to the 
idea of treating non-diabetic PH patients who have an AGM before they develop overt 
diabetes mellitus. However, before initiation of an interventional trial, more data must 
be generated to support this idea. 




Assessment and Prognostic Relevance of Right Ventricular Contractile 
Reserve in Patients with Severe Pulmonary Hypertension
Patients with pulmonary hypertension (PH) present with exercise intolerance in daily 
clinical practice, but the prognostic value of exercise to right heart echocardiography 
remained unknown. Prospectively, PH patients on stable PH-targeted therapy were 
evaluated regarding their increase in pulmonary arterial systolic pressure (PASP) in 
response to exercise in chapter 4.1. Our data indicated for the first time that patients 
with an increase in PASP during exercise showed a significantly better long-term outcome. 
The ability of the right ventricle (RV) to adapt to exercise (RV contractile reserve) was 
identified as an independent prognostic factor in PH patients.
Pathophysiologically, patients with PAH exhibit a limited increase in stroke volume due 
to systolic and diastolic impairment, increased RV afterload and impaired ventriculo-
arterial coupling, while the diastolic pressure–volume relationship determines filling and 
CO. 40,41 Therefore, in terms of clinical decision making, prognostic factors derived from 
right ventricular dysfunction are valuable.42 The results of this study indicate for the 
first time that non-invasive, echocardiographic assessment of RV contractile reserve is a 
significant predictor of outcome. In our prospective study, exercise-induced PASP-increase 
was chosen for estimation of RV contractile reserve.  A large increase in PASP in response 
to exercise implies the capacity of the RV to eject a large stroke volume despite high 
pressures, reﬂecting a preserved RV contractile reserve. In case of maladaptation to high 
afterload the RV loses its capability to pump enough blood into the pulmonary circulation. 
This is clear in the case of a decreasing PAP as a sign of a failing right heart. A limited 
increase in systemic blood pressure in response to exercise can also be interpreted as 
a possible sign of severely reduced RV contractile reserve. The pathophysiology behind 
this may in part be explained by the missing capability of the RV to pump enough blood 
against the raised pulmonary vascular resistance (PVR) to fill the left atrium. As a 
consequence, even a healthy LV could not pump sufficient amounts of blood into the 
systemic circulation to cause an increase in systemic blood pressure. In addition, the 
dissociation between RV ejection fraction (EF) and PVR was described previously.43 Thus, 
a decreased PVR under targeted therapy could be associated with either deterioration 
or improvement in RV function. 43,44 Notion emerges that PAH is a disease of RV–arterial 
uncoupling rather than only of pathological pulmonary vascular remodeling. 41 Our study 
indicates that the increase in PASP during exercise is dependent on maintenance of RV 
pulmonary arterial coupling and the ability to increase or maintain stroke volume. These 
two factors are essential for good right ventricular function. So far, there have been no 
studies on RV contractile reserve in patients with right heart failure due to PAH or chronic 
thrombo-embolic PH (CTEPH). The concept of estimating RV contractile reserve by PASP-
increase during exercise has not previously been used in patients with PH. Therefore we 
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might conclude that the measurement of RV contractile reserve in patients with PAH 
may inﬂuence clinical decision making, given its independent association with mortality, 
while prognostic factors are not only important to guide treatment, but also to inform 
the patient about his or her prognosis. Impairment of RV contractile reserve is likely 
to be one mechanism underlying the development of right heart failure and frequent 
assessments might be beneficial in clinical practice. RV contractile reserve has not been 
used as endpoint in clinical trials yet. Future trials could include RV contractile reserve 
as a possible endpoint. 
Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary 
arterial hypertension
Right heart catheterization with acute vasodilator testing is mandatory in every newly 
diagnosed patient with PAH.8 However, the acute vasoresponse of targeted PAH therapy in 
comparison with the standard challenge of nitric oxide (NO) and their prognostic value has 
not been investigated previously. In chapter 4.2 we compared the acute vasoresponse to 
inhaled NO (iNO) and oral sildenafil in a large cohort of patients with IPAH and associated 
PAH (APAH), and assessed the prognostic value for prediction of long-term outcomes in 
this population. Using current criteria, the detection rate of responders was similar with 
administration of sildenafil and with inhaled nitric oxide and the prognostic accuracy was 
similar.
Currently approved targeted therapies for the treatment of PAH have been shown to 
significantly improve long-term outcome und quality of life. 42 However, treatment 
response is not uniform. 45 Parameters that help patients and clinicians to anticipate 
the natural course of a disease are warranted. Acute vasodilator testing has the ability 
to identify a small subgroup of patients with IPAH with favorable long-term response 
to treatment with high dose calcium channel blockers. Therefore, performing acute 
vasodilator testing is mandatory in every newly diagnosed patient with PAH. Performing 
an acute vasodilator challenge involves drugs that are expensive and difficult to manage, 
such as iNO or epoprostenol, so it is therefore currently limited to specialized centers 
in developed countries.46 With PAH increasingly recognized as a disease that is common 
in developing countries where resources may be limited, a less complex and costly 
way of vasoreactivity testing is needed. The aim of our study was to establish an acute 
vasodilator testing setting with the comparably inexpensive, orally administered, and 
widely used phosphodiesterase-5 inhibitor sildenafil. Pathophysiologically, sildenafil 
targets the NO pathway downstream of NO. Sildenafil exhibits systemic vasodilatory 
effects and animal studies suggest it might have additional long-term effects beyond 
vasodilation that counteract remodeling processes in the heart and pulmonary vasculature. 
47,48 There is evidence that phosphodiesterase-5 inhibitors may directly enhance right 




ventricular contractility through cyclic guanosine monophosphate–mediated inhibition of 
phosphodiesterase-3. 49 As sildenafil also causes systemic vasodilation and has a half-
life of four hours, it might induce more adverse effects or more severe adverse effects 
compared to iNO. We found that administration of sildenafil was safe as no severe adverse 
effects were observed using 25mg of sildenafil. Our data suggested for the first time that 
sildenafil may also be used for vasoreactivity testing in patients with IPAH identifying the 
same number of long-term responders to CCBs as the gold-standard iNO when current 
criteria are used. Moreover, the intra-individual responses to both drugs were highly 
correlated and the specificity to identify long-term CCB responders by vasoreactivity 
testing was similar with both drugs. 
Our data indicate that initial vasoreactivity to both iNO and sildenafil, irrespective of the 
modern specific treatments later applied in the non-responders, might be of prognostic 
value for the long-term outcome. It has been suggested that patients with good initial 
vasoreactivity may present in an earlier disease state or exhibit a more benign variant of 
the disease. 50,51 For further evaluation future prospective studies in larger patient groups 
are warranted.
Survival with sildenafil and inhaled iloprost in a cohort with pulmonary 
hypertension
Individualized and goal-oriented therapy has recently emerged as a cornerstone in the 
treatment of patients with PH. Observational data, especially for combination therapy, 
regarding long-term outcome are currently lacking. We conducted a retrospective 
analysis of PH patients who were treated with combination therapy of inhaled iloprost and 
sildenafil (chapter 4.3). The cohort was divided into patient groups receiving up-front 
combination therapy, monotherapy with inhaled iloprost and add-on oral sildenafil, or 
monotherapy with oral sildenafil and add-on inhaled iloprost. Our data indicated for the 
first time that overall survival depended on the chosen treatment regimen, with first line 
iloprost before addition of sildenafil was associated with the best survival, and in addition 
that functional class, hemodynamics, and exercise capacity improved after addition of a 
second drug regardless of the order of drugs.
Combination therapy is often prescribed for long-term use in the modern treatment era 
despite the absence of broad scientific evidence. While some studies evaluated the short-
term efficacy of different combination regiments, long term survival data are lacking. 52 
Iloprost and sildenafil address different pathways to evoke their therapeutic potential, 
but synergistic cross-talk between the cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) cascades has been described. 53 In acute haemodynamic 
testing in patients with PH, the combination of sildenafil and iloprost produced a greater 
vasodilatory response than either agent alone. 54 No published data are available for long-
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term combination therapy of sildenafil and iloprost, but combination of sildenafil as add-
on to parenteral epoprostenol improved exercise capacity and pulmonary hemodynamics. 
55,56 Taken together, there is good reason to combine inhaled iloprost with oral sildenafil 
for the treatment of PH patients. Our study is adding long-term survival data to this field, 
providing evidence for the first time that combination of inhaled iloprost/sildenafil is 
associated with a better outcome than with established monotherapy. Our findings are in 
accordance with two recently published meta-analyses that demonstrated a reduction in 
the risk of clinical worsening by combination therapies in PAH. 52,57 Also experiences with 
left heart disease and systemic hypertension speak in favor of combination therapies. 
58,59 The question remains which drugs could be good combination partners and what is 
the best timing for combination. Drug-drug interactions are always an important issue. 
Individualized therapy is therefore necessary in order to find the optimal treatment 
regimen for each patient. Our study provided evidence for a combination therapy of 
inhaled iloprost and sildenafil. However, prospective, randomized long-term data 
for combination treatment are still lacking.8 A recently published large, prospective, 
randomized controlled trial combining Ambrisentan and Tadalafil has shown encouraging 
results with a significant reduction of clinical events by 50%. 60
Methodological considerations
Studies in the General Population
The large sample size and the population-based nature are clear strengths of these 
studies. The standardized echocardiographic assessment, the availability and prospective 
collection of a large number of covariates are also strong points. However, a number of 
limitations need to be addressed. The data we used for our analyses were measured cross-
sectionally. As a consequence our study may suffer from selection bias, as the persons 
with severe PH could have died before the echocardiographic evaluation (survivor bias). 
This could have led to an underestimation of the prevalence of PH in our study.
Echocardiography can only estimate the PASP. The gold standard for measurement of PASP 
is right heart catheterization. 8 This is a very invasive and costly procedure and, hence, 
is unsuitable for use in population-based studies. Therefore, we used echocardiography 
to estimate PASP in our population. Echocardiography is often used as a first step in the 
PH evaluation or for screening for PH. 8 As discussed earlier, in a meta-analysis the pooled 
sensitivity and specificity for detecting PH by using echocardiographically estimated PASP 
for the diagnosis of PH were 88% and 56%, respectively, using RHC as the gold standard.35 
Thus, we believe that echocardiography could be considered an acceptable tool for 
PH research on the population level. Studies comparing invasively measured PASP with 
echocardiographic values report both overestimation and underestimation of the true 




PASP when using with echocardiography. 61 Also, the largest differences between PASP 
measured by right heart catheterization and PASP measured by echocardiography have 
been reported to occur at the high end of the spectrum of PASP, a range which few of 
our participants were in, but not all reports are in agreement.62 A limitation of previous 
studies is that they were not done in the general population, but were usually done in 
patients with confirmed or suspected PH. It is not clear to which extent they apply to the 
general population in our studies. Residual confounding is also a possible limitation we 
have to discuss. As unmeasured potential confounders are not entered into our regression 
models we could not account for those. 
Our study was performed in an elderly population. Hence, the generalizability of our 
findings to other populations needs to be determined by future studies.
Studies in the Giessen Pulmonary Hypertension Registry 
A potential limitation of the studies performed in the Giessen Pulmonary Hypertension 
Registry is the fact that we studied a single-center cohort. Our reference center is one 
of the largest in Germany and therefore data may be representative of the overall PH 
population, though milder cases may not be referred to us. We did not have complete 
data on right heart catheterization at baseline: some patients came with clinically 
acceptable right heart catheterization values from secondary centers but these data were 
not entered into the database. This results in missing data, but is most likely not missing 
in a particular group more so than in another.
The evaluation of two proteins as novel biomarkers for PH (chapter 3.2) has only been 
done in our study population and needs further validation. We used blood drawn from the 
pulmonary artery. Future studies will have to determine whether using blood from the 
cubital vein, which is much easier to access, gives the same results.
The HbA1C study described in chapter 3.3 has several limitations. Second, we cannot 
exclude selection bias as HbA1c data were missing at baseline in many patients. We did 
not analyze differences between patients with missing HbA1c and included patients. We 
did not perform serial HbA1c measurements during treatment and by that we cannot 
describe the impact of treatment on HbA1c. We also cannot evaluate if HbA1c is a good 
marker for follow up. Thus, HbA1c should be evaluated in a prospective manner in future 
studies and the impact of treatment with PH drugs on HbA1c should be analyzed.
In the study assessing the prognostic relevance of RV contractile reserve (chapter 4.1), 
selection bias may have played a role as we only selected clinically stable patients for 
the study. This selection may have contributed to the comparably good long-term survival 
in the described patient group. Only patients with moderate to severe impairment of RV 
function, mostly WHO functional class III-IV were included. The maximum workload was 
not defined beforehand. This was done for safety reasons, but may also have an impact 
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on the maximum PASP increase as higher workload may lead to higher increase in PASP. 
We included patients who were on stable background therapy, so the prognostic relevance 
may not be true for newly diagnosed treatment naïve patients. Most other prognostic 
parameters were assessed at time of diagnosis. The impact of PASP increase at time of 
diagnosis on survival should be investigated in the future.
Apart from the physiologic rationale for choosing exercise-induced PASP-increase for 
estimation of RV contractile reserve, there are also technical advantages. Estimation of 
PASP by echocardiography is easier and more precise than echocardiographic assessments 
of RV ejection fraction or cardiac output during exercise.63 However, the best way to 
measure contractile reserve has not been defined. Catheter or MRI derived pressure 
volume loops; their intercepts and slopes are within the scope of technical approaches 
and have shown good performance. 64 
In chapter 4.2, in which we studied the potential of sildenafil in acute vasodilator testing, 
we had a low number of patients in the long-term CCB analyses, which is due to the 
low rate of positive vasoreactivity. Also, the decision to start long-term CCB treatment 
was solely based on the hemodynamic criteria achieved with inhaled NO and not with 
sildenafil. Therefore, we could not provide data on the long-term CCB response of patients 
that responded to sildenafil, but not to iNO. 
The retrospective design leads to the major limitation of missing randomization in our study 
into survival in patients treated with sildenafil monotherapy and add-on inhaled iloprost, 
or with inhaled iloprost monotherapy and add-on inhaled sildenafil, or a combination of 
the two (chapter 4.3). As a consequence, there were significant and relevant differences 
in the baseline characteristics of the treatment groups. Missing data are also a problem. 
Despite the fact that initial monotherapy (upfront) with sildenafil substantially improved 
pulmonary hemodynamics, survival was shorter than in the iloprost upfront group. We 
have no clear explanation for this fact, but the difference in baseline characteristics may 
be a factor. Selection bias may play a role here too. Sildenafil became available some 
years after inhalation of iloprost was available for PH patients, so only those patients on 
inhaled iloprost who survived until the availability of iloprost were included in the study. 
Confounding by indication may also be an issue. The more severely affected persons 
may have received one of the treatments over the other or may have received earlier 
treatment with combination therapy.




Implications and future steps
Overall the findings of this thesis contribute to the understanding of PH. First, in 
unselected, elderly volunteers living in northwestern Europe the overall prevalence of 
ePH seems to be low and second, patients with COPD, diabetes or LV systolic or diastolic 
dysfunction have higher prevalence of ePH than their non-diseased counterparts, although 
the association was not significant for diabetes. Therefore, our data suggest that patients 
with these diseases may benefit from careful evaluation for PH and we may have to consider 
more aggressive treatment and prevention of underlying diseases. In aging populations, 
increasing the prevalence of LV disease and COPD may cause a rise in the prevalence of 
ePH, or subclinically increased ePASP, in future years. In the literature, an increased PASP 
has been associated with an increased mortality in the general population, both in the full 
population and in people free of cardiopulmonary disease.65 As a population-based study 
with detailed follow-up information, the Rotterdam Study is ideal for further evaluation 
of the association between an increased PASP and different outcomes. Mortality would 
be a clear primary outcome to analyze. In addition, the unique setting of the Rotterdam 
Study makes it possible to study associations of PASP or right heart function with function 
and dysfunction of many further organ systems. Of particular interest might be the 
association of right heart function or failure with the development of neurological or 
cognitive disorders, through lowered cerebral perfusion, hypoxemia and resulting tissue 
hypoxia. In addition, backward congestion to the intestine that may occur in poor right 
heart function may lead to liver, gastro-intestinal, or endocrine disease. 39
Besides prevalence, incidence of PH in the general population may also be of interest, 
especially if we could identify factors associated with a new diagnosis of PH. To study 
this in the Rotterdam Study, we would have to follow participants with a normal PASP at 
the first right heart evaluation over time to study if they develop PH. The wide range of 
information collected in the Rotterdam Study would then allow us to study associated 
factors. This could be done on a phenotypic level including anthropometric data (e.g. 
body mass index), systemic circulatory measures (e.g. systemic pressures, oxygen pulse, 
breathing rate), lung function test results, or metabolic measures such as HbA1c. Also, 
the genome-wide data on single-nucleotide polymorphisms (SNPs) collected in the 
Rotterdam Study could be associated with the echocardiographic data, preferably in large 
collaborations with other similar studies. This approach has already been successfully 
followed for the left heart. 66 Additionally, French registry data show that in patients with 
PAH genome-wide association studies (GWAS) can successfully reveal SNPs with potential 
pathophysiologic relevance. 67 
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Reference values for left heart echocardiography are established.68 For right heart 
echocardiography the guidelines of the European Society of Cardiology and the American 
Heart Association report values for which limited published evidence exists according 
to the authors of those guidelines.69 Reference values for right atrial dimensions have 
been published by Gruenig et al. 70 This publication takes sex into account, but not age, 
ethnicity, or body surface area. Standardization to a measure of body size, such as body 
surface area, is especially important for echocardiographic measurements. Age and body 
surface are relevant on the patient level to improve the prognostic relevance of right 
heart measures, but for the general population these factors may also be important 
to differentiate patients with normal values from those with pathologies or those at 
increased risk of disease. Population-based data such as those from the Rotterdam Study 
can provide important information for such reference values. 
Previous work showed that patients with HFpEF had a milder degree of RV systolic 
dysfunction compared with those with HFrEF. 71 In our analysis of the Rotterdam Study 
population, to date we have not analyzed the association parameters of LV dysfunction 
and RV function. Future studies could focus on comparing parameters of LV dysfunction 
to TAPSE, S´, RV diameter, RV ejection and contraction times, and right atrial size as an 
indirect measure for right ventricular congestion. This would give further insight into the 
association with RV function rather than PASP with left heart disease.
A major advantage of the Giessen PH registry is the link to thousands of blood samples 
drawn from the patients at time of diagnosis and at each follow up right heart 
catheterization. This enables us to try and answer uncountable research questions using 
high-throughput techniques including proteomics, metabolomics, and lipidomics, and 
also study in detail the genetic and epigenetic background of pulmonary hypertension. 
Such studies may help discover new biomarkers for diagnosis and prognosis and help to 
guide treatment decisions. A large global database is critical to gain the data needed to 
determine the intra- and inter-patient genetic and environmental susceptibilities and 
differences between PH etiologies. A single-center approach has inherent advantages, 
namely homogeneity of data quality and consistency of standards and procedures. Both 
types of registries have their advantages and should exist in parallel. Depending on the 
research question the optimal source of data and trial design should be utilized. As the 
population ages, so will the population of patients with PH and, with that, the number 
of comorbidities will rise. This may also be true for our cohort but the finding has not 
been analyzed, yet. It would be of major interest to see the differences in comorbidities 
between the etiologic groups. Also the impact of comorbidities on adverse drug reactions 
could be analyzed and could lead to more effectively personalized treatment.




The association of HbA1c and right heart parameters or outcomes could be evaluated 
on a population level. One possible protocol could include the measurement of HbA1c 
and PASP at one scheduled follow-up visit of the Rotterdam Study. This cross-sectional 
approach has the advantage of earlier completion of data. In a follow-up assessment the 
change in PASP and HbA1c over time could be analyzed.
Diabetes mellitus and AGM are highly prevalent in the general population and are further 
increasing. 72 The association of manifest DM with the prevalence of ePH has been shown 
in chapter 2.1. However, that association was not significant, possibly in part due to 
limited power. Increasing the physical fitness of the general population could lower the 
prevalence of DM and with that, potentially, the prevalence of PH, if the association is 
causal. 72 
Personalized medicine is offering hope for patients to receive better treatment with 
lower risk of unintended drug effects. 73 For pulmonary hypertension, acute vasodilator 
testing has been found to predict long-term response to oral calcium channel blockers 
in 1992. 50 Since that landmark result, no further advances for patients with PH with 
regard to personalized treatment have found their way into daily clinical practice and 
patient treatment.8 With our results on acute hemodynamic testing and follow-up of the 
patients with drug therapy we open the door for further steps to personalized medicine. 
We could combine the acute hemodynamic response (either in echocardiography or with 
right heart catheterization) with the follow-up data to predict outcome on the one hand 
but also gain further insight in the individual response to a specific drug treatment. This 
individual response could include benefits as well as unintended drug effects. Genetic and 
epigenetic information could be linked to hemodynamic and biomarker data to predict 
treatment response.
In conclusion, this thesis casts light on different aspects of pulmonary hypertension: from 
population cohort to the individual patient, providing insight into pathophysiology and 
thereby presenting advances in diagnosis and prognosis. The translational approach may 
aid in taking further steps into better understanding of the disease and optimized and 
personalized treatment for these patients. General screening in the elderly population 
is not warranted. However, in patients with underlying cardiac or pulmonary diseases, 
possibly enriched by the presence of symptoms like dyspnea, further population-based 
studies may provide valuable information to better identify populations at risk for the 
development of PH who might benefit from early diagnosis and treatment. 
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Pulmonary hypertension (PH) is a disease of the pulmonary vasculature with high morbidity 
and mortality in the affected individuals. We carried out research in two different 
populations: the Rotterdam Study, which is a population-based cohort study, and the 
Giessen PH registry, a patient population. In the present thesis we aimed to elucidate the 
prevalence of PH and its associated factors in the general population. We also studied 
improvement of prognostic and diagnostic evaluation in our patient population by means 
of biomarkers and exercise testing, and we analyzed the effects of combination therapy 
and personalized treatment approaches.
The participants of the Rotterdam Study had a mean age of 76.4 years. The prevalence 
of PH, measured by echocardiography, in this elderly Rotterdam population was 2.6%. We 
identified associated factors for PH in this population. Among the common diseases, COPD 
and left heart disease were associated with the highest prevalences of PH (chapter 2.1). 
Among parameters of left heart function and morphology, measures of diastolic function 
and left atrial diameter showed the strongest associations with pulmonary artery systolic 
pressure (PASP), measured by echocardiography (chapter 2.2).
The Giessen PH registry comprises the largest single center registry and is linked to a 
biobank. Wepresented baseline and survival data in chapter 3.1. Patients in our registry 
had similar baseline characteristics to those in other national registries in terms of age, 
six-minute walking test, New York Heart Association functional class, female-to-male-
ratio, and hemodynamic parameters.  Several prognostic markers were evaluated across 
all etiologic groups.
A definite diagnosis of PH requires invasive hemodynamic evaluation by means of right 
heart catheterization. This invasive evaluation carries risks and costs and is in some cases 
done for exclusion of the disease only. We aimed to find a diagnostic marker for PH to rule 
out or diagnose PH without invasive tests. In chapter 3.2, we found that the biomarkers 
soluble vascular endothelial growth factor receptor 1 and placental growth factor when 
analyzed together provide a relatively high diagnostic accuracy. This possibly enables us 
to obtain diagnostic information earlier in the long process from symptoms via screening 
to a definite diagnosis (chapter 3.2). 
Previous work has shown pathophysiological links between PH and altered glucose 
metabolism (AGM). AGM and PH were linked to pathophysiological changes such as right 
heart congestion. Also, changes in signaling pathways, such as the bone morphogenic 
protein pathway, may play a role. We described the association of AGM with prognosis 
in patients with PH in chapter 3.3. Patients with PH who had an AGM as defined by an 
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HbA1c above the median had a 3.9 times increased mortality as compared to those with 
an HbA1c below the median.
The concept of right ventricular contractile (RV) reserve is discussed in chapter 4.1. 
The increase in PASP upon physiological exercise is introduced as a possible measure of 
RV contractile reserve. An increase in PASP below the median was associated with an 
increased risk of mortality in a prospective cohort of patients with PH.
In chapter 4.2 we compared the acute vasoreactivity of patients with PH in response to 
inhaled nitric oxide and oral sildenafil. Both agents were shown to be of similar prognostic 
value. Nitric oxide is known to guide therapeutic decisions. We were able to show that 
sildenafil may also have the potential to personalize therapy.
Combination therapy of oral sildenafil with inhaled iloprost was evaluated in chapter 4.3.
Sequential addition of a second drug on top of the first can improve functional class, 
pulmonary hemodynamics, and exercise capacity irrespective of the order in which these 
are given. Iloprost as a first therapy with later add-on of sildenafil shows the best long 
term survival in our retrospective uncontrolled study.
The main findings of this thesis are reviewed and discussed in detail in chapter 5, as well 
as relevant methodological issues.
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Pulmonale hypertensie (PH) is een aandoening van de bloedvaten in de longen die gepaard 
gaat met een hoge morbiditeit en mortaliteit. Wij hebben deze aandoening onderzocht 
in twee verschillende groepen: het ERGO onderzoek (Erasmus Rotterdam Gezondheid 
Onderzoek of de “Rotterdam Study”), een populatie-gebaseerde cohortstudie, en de 
Giessen PH registry, een patiëntenpopulatie. Het doel van dit proefschrift was om de 
prevalentie van PH in de algemene bevolking te bestuderen, evenals de factoren die 
geassocieerd zijn met PH. Daarnaast hebben we in de patiëntenpopulatie onderzocht 
of het stellen van de diagnose en het inschatten van de prognose verbeterd zouden 
kunnen worden door het gebruik van biomarkers en inspanningstesten en we hebben de 
effecten geanalyseerd van combinatietherapie en “personalized” (gepersonaliseerde) 
behandelingen.
De deelnemers aan het ERGO onderzoek waren gemiddeld 76,4 jaar oud. De prevalentie 
van PH, gemeten met echocardiografie, in deze oudere Rotterdamse populatie was 2,6%. 
In het onderzoek hebben wij factoren gevonden die geassocieerd zijn met PH in deze 
populatie. Chronisch Obstructieve Longziekten (Chronic Obstructive Pulmonary Disease, 
COPD) en linkszijdige hartziekten gingen gepaard met de hoogste prevalenties van PH 
(hoofdstuk 2.1). Van de metingen van hartfunctie en hartstructuur hadden diastolische 
functie en diameter van het linker atrium de sterkste associaties met pulmonaal arteriële 
systolische druk (pulmonary artery systolic pressure, PASP), gemeten met echocardiografie 
(hoofdstuk 2.2).
De Giessen PH registry is het grootste register van PH patiënten uit één centrum en is 
gekoppeld aan een biobank. In hoofdstuk 3.1 beschrijven we kenmerken van de populatie 
en gegevens over de overleving. Patiënten in dit register waren vergelijkbaar met 
patiënten in andere nationale registers wat leeftijd, zes minuten wandeltest (six-minute 
walking test), New York Heart Association functionele klasse, de man-vrouw-verhouding 
en hemodynamische parameters betreft. Wij hebben een aantal prognostische factoren 
bestudeerd in alle etiologische groepen van patiënten met PH.
Een definitieve diagnose van PH kan alleen gesteld worden met invasieve hemodynamische 
diagnostiek, via een rechtszijdige hartcatheterisatie. Dit invasieve onderzoek gaat 
gepaard met risico’s en kosten en wordt soms alleen gedaan om de diagnose PH uit te 
sluiten. Wij wilden een diagnostische marker voor PH vinden die PH zou kunnen uitsluiten 
of aantonen zonder het gebruik van een invasieve test. In hoofdstuk 3.2 hebben we laten 
zien dat de biomarkers soluble vascular endothelial growth factor receptor 1 en placental 
growth factor samen een relatief hoge diagnostische nauwkeurigheid hebben. Dit zou het 
mogelijk kunnen maken om al eerder diagnostische informatie te verkrijgen in het lange 
proces van symptomen via diagnostiek naar een uiteindelijke diagnose.
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Eerder onderzoek heeft pathofysiologische verbanden laten zien tussen PH en 
veranderingen in het glucosemetabolisme (altered glucose metabolism, AGM). AGM en PH 
gaan allebei gepaard met pathofysiologische veranderingen zoals rechtszijdige stuwing 
van het hart. Mogelijk spelen ook dezelfde onderliggende mechanismen een rol, zoals 
veranderingen in het bone morphogenic protein pathway. In hoofdstuk 3.3 beschrijven 
we de associatie van AGM met de prognose van patiënten met PH. Patiënten met PH die 
een AGM hadden, gedefinieerd als een HbA1c boven de mediaan, hadden een 3.9 keer 
verhoogde sterfte vergeleken met patiënten met een HbA1c onder de mediaan. 
Het concept van contractiele reserve van de rechter hartkamer wordt besproken in 
hoofdstuk 4.1. Wij introduceren de toename in PASP in reactie op inspanning als een 
mogelijke maat van de contractiele reserve van de rechter hartkamer. Een toename 
in PASP onder de mediaan was geassocieerd met een verhoogd risico op sterfte in een 
prospectief cohort van patiënten met PH.
In hoofdstuk 4.2 hebben we de acute vasoreactiviteit van patiënten met PH in reactie 
op inhalatieve stikstofmonoxide vergeleken met de acute vasoreactiviteit in reactie 
op orale toediening van sildenafil. Beide medicamenten hadden een vergelijkbare 
prognostische waarde. Stikstofmonoxide wordt al gebruikt om beslissingen te nemen over 
de behandeling. Wij hebben nu laten zien dat sildenafil mogelijk ook de behandeling meer 
op de individuele persoon zou kunnen afstemmen.
Hoofdstuk 4.3 beschrijft combinatietherapie met orale sildenafil en inhalatieve iloprost. 
Het toevoegen van een tweede medicament bovenop het eerste kan de functionele 
klasse verbeteren, evenals de pulmonale hemodynamiek en het inspanningsvermogen. 
Het maakt hierbij niet uit in welke volgorde de medicijnen gegeven worden. Iloprost als 
eerste behandeling met het daarna toevoegen van sildenafil gaf de beste lange-termijn 
overleving in onze retrospectieve studie zonder controlegroep.
De belangrijkste bevindingen van dit proefschrift worden beschreven en bediscussieerd in 
hoofdstuk 5, evenals relevante methodologische aspecten.
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auf die akute Vasoreaktivität, 2012)
Müller, Henning (Prädiktion des Sildenaﬁl-Langzeittherapie-Effekts 
durch akute Vasoreaktivitäts-Testung, 2012)
Hecker, Franziska (Überleben der Giessener Lungenhochdruck-
Patienten, 2013)
Menkel, Vera (Klinischer Verlauf unter inhalativen Ventavis – 
aktuelle Aspekte, 2013)
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